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INTRODUCTION	  
In	  recent	  years	  significant	  progresses	  have	  been	  made	  in	  the	  understanding	  of	  multiple	  myeloma	  
(MM)	   biology.	   These	   advances	   have	   translated	   into	   the	   development	   of	   new	   drugs	   and	   in	   a	  
different	  approach	   to	   treatment,	  which	  has	  ultimately	   translated	   into	  an	  unprecedented	   rate	  of	  
responses	  and	  complete	  remissions	  (CR).	  Current	  strategies	  for	  the	  treatment	  of	  MM	  involve	  both	  
the	  concept	  of	  sequential	  blocks	  of	   therapy	  given	  as	  an	   induction	  followed	  by	  consolidation	  and	  
maintenance	  and	  the	  concept	  of	  a	  continuous	  treatment.	   Immunomodulatory	  drugs	   (IMiDs)	  and	  
proteasome	  inhibitor	  form	  the	  backbone	  of	  modern	  MM	  treatment,	  but	  new	  and	  more	  targeted	  
treatments	   are	   under	   development	   and	   are	   being	   tested	   in	   the	   contest	   of	   clinical	   trials.	   It	   is,	  
therefore,	  of	  primary	  importance	  to	  understand	  the	  biology	  of	  MM	  and	  how	  this	  biology	  can	  guide	  
us	  in	  the	  development	  of	  new	  treatment	  strategies	  with	  the	  aim	  of	  personalising	  therapy.	  Cancer	  
is	  initiated	  and	  then	  progresses	  through	  a	  complex	  mechanism	  based	  on	  the	  acquisition	  of	  genetic	  
“hits”	   that	   change	   the	   biology	   of	   the	   target	   cell	   from	   normal	   to	   malignant.	   The	   “hits”	   can	   be	  
broadly	  divided	  into	  “driver”	  lesions	  contributing	  to	  a	  selective	  advantage,	  and	  “passenger”	  lesions	  
that	  are	  neutral	  in	  their	  effect	  1,2.	  It	  is	  important	  to	  understand	  the	  complex	  genetic	  landscape	  of	  
cancer	   not	   only	   because	   it	   can	   inform	   us	   on	   how	   individual	   genetic	   lesions	   interact	   leading	   to	  
disease	   progression,	   but	   also	   because	   of	   its	   impact	   on	   treatment	   3-­‐5.	   Studies	   both	   on	   solid	   and	  
haematological	   tumours	   have	   shown	   that	   cancer	   comprises	   a	   collection	   of	   related	   but	   subtly	  
different	  clones,	  a	  feature	  that	  has	  been	  termed	  “intra-­‐clonal	  heterogeneity”	  6-­‐9.	  This	  intra-­‐clonal	  
heterogeneity	   is	   likely,	   from	   a	   “Darwinian”	   natural	   selection	   perspective,	   to	   be	   the	   essential	  
substrate	   for	   cancer	   evolution,	   disease	   progression	   and	   relapse.	   These	   ideas	   derived	   from	  
evolutionary	  biology	  are	  teaching	  us	  that	  cancer	  progression	  is	  driven	  via	  branching	  evolutionary	  
patterns,	  rather	  than	  following	  a	  linear	  multistep	  process	  as	  was	  thought	  previously	  4,6,10-­‐12.	  In	  this	  
context	   the	  critical	  mechanism	  for	   tumour	  progression	   is	  competition	  between	   individual	  clones	  
(and	  cancer	  stem	  cells)	   for	  the	  same	  microenvironmental	  “niche”,	  combined	  with	  the	  process	  of	  
adaptation	   and	   natural	   selection	   4,10.	   The	   Darwinian	   behavioural	   characteristics	   of	   cancer	   stem	  
cells	  are	  applicable	  to	  the	  plasma	  cell	  neoplasm	  MM.	  Treatment	  of	  myeloma	  is	  undergoing	  an	  age	  
of	  new	  discoveries	  and	  improvements.	  New	  mutations	  which	  are	  susceptible	  to	  targeted	  therapy	  
are	  being	  discovered	  and	  tools	  for	  better	  analysing	  the	  molecular	  hallmarks	  of	  myeloma,	  such	  as	  
high	   throughput	   sequencing,	   single-­‐cell	   analysis	   and	   analysis	   of	   paired	   patient	   samples	   are	  
enabling	  us	  to	  understand	  the	  evolutionary	  landscape	  of	  MM	  as	  well	  as	  its	  natural	  history	  in	  much	  
more	  detail.	  The	  knowledge	  that	  intra-­‐clonal	  heterogeneity	  is	  an	  important	  feature	  of	  MM	  biology	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has	  changed	  our	  way	  to	  addressing	  cancer,	  now	  considered	  as	  a	  composite	  mixture	  of	  clones	  and	  
not	  as	  a	  linear	  evolving	  disease.	  In	  this	  variable	  therapeutic	  landscape	  it	  is	  important	  for	  clinicians	  
and	   researchers	   to	   consider	   the	   impact	   that	  evolutionary	  biology	  and	   intra-­‐clonal	  heterogeneity	  
have	  on	  the	  treatment	  of	  myeloma	  and	  the	  emergence	  of	  treatment	  resistance.	  It	   is	  clear	  that	  if	  
we	  want	  to	  effectively	  cure	  myeloma	  it	   is	  of	  primarily	   importance	  to	  understand	  disease	  biology	  
and	  evolution.	  Only	  by	  doing	  so	  will	  we	  be	  able	  to	  effectively	  use	  all	  of	  the	  new	  tools	  we	  have	  at	  
our	  disposable	  to	  cure	  myeloma	  and	  to	  use	  treatment	  in	  the	  most	  effective	  way	  possible.	  The	  aim	  
of	  the	  present	  research	  project	  was	  to	   investigate	  at	  different	   levels	  the	  presence	  of	   intra-­‐clonal	  
heterogeneity	  in	  MM	  patients,	  and	  to	  evaluate	  the	  impact	  of	  treatment	  on	  clonal	  evolution	  and	  on	  
patients’	  outcomes.	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BACKGROUND	  
1.	  MULTIPLE	  MYELOMA	  
Multiple	  myeloma	  is	  a	  haematological	  neoplasia	  characterised	  by	  the	  abnormal	  proliferation	  in	  the	  
bone	  marrow	  of	  clonal	  plasma	  cells	  and	  B-­‐lymphocytes.	  Rarely,	  in	  7%	  to	  15%	  of	  cases,	  plasma	  cells	  
can	  accumulate	  in	  extramedullary	  tissues,	  giving	  rise	  to	  extramedullary	  myeloma	  13,14.	  	  
MM	  represents	  10-­‐15%	  of	  all	  hematologic	  malignancies,	  being	  second	  only	  to	  Hodgkin	  lymphoma	  
14.	   It	   accounts	   for	   1%	  of	   all	   cancer	   and	   to	   2%	  of	   all	   cancer	   deaths,	  with	   an	   annual	   incidence	  of	  
about	   4.6/100000	   15-­‐17.	   MM	   is	   a	   disease	   of	   old	   adults,	   and	   its	   frequency	   increases	   with	   aging:	  
median	  age	  at	  diagnosis	   is	   65-­‐70	  years	   and	   it	   is	   rare	   in	  people	   younger	   than	  40	   14,18.	   There	   is	   a	  
slightly	   higher	   incidence	   in	  men	   and	   Afro-­‐Americans	   have	   a	   probability	   to	   develop	   the	   disease	  
double	  the	  one	  of	  Caucasians	  14.	  
The	   neoplastic	   clone	   is	   characterised	   by	   its	   ability	   of	   synthesising,	   and	   in	   most	   case	   secreting,	  
monoclonal	  immunoglobulin,	  either	  the	  complete	  immunoglobulin	  or	  only	  the	  light	  chain	  portion	  
of	  it.	  These	  monoclonal	  immunoglobulins,	  called	  paraprotein	  or	  M	  component,	  can	  be	  detected	  in	  
the	   serum	   and	   urine	   of	   the	   vast	   majority	   of	   MM	   patient;	   in	   a	   small	   percentage	   (1	   to	   2%)	   of	  
patients,	   however,	   the	   paraprotein	   is	   detected	   neither	   in	   the	   serum	   nor	   in	   the	   urine,	   a	   form	  
known	  as	  non-­‐secretory	  MM	  (NSMM)	  19.	  It	  is	  believed	  that	  in	  NSMM	  the	  neoplastic	  cells	  produce	  a	  
small	  amount	  of	  paraprotein	  that	  cannot	  be	  detected	  by	  serum	  or	  urine	   immunofixation.	   In	  this	  
group	  of	  patients	   it	   is	  mandatory	  therefore	  to	  perform	  a	  test	  to	  dose	  the	  amount	  of	  serum	  free	  
light	  chains	  (FLC)	   in	  order	  to	  monitor	  the	  disease	  and	   its	  response	  to	  treatment.	  The	  serum	  free	  
light	  chain	  assay	  is	  able	  to	  evaluate	  both	  kappa	  (normal	  values	  3.3-­‐19.4	  mg/L)	  and	  lambda	  (normal	  
values	  5.7-­‐26.3	  mg/L)	  light	  chain.	  The	  clonality	  of	  the	  production	  is	  than	  established	  based	  on	  the	  
ratio	  between	  kappa	  and	  lambda	  values	  (FLC	  ratio,	  normal	  values	  0.26-­‐1-­‐65):	  if	  the	  ration	  is	  below	  
0.26	  there	  is	  an	  excess	  of	  lambda	  light	  chains	  production,	  whilst,	  a	  ratio	  higher	  that	  1.65	  indicates	  
an	   excess	   of	   kappa	   light	   chains	   19,20.	  With	   the	   use	   of	   the	   serum	   FLC	   assay	   70%	  of	  NSMM	  were	  
actually	  shown	  to	  have	  a	  measurable	  disease.	  Furthermore	  serum	  FLC	  assay	  is	  not	  useful	  only	   in	  
this	  subset	  of	  patients,	  but	  has	  different	  uses	  also	  in	  patients	  with	  secreting	  MM	  and	  patients	  with	  
AL	  amyloidosis	  20.	  	  
MM	   aetiology	   is	   still	   nowadays	   not	   completely	   understood;	   from	   a	   number	   of	   epidemiologic	  
observations	  a	   factor	   likely	   to	  predispose	   to	   the	  disease	   is	   the	  exposure	   to	   toxic	  agents	   such	  as	  
radiations,	   pesticides	   and	   products	   derived	   from	   petroleum.	   Family	   clusters	   and	   genetic	   loci	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associated	   with	   an	   increased	   risk	   of	   developing	   MM	   have	   also	   been	   described	   in	   the	   general	  
population,	  however	  without	  clear	  inheritance	  21,22.	  
1.1	  NATURAL	  HISTORY	  AND	  CLINICAL	  PRESENTATION	  
The	  natural	  history	  of	  MM	  proceeds	  from	  a	  phase	  characterised	  by	  a	  low	  tumour	  burden	  and	  the	  
absence	   of	   end	   organ	   damage	   (Monoclonal	   gammopathy	   of	   undetermined	   significance,	  MGUS,	  
and	  asymptomatic	  or	  smouldering	  MM,	  SMM)	  to	  a	  phase	  of	  active	  disease	  with	  end	  organ	  damage	  
that	  requires	  treatment	  (symptomatic	  or	  active	  MM)	  23-­‐27.	  
Before	  MM	  becomes	  evident,	   in	   about	  one	   third	  of	   the	  patients,	   the	  occasional	  presence	  of	   an	  
MGUS	   can	   be	   detected.	  MGUS	   is	   a	   premalignant	   condition,	   characterised	   by	   the	   presence	   of	   a	  
small	  paraprotein	  (mainly	  in	  the	  serum)	  and	  the	  absence	  of	  any	  clinical	  manifestation	  (Table	  1)	  26.	  
	  
Table	  1.	  Definition	  of	  MGUS	  14,27.	  
MGUS	  
All	  three	  criteria	  must	  be	  fulfilled:	  
Paraprotein	  <	  3g/dl	  
Bone	  marrow	  plasma	  cells	  <	  10	  %	  
Absence	  of	  organ	  damage	  as	  defined	  by	  CRAB	  criteria	  
	  
The	  presence	  of	  an	  MGUS	  can	  be	  detected	  3%	  of	  people	  older	  than	  50	  years	  and	  in	  5%	  of	  people	  
older	  than	  70	  years,	  and	  it	  has	  a	  risk	  of	  progression	  of	  about	  1%	  per	  year	  26,28.	  
Some	  patients	  can	  also	  be	  diagnosed	  with	  the	  intermediate	  phase	  of	  SMM,	  characterised	  by	  high	  
levels	   of	   paraprotein	   and	   bone	   marrow	   plasma	   cells,	   but	   no	   end	   organ	   damage.	   The	   risk	   of	  
progression	  from	  SMM	  to	  symptomatic	  MM	  requiring	  treatment	  can	  be	  estimated	   in	  about	  10%	  
per	  year	  and	  is	  50%	  in	  the	  first	  5	  years	  25,27.	  Criteria	  for	  the	  definition	  of	  SMM	  are	  summarised	  in	  
Table	  2.	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Table	  2.	  Definition	  of	  SMM	  14,27	  
SMOULDERING	  MM	  
All	  three	  criteria	  must	  be	  fulfilled*:	  
Paraprotein	  ≥	  3g/dl	  
Bone	  marrow	  plasma	  cells	  ≥	  10	  %	  
Absence	  of	  organ	  damage	  as	  defined	  by	  CRAB	  criteria	  
*Any	  one	  of	  the	  following	  biomarkers	  of	  malignancy	  upgrades	  the	  diagnosis	  of	  SMM	  to	  MM	  even	  if	  CRAB	  criteria	  are	  
absent:	  
•	  Clonal	  bone	  marrow	  plasma	  cell	  percentage	  ≥60%	  
•	  Involved:uninvolved	  serum	  free	  light	  chain	  ratio	  ≥100	  
•	  >1	  focal	  lesions	  on	  MRI	  studies	  
	  
The	  diagnosis	  of	  active	  or	  symptomatic	  MM	  is	  based	  on	  the	  following	  criteria	  (all	  three	  conditions	  
must	  be	  fulfilled)*	  14,27:	  
	  
Table	  3.	  Definition	  of	  MM	  requiring	  treatment	  
Bone	  marrow	  plasma	  cells	  ≥10%	  and/or	  histologically	  confirmed	  plasmocytoma	  
Presence	  of	  paraprotein	  in	  serum	  or	  urine	  a	  
End	  organ	  damage	  defined	  as	  follows	  (at	  least	  one)b:	  
[C]	  Elevated	  serum	  calcium	  (calcemia	  >	  10.5	  mg/L	  or	  higher	  than	  normal	  values)	  
[R]	  Renal	  impairment	  (creatinine	  >	  2	  mg/dL)	  
[A]	  Anaemia	  (Hb	  <	  10	  g/dL	  or	  2	  g	  <	  normal	  value)	  
[B]	  Osteolytic	  bone	  lesions	  or	  osteoporosisc	  
*These	  criteria	  identify	  stages	  IB,	  II	  e	  III	  A/B	  of	  Durie	  and	  Salmon	  classification.	  Stage	  IA	  corresponds	  to	  SMM.	  
aIf	   no	   paraprotein	   can	   be	   detected	   a	   bone	   marrow	   plasma	   cell	   infiltration	   ≥30%	   or	   a	   histologically	   defined	  
plasmocytoma	  are	  mandatory	  (NSMM)	  
bOrgan	  damages	  other	  than	  the	  one	  reported	  can	  occasionally	  be	  present.	  In	  this	  case	  it	  must	  be	  clearly	  demonstrated	  
that	  organ	  dysfunction	  is	  due	  to	  MM.	  
cIf	  only	  osteoporosis	  or	  a	  single	  bone	  lesion	  or	  a	  solitary	  plasmocytoma	  are	  detected	  it	  is	  mandatory	  a	  bone	  marrow	  
plasma	  cell	  infiltration	  ≥30%.	  
	  
The	  uncontrolled	  proliferation	  of	  neoplastic	  plasma	  cells	  within	   the	  bone	  marrow,	   the	   increased	  
production	  of	   immunoglobulin	  and	  their	  peculiar	  characteristics	  together	  with	  the	  autocrine	  and	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paracrine	   production	   of	   cytokines	   are	   responsible	   for	   the	   main	   clinical	   manifestations	   of	   the	  
disease	  13,29:	  
•	   Bone	   involvement	   mainly	   characterised	   by	   osteoporosis	   and	   osteolysis:	   it	   is	   the	   most	  
frequent	  way	  of	  presentation	  of	  MM,	  and	  it	  is	  secondary	  to	  the	  increased	  osteoclast	  activity	  and	  to	  
the	  reduced	  osteoblast	  action	  (uncoupled	  bone	  reshaping).	  It	  is	  associated	  with	  severe	  bone	  pain,	  
pathological	  fractures,	  spinal	  cord	  compression	  and	  hypercalcemia.	  
•	   Renal	  involvement:	  it	  is	  due	  to	  the	  increased	  production	  and	  the	  aberrant	  nephrotoxicity	  of	  
light	  chains	  that	  are	  able	  to	  selectively	  target	  the	  renal	  tubules	  of	  the	  nephron,	  giving	  the	  typical	  
feature	  called	  “myeloma	  kidney”	  or	  “myeloma	  cast	  nephropathy”.	  More	  rarely	  renal	  involvement	  
can	  occur	  as	  a	  tubular	  and/or	  glomerular	  damage,	  such	  as	  Fanconi	  syndrome,	  AL	  amyloidosis,	  light	  
chain	  deposition	  disease	  or	  heavy	  chain	  deposition	  disease.	  
•	   Bone	   marrow	   insufficiency:	   the	   most	   common	   feature	   is	   that	   of	   a	   normochromic	   and	  
normocytic	  anaemia,	  due	  to	  heavy	  plasma	  cell	  infiltration	  within	  the	  bone	  marrow	  abrogating	  the	  
normal	  myelopoiesis.	  
•	   Increased	  infective	  morbidity:	  it	  is	  linked	  to	  a	  reduced	  humoral	  and	  cellular	  immunity,	  due	  
to	  the	  suppression	  of	  normal	   immunoglobulin	  synthesis	  and	  antibody	  response,	  reduction	  of	  the	  
number	  and	  activity	  of	  CD4+	  Th1	  T	  lymphocytes,	  a	  reduced	  cytotoxicity	  of	  CD8+	  T	  lymphocytes,	  and	  
abnormal	  function	  of	  NK	  and	  dendritic	  cells.	  All	  these	  features	  are	  linked	  to	  an	  aberrant	  cytokine	  
production	   (mainly	   TGFβ,	   IL10,	   IL6,	   VEGF)	   from	   the	   neoplastic	   plasma	   cells	   and	   bone	   marrow	  
stromal	  cells,	  and	  result	  in	  an	  immunoparesis	  
The	   natural	   history	   of	   MM	   is	   characterised	   by	   subsequent	   phases	   of	   remission	   and	   relapse,	  
defined	   by	   one	   or	  more	   of	   the	   above-­‐mentioned	   clinical	   features.	   At	   each	   relapse	   response	   to	  
treatment	   is	   less	   profound	   and	   shorter,	   with	   relapses	   that	   are	   more	   frequent	   over	   time	   until	  
eventually	   the	   disease	   becomes	   resistant	   to	   treatment	   (relapsed/refractory	   phase),	   leading	   to	  
patient’s	  death	  (Figure	  1).	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Figure	  1.	  Modified	  from	  Hajek	  30	  
1.2	  INTERNATIONAL	  STAGING	  SYSTEM	  AND	  PROGNOSTIC	  FACTORS	  
The	   high	   grade	   of	   heterogeneity	   in	   MM	   clinical	   presentation	   and	   clinical	   course	   has	   made	  
mandatory	  the	  individuation	  of	  parameters	  to	  distinguish	  between	  a	  more	  aggressive	  and	  a	  more	  
indolent	  disease,	  in	  order	  to	  predict	  patients’	  survival	  and	  possibly	  their	  response	  to	  treatment.	  In	  
1975	   the	   first	   staging	   system,	   the	   Durie	   &	   Salmon	   staging	   system,	  was	   introduced.	   This	  model	  
identified	   three	  different	  clinical	   stages	   (I,	   II	  e	   III),	   corresponding	   to	  an	   increasingly	  high	   tumour	  
burden.	   The	   stages	   are	  defined	  based	  on	   the	   levels	   of	   haemoglobin,	   serum	  calcium,	  number	  of	  
skeletal	  lesions	  and	  paraprotein	  concentration.	  Each	  stage	  can	  be	  than	  divided	  in	  two	  classes	  (A	  e	  
B)	  according	  if	  renal	  function	  is	  normal	  (creatinine	  <	  2mg/dl,	  stage	  A)	  or	  abnormal	  (creatinine	  >	  2	  
mg/dl,	  stage	  B)	  31.	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Table	  4.	  Durie	  and	  Salmon	  staging	  system	  31	  
STAGE	  I	  
All	  criteria	  must	  be	  fulfilled:	  
Hb	  >	  10	  g/dl,	  normal	  calcium,	  ≤1	  bone	  lesion,	  low	  levels	  of	  paraprotein	  (IgG	  <	  
50	  g/l,	  IgA	  <	  30	  g/l,	  BJ	  <	  4	  g/24	  h)	  
STAGE	  II	  
Not	  stage	  I	  nor	  III	  
STAGE	  III	  
At	  least	  one	  between:	  
Hb	  <	  8,5	  g/dl,	  calcium	  ≥	  12	  mg/dl,	  ≥	  3	  bone	  lesions,	  high	  levels	  of	  paraprotein	  
(IgG	  >	  70	  g/l,	  IgA	  >	  50	  g/l,	  BJ	  >	  12	  g/24	  h)	  
	  
More	   recently	   the	   International	  Staging	  System	  (ISS)	  was	  developed.	  This	  model	   identifies	   three	  
stages	  based	  on	  the	  levels	  of	  albumin	  (indirect	  expression	  of	  the	  secretion	  of	  IL6,	  and	  therefore	  of	  
plasma	   cells	  malignancy)	   and	  β2	  microglobulin	   (corresponding	   to	   level	   of	   tumour	   burden,	   renal	  
function	  and	  immune	  system	  function)	  32.	  
	  
Table	  5.	  International	  Staging	  System	  (ISS)	  32	  
STAGE	  I	  
β2m	   <	   3.5	   mg/l	   and	   Albumin	   ≥	   3,5	  
g/dl	  
STAGE	  II	  
Not	  stage	  I	  nor	  III	  	  
STAGE	  III	  
β2m	  >	  5.5	  mg/l	  	  
	  
These	  stages	  are	  linked	  to	  patients’	  prognosis,	  with	  patients	  presenting	  with	  a	  stage	  III	  MM	  having	  
a	  shorter	  survival	  compared	  to	  patients	  presenting	  in	  stage	  I.	  	  
Other	   important	   prognostic	   factors	   are	   patient’s	   age,	   performance	   status	   and	   the	   presence	   or	  
absence	  of	  comorbidities.	  	  
Disease	  related	  prognostic	  factor	  are	  be	  divided	  in	  those	  linked	  to	  the	  tumour	  burden	  and	  those	  
linked	  to	  the	  intrinsic	  malignancy	  of	  the	  plasma	  cells.	  Factors	  related	  to	  the	  tumour	  burden	  other	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than	   the	   ISS	   are:	   1)	   renal	   function;	   2)	   the	   degree	   of	   bone	   marrow	   infiltration;	   3)	   skeletal	  
involvement	  identified	  by	  TC-­‐PET	  of	  MRI;	  4)	  platelets	  value	  at	  diagnosis;	  5)	  levels	  of	  LDH.	  	  
Factor	   related	   to	   the	   plasma	   cells	   themselves	   are:	   1)	   the	   levels	   of	   C	   reactive	   protein	   (PCR,	  
expression	  of	  IL-­‐6	  secretion);	  2)	  presence	  of	  circulating	  plasma	  cells	  in	  peripheral	  blood;	  3)	  lack	  of	  
response	  to	  first	  line	  treatment;	  4)	  presence	  of	  cytogenetic	  abnormalities.	  	  
Recently	  the	  importance	  of	  serum	  FLC	  levels	  as	  a	  prognostic	  factor	  has	  also	  been	  described	  27,33,34.	  
2.	  MYELOMAGENESIS	  
Pre-­‐B	  cells	  develop	   in	  the	  bone	  marrow,	  where	  the	  V(D)J	  rearrangement	  for	  the	  heavy	  and	   light	  
chain	  portion	  of	  the	  immunoglobulin	  takes	  place.	  These	  cells	   leave	  the	  bone	  marrow	  as	  naïve	  or	  
mature	  B	  cells	  and	  migrates	  in	  the	  secondary	  lymphoid	  tissues,	  where	  they	  meet	  the	  antigens	  and	  
proliferate	   differentiating	   either	   into	   plasma	   blasts	   or	   in	   memory	   B	   cells.	   Plasma	   blasts	   can	  
differentiate	   in	   short-­‐lived	   plasma	   cells	   (that	   normally	   dye	   within	   3	   days	   and	   produce	   mainly	  
unmutated	   IgM)	   (22)	  or	   in	   long-­‐lived	  plasma	  cells,	   that	  have	  undergone	  somatic	  hypermutation,	  
isotypic	  switch	  and	  return	  to	  the	  bone	  marrow,	  where	  they	  can	  live	  up	  to	  30	  days	  35.	  
MM	   plasma	   cells	   are	   normally	   identified	   as	   the	   long-­‐lived	   plasma	   cells	   that	   reside	   in	   the	   bone	  
marrow.	  	  
The	   study	   of	   the	   immunoglobulin’s	   rearrangement	   through	   molecular	   techniques,	   such	   as	   for	  
example	   polymerase	   chain	   reaction	   (PCR),	   demonstrated	   the	   presence,	   in	   MM	   patients,	   of	   a	  
population	   of	   circulating	   B	   cells	   harbouring	   the	   same	   Ig	   rearrangement	   of	   the	   neoplastic	  
population	  36,37.	  These	  data	  allowed	  scientists	  to	  conclude	  that	  the	  transforming	  event	  happens	  at	  
the	  level	  of	  a	   lymphoid	  progenitor	  and	  that	  the	  germinal	  centre	  reaction	  drives	  the	  origin	  of	  the	  
disease	   35,38-­‐41,	   however,	   recent	   evidence	   suggests	   that,	   at	   least	   in	   a	   proportion	   of	   patient,	   the	  
transforming	  event	  can	  be	  attributable	  at	  a	  proB	  cell	  stage	  35,41.	  
B	  cells	   circulating	   in	   the	  peripheral	  blood	  can	  home	  specifically	   in	   the	  bone	  marrow	  where	   they	  
establish	  stringent	  interactions	  with	  bone	  marrow	  stromal	  cells	  (BMSC),	  from	  which	  they	  receive	  
signals	   to	   differentiate	   and	   proliferate	   in	   mature	   plasma	   cells	   42.	   In	   this	   process	   this	   role	   of	  
cytokines	  produced	  both	  by	  MM	  plasma	  cells	  and	  BMSC	  is	  crucial.	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2.1	  BONE	  MARROW	  MICROENVIRONMENT	  AND	  CYTOKINES1	  
Bone	   marrow	   microenvironment	   is	   constituted	   by	   a	   cellular	   compartment,	   comprising	  
haematopoietic	   stem	   cells	   (HSCs),	   progenitors	   and	   precursor	   cells,	   NK	   cells,	   platelets,	  
megakaryocytes,	  erythrocytes,	  lymphocytes,	  dendritic	  cells,	  fibroblasts,	  chondrocytes,	  osteoblasts,	  
osteoclasts	  and	  endothelial	  cells.	  The	  extracellular	  compartment	  of	  the	  bone	  marrow	  is	  made	  of	  
protein	   of	   the	   extracellular	   matrix	   (ECM)	   like	   collagens,	   fribronectin,	   laminine,	   proteoglycans,	  
glycosaminoglycan	  and	  many	  soluble	  factors	  like	  cytokines,	  chemokine	  and	  growth	  factors	  44.	  The	  
complex	  network	  between	  myeloma	  plasma	  cells	  and	  the	  bone	  marrow	  microenvironment,	  acting	  
throughout	  autocrine	  and	  paracrine	  cytokinic	  loops	  and	  cell-­‐cell	   interactions,	  is	  necessary	  for	  the	  
growth,	  survival	  and	  proliferation	  of	  plasma	  cells	  and	  the	  acquisition	  of	  drug	  resistance.	  
The	  major	  families	  of	  molecules	  of	  adhesion	  involved	  are	  those	  of	  the	  integrin,	  cadherin,	  selectin,	  
syndecans	  and	  of	  the	  superfamily	  of	  the	  immunoglobulin	  such	  as:	  syndecan-­‐1	  (also	  called	  CD138),	  
VLA4,	  H-­‐CAM,	   ICAM1,	  N-­‐CAM,	  LFA3,	  CD56,	  CD74,	  VLA5,	  β2m.	  The	   liquid	  milieu	   is	  made	  of	  many	  
soluble	   factors,	   such	  as	   IL6,	  VEGF,	   IGF1,	  TNFα,	  SDF1α,	  CD40,	  TGFβ,	  bFGF,	  MIP1α,	  SCF,	  HGF,	   IL3,	  
IL1β,	  metalloproteasis	  44.	  
Cytokines,	   growth	   factors	   and	   adhesion	   molecules	   are	   able	   to	   activate	   numerous	   signal	  
transduction	  pathways	  within	  the	  plasma	  cells,	  the	  most	  important	  being	  (Figure	  2	  and	  3):	  
v Ras/Raf/MEK/MAPK	  pathway,	  activated	  by	  IL6,	  IGF1,	  VEGF	  and	  integrines:	  it	  leads	  to	  cell	  
proliferation	  and	  drug	  resistance.	  
v PI3K/Akt	  pathway,	  activated	  by	  IL6,	  IGF1,	  VEGF	  and	  integrines:	  inhibits	  apoptosis.	  	  
v JAK/STAT3	  pathway,	  activated	  by	  IL6:	  leads	  to	  cell	  proliferation.	  
v NFkB	  pathway,	  constitutively	  activated.	  
v Wnt/APC/βcatenin	   canonical	   pathway	   and	  Wnt/RhoA	   alternative	   pathway,	   involved	   in	  
the	  pathogenesis	  of	  bone	  disease.	  
The	   adhesion	   of	  MM	   plasma	   cells	   to	   the	   BMSCs	   determines	   an	   antiapoptotic	   and	   proliferative	  
effect	  in	  the	  plasma	  cells,	  and	  stimulates	  the	  production	  from	  the	  BMSCs	  of	  IL6.	  IL-­‐6	  is	  one	  of	  the	  
main	  cytokines	   involved	   in	  MM	  development,	  supporting	  the	  growth,	  survival	  and	  acquisition	  of	  
drug	  resistance	  in	  MM	  cells,	  thus	  creating	  a	  vicious	  circle	  44.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  	  Contains	  quotes	  from	  “The	  Impact	  of	   Intra-­‐Clonal	  Heterogeneity	  on	  the	  Treatment	  of	  Multiple	  
Myeloma”	  (43.	   Brioli	   A,	   Melchor	   L,	   Cavo	   M,	   Morgan	   GJ.	   The	   impact	   of	   intra-­‐clonal	  
heterogeneity	   on	   the	   treatment	   of	   multiple	   myeloma.	   British	   journal	   of	   haematology.	  
2014;165(4):441-­‐454.	  )	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Figure	  2.	  Interactions	  between	  cells	  in	  the	  BM	  microenvironment.	  Modified	  from	  Anderson	  et	  al.	  
45	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Figure	  3.	  Cross	  talk	  in	  MM	  plasma	  cells.	  Modified	  from	  Podar	  et	  al.	  44	  	  
	  
Recent	   evidences	   suggest	   the	   existence	   of	   a	   MM	   stem	   cell	   or	   MM	   propagating	   cell	   (MPC)	  
characterised	   by	   self-­‐renewal	   and	   proliferation	   properties	   46.	   The	   nature	   and	   phenotype	   of	   the	  
MPC	  has	  still	  to	  be	  fully	  elucidated,	  but	  plasma	  cells	  which	  are	  CD38high	  and	  CD45-­‐	  can	  replicate	  the	  
features	   of	  myeloma	   in	   SCID-­‐hu	  mouse	  models	   47,48.	   In	   the	   same	  mouse	  model	   the	  MPC	  were	  
CD138+	  and	  cells	  with	  this	  feature	  could	  transfer	  the	  disease	  49.	  In	  contrast	  to	  these	  findings	  some	  
studies	   have	   claimed	   that	   the	  MPC	   is	   CD138-­‐	   50,51,	   but	   this	   has	   not	   been	   confirmed	   52.	   In	   this	  
context	  more	  recent	  flow	  cytometry	  studies	  have	  suggested	  that	  there	  is	  equilibrium	  between	  the	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located	  53.	  It	  seems,	  therefore,	  that	  CD138+	  and	  CD138-­‐	  are	  not	  two	  separate	  entities,	  but	  rather	  
populations	  with	  a	  different	  phenotype	  that	  move	  from	  one	  state	  to	  the	  other	  53.	  
In	   the	   BM	  microenvironment	   reside	   also	   B	   ant	   T	   Lymphocytes,	   together	  with	   NK	   and	   dendritic	  
cells.	  The	  activity	  of	  all	  these	  cells	  is	  highly	  down	  regulated,	  creating	  an	  immune	  tolerance	  towards	  
the	  neoplastic	  cells	  that	  are	  therefore	  left	  free	  to	  proliferate.	  	  
The	   efficacy	   of	   the	   so	   called	   “novel	   drugs”	   (such	   as	   immunomodulatory	   drugs,	   IMiDs,	   and	  
proteasome	  inhibitors,	  PIs)	  is	  linked	  to	  their	  ability	  to	  act	  on	  the	  BM	  microenvironment,	  disrupting	  
the	  cross	  talk	  between	  the	  MM	  plasma	  cells	  and	  the	  BM	  milieu.	  	  
2.2	  ANGIOGENESIS	  
Blood	   vessel	   can	   be	   developed	   through	   two	   different	  mechanism:	   vasculogenesis	   (active	   in	   the	  
embryo),	  during	  which	  progenitor	  cells	  differentiate	   in	  endothelial	  cells	  and	  angiogenesis	   (active	  
both	  in	  embryo	  and	  in	  adults),	  where	  starting	  from	  blood	  vessels	  already	  present	  new	  capillaries	  
are	  generated.	  
Angiogenesis,	  as	  a	  source	  of	  oxygen	  and	  nutrients,	  is	  crucial	  in	  tumour	  development.	  Studies	  both	  
on	  animal	  models	  and	  on	  men	  have	  demonstrated	  the	  development	  of	  new	  blood	  vessels	   in	  the	  
early	  stages	  of	  tumour	  development,	  as	  well	  as	  in	  the	  late	  stages	  of	  metastatic	  dissemination	  54,55.	  	  
It	   has	   long	   been	   known	   that	   both	   solid	   and	   haematological	   tumours	   have	   a	   great	   angiogenic	  
potential,	  which	  correlates	  with	  their	  growth	  and	  dissemination.	  The	  observation	  that	  cancer	  can	  
develop	  both	  in	  tissues	  rich	  of	  blood	  vessels	  and	  in	  tissues	  with	  a	  low	  blood	  density,	  suggest	  that	  
tumour	  cells	  themselves,	  or	  the	  microenvironment	  in	  which	  they	  grow,	  are	  able	  to	  produce	  factors	  
that	  stimulates	  angiogenesis.	  	  
Angiogenesis	   is	   regulated	   by	   the	   equilibrium	   of	   pro	   and	   anti	   angiogenic	   molecules.	   When	   this	  
equilibrium	   is	   disrupted	   happen	   the	   so-­‐called	   angiogenic	   switch	   56.	   The	   decrease	   of	   inhibitors	  
concentration	   and	   activity,	   together	   with	   the	   increase	   in	   pro-­‐angiogenic	   factors	   can	   occur	   in	  
different	   situations,	   such	  as	  hypoxia	  of	   the	   tumour	  cells	   (due	   to	  an	   increase	  of	   the	   tumour	  bulk	  
without	  a	  corresponding	  increase	  in	  vessel	  density),	  oncogene	  activation	  (such	  as	  H-­‐RAS	  or	  V-­‐SRC)	  
or	  the	  inactivation	  of	  oncosuppressor	  genes.	  Furthermore	  macrophages	  (present	  in	  high	  quantity	  
in	   area	   poor	   of	   blood	   vessels)	   are	   able	   to	   release	   pro-­‐angiogenic	   factors,	   such	   as	   VEGF,	   FGF-­‐2,	  
TNFα	  and	  nitric	  oxide	  57,58.	  
During	   the	   development	   of	  MM,	   hypoxia	   and	   cellular	   stress	   are	   able	   to	   induce	   the	   angiogenic	  
switch,	  giving	  rise	  to	  the	  vascular	  phase	  or	  symptomatic	  MM.	  Many	  studies	  have	  shown	  that	  the	  
secretion	  of	  di	  VEGF	  by	  CD45-­‐	  plasma	  cells	   is	  crucial	   in	  this	  step	  59;	  VEGF	  is	  able	  to	  stimulate	  the	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chemotaxis	  and	  proliferation	  both	  of	  endothelial	  (through	  VEGFR2)	  and	  of	  stromal	  cells	  (through	  
VEGFR1).	   Other	   pro-­‐angiogenic	   factors	   that	   are	   increased	   in	  MM	   are	   FGF,	   HGF,	   IGF1,	   IGF-­‐BP3,	  
whilst	  an	  antagonist	  of	  VEGF,	  semaphorin	  3a,	  is	  reduced.	  This	  process	  contributes	  to	  the	  formation	  
of	   an	   intricate	   net	   of	   new	   blood	   vessels,	   which	   sustain	   the	   growth	   of	   the	   neoplastic	   clone.	   A	  
vicious	   circle	   is	   created	   in	   which	   plasma	   cells	   promote	   angiogenesis,	   whilst	   endothelial	   cells	  
produce	  VEGF,	  FGF2,	  MMP	  and	  chemokines	  that	  support	  the	  growth	  and	  migration	  of	  neoplastic	  
cells.	   The	   microvessel	   density	   (MVD)	   in	   the	   BM	   of	   MM	   patients	   is	   strictly	   linked	   to	   a	   higher	  
proliferation	   index	   of	   the	   PC	   (plasma	   cells	   labelling	   index:	   PCLI)	   and	   to	  more	   advanced	   disease	  
stages.	  	  
The	  persistence	  of	  angiogenesis	   in	   the	  BM	  of	  patients	   that	  have	  achieved	  a	   complete	   remission	  
has	   also	   been	   shown,	   probably	   linked	   to	   a	   persistent	   angiogenetic	   stimulus	   from	   a	   minimal	  
amount	  of	  residual	  disease.	  This	  persistent	  angiogenesis	  is	  able	  to	  increase	  the	  secretion	  of	  growth	  
factors	   important	  for	  the	  malignant	  clone,	  thus	  contributing	  to	  disease	  relapse.	  Furthermore	  the	  
aberrant	   vascularisation	   of	   the	   tumour	   can	   be	   an	   obstacle	   to	   an	   effective	   drug	   delivery	   in	   the	  
tumour.	  	  
The	   pivotal	   importance	   of	   angiogenesis	   in	   MM	   development	   has	   been	   confirmed	   also	   by	   the	  
success	  of	  IMiDs	  e	  PI,	  whose	  antitumor	  action	  involves	  an	  anti-­‐angiogenic	  effect.	  	  
2.3	  BONE	  DISEASE	  	  
Bone	  disease	  is	  the	  most	  frequent	  and	  serious	  manifestation	  of	  MM.	  During	  the	  disease	  course	  70-­‐
80%	  of	  the	  patients	  will	  develop	  bone	  lesions,	  frequently	  associated	  with	  bone	  pain	  and,	  in	  60%	  of	  
the	  cases,	  with	  pathological	  fractures.	  	  
The	  area	  most	  frequently	  involved	  are	  those	  rich	  in	  BM,	  such	  as	  the	  spine	  (49%),	  the	  skull	  (35%),	  
the	  hips	  (34%),	  the	  ribs	  (33%),	  the	  jaw	  and	  the	  long	  bones.	  
MM	   bone	   lesions	   are	   due	   to	   an	   increased	   bone	   resorbtion	   without	   a	   correspondent	   bone	  
neoformation	  in	  areas	  where	  plasma	  cells	  are	  infiltrated;	  these	  lesions	  are	  therefore	  lytic	   lesions	  
and	  do	  not	  repair	  over	  time,	  even	  if	  a	  complete	  remission	  is	  achieved.	  
Bone	  pain	  can	  seriously	  impair	  patients’	  quality	  of	  life;	  bone	  pain	  is	  usually	  greater	  in	  the	  spine	  and	  
is	  increased	  by	  movement,	  being	  different	  from	  metastatic	  carcinoma	  pain	  that	  is	  worse	  at	  night.	  
In	  these	  cases	  a	  correct	  pain	  therapy	  is	  mandatory,	  following	  the	  WHO	  recommendations;	  antalgic	  
radiotherapy	   and	   orthopaedic	   surgery	   (vertebra	   or	   kyphoplasty)	   can	   also	   be	   helpful	   in	   selected	  
cases.	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A	   more	   rare	   (15%),	   but	   also	   very	   serious	   complication	   of	   bone	   disease	   can	   be	   hypercalcemia.	  
Hypercalcemia	   is	  due	  to	  calcium	  mobilization	   from	  the	  bones	   into	  the	  blood	  stream,	  to	  reduced	  
bone	  mineralization	  and	  to	  renal	  impairment;	  a	  prompt	  recognition	  and	  treatment,	  with	  the	  use	  of	  
hydration	  and	  intravenous	  administration	  of	  bisphosphonates,	  is	  of	  uttermost	  importance.	  
2.3.1	  PATHOGENESIS	  OF	  BONE	  DISEASE	  
In	   physiologic	   condition	   there	   is	   a	   constant	   bone	   remodelling	   during	   life.	   Bone	   remodelling	   is	  
sustained	   both	   from	   mechanical	   solicitation	   (traction	   forces	   given	   by	   muscles,	   tendons	   and	  
ligaments)	  and	  from	  the	  metabolic	  calcium	  request,	  regulated	  by	  parathormon	  and	  vitamin	  D.	  
In	  order	   to	  have	  an	  optimal	   function	  of	   the	  skeletal	   tissue	   it	   is	  necessary	   that	  bone	  remodelling	  
works	   as	   a	   harmonic	   process	   (coupled	   bone	   remodelling):	   bone	   resorbtion	   from	   the	   osteoclast	  
must	  be	  balanced	  by	  a	  correspondent	  bone	  neoformation	  by	  the	  osteoblasts.	  
In	  MM	   patients	   bone	   remodelling	   is	   uncoupled,	   unbalanced	   in	   favour	   of	   bone	   resorbtion.	   The	  
decrease	   in	  bone	  mass	   is	  a	  consequence	  of	  the	  augmented	  osteoclasts	  (OC)	  activity	  and	  of	  their	  
longer	   survival,	   with	   a	   correspondent	   inhibition	   of	   osteoblast	   (OB)	   and	   decrease	   in	   bone	  
neoformation	  60,61.	  The	  increased	  OC	  activity	  is	  evident	  already	  in	  the	  earlier	  stages	  of	  the	  disease,	  
whilst	  the	  inhibition	  of	  OB	  activity	  is	  a	  later	  event.	  	  
Pathogenesis	  of	  OC	  stimulation	  
Since	   the	   beginning	   of	   the	   70s	   it	   has	   been	   hypothesised	   that	   the	   increased	   OC	   activity	   was	  
mediated	  by	   local	   factors	   (OAF)	  produced	  either	  by	   the	  plasma	  cells	   (PCs)	   themselves	  or	  by	   the	  
interaction	  of	  the	  PC	  and	  the	  BMSCs.	  In	  the	  last	  thirty	  years	  a	  number	  of	  cytokines,	  growth	  factors	  
and	   hormones	   that	   stimulates	   OC	   activity	   have	   been	   found.	   Among	   these	   factors	   the	   most	  
important	   are	   RANKL	   (receptor	   activator	   of	   NFkB	   ligand),	   MIP1α	   (macrophage	   inflammatory	  
protein	  1	  alfa),	   IL3,	  IL6,	  IL1β.	  PCs	  produce	  cytokines	  that	  increase	  OC	  differentiation,	  activity	  and	  
survival,	   whilst	   bone	   reabsorption	   induces	   the	   release	   of	   PCs	   growth	   factors,	   increasing	   the	  
tumour	  burden.	  This	  further	  stimulates	  bone	  reabsorption	  in	  a	  vicious	  circle	  62,63.	  
The	   RANK/RANKL	   pathway	   is	   highly	   important	   in	   bone	   remodelling	   both	   physiological	   and	  
pathological.	  RANK	  is	  a	  transmembrane	  receptor	  of	  the	  family	  of	  the	  tumour	  necrosis	  factors,	  and	  
it	  is	  expressed	  on	  OC	  precursors	  64.	  It’s	  ligand	  RANKL	  is	  expressed	  on	  OB	  precursors	  and	  BMSCs	  as	  
an	  extramembrane	  protein,	  and	  is	  secreted	  by	  T	  lymphocytes	  65.	  	  
Upon	  binding	  to	  RANKL,	  RANK	  is	  able	  to	  stimulate	  OC	  differentiation	  and	  proliferation,	   inhibiting	  
apoptosis	  through	  the	  NFkB	  pathway.	  Osteoprotegerin	  (OPG),	  a	  soluble	  receptor	  of	  RANKL,	  is	  able	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to	   inhibit	   this	  pathway,	   limiting	  osteoclastogenesis.	  OPG	   is	   synthesised	  by	  OB,	  BMSCs	  and	  other	  
cell	  types	  66,67.	  	  
The	  equilibrium	  between	  the	  synthesis	  of	  RANK	  and	  OPG	  is	  altered	  in	  MM	  patients,	  in	  which	  there	  
is	  an	  overproduction	  of	  RANKL	  and	  a	  decrease	  in	  OPG	  levels;	  these	  two	  aspects	  together	  stimulate	  
OC	  activity	  and	  bone	  reabsorption	  66,68.	  MM	  PCs	  are	  not	  able	  to	  produce	  RANKL,	  but	  are	  able	  to	  
induce	  RANKL	  production	  and	   to	   inhibit	  OPG	   synthesis	   in	  BMSCs	   69.	   Furthermore	   the	  neoplastic	  
PCs	  are	  able	  to	  internalise	  OPG	  through	  syndecan-­‐1,	  destroying	  it	  in	  the	  liposomial	  compartment	  
70.	  	  
Another	   important	   chemokine	   for	   osteoclastogenesis	   is	   MIP1α	   (Macrophage	   inflammatory	  
protein-­‐1α),	  produced	  by	  the	  neoplastic	  cells	  in	  70%	  of	  the	  patients.	  MIP1α	  supports	  the	  adhesion	  
between	  PCs	  and	  BMSCs,	  with	  a	  consequent	  increase	  in	  the	  production	  of	  RANKL,	  VEGF,	  IL6,	  TNFα,	  
and	  in	  MM	  cell	  growth,	  angiogenesis	  and	  bone	  disruption.	  Gene	  expression	  profiling	  (GEP)	  studies	  
have	   shown	   that	   the	   gene	   encoding	   for	   MIP1α	   is	   overexpressed	   in	   MM	   patients;	   furthermore	  
blood	   levels	  of	  MIP1α	  correlates	  with	   the	  extension	  of	  bone	   loss	  and	  patients’	   survival	   71.	  Some	  
studies	   have	   also	   shown	   a	   correlation	   between	   the	   levels	   of	   MIP1α	   and	   patients	   harbouring	  
t(4;14).	   In	   these	   patients	   FGFR3	   is	   constitutively	   activated,	   resulting	   into	   and	   overexpression	   of	  
MIP1	  α,	  a	  more	  serious	  bone	  disease	  and	  a	  worse	  prognosis	  72,73.	  	  
Higher	   levels	  of	   IL3	  where	  also	   seen	   in	  MM	  patients.	   IL3,	   in	   vitro,	   promotes	  osteoclastogenesis,	  
increases	   the	   action	   of	   RANKL	   and	   MIP1α,	   supports	   proliferation	   of	   MM	   PCs	   and	   inhibits	   OB	  
formation	  74.	  
IL6	   has	   a	   pivotal	   role	   both	   in	   supporting	   the	   tumour	   clone	   growth	   and	   in	   increasing	   OC	  
differentiation.	  Levels	  of	  IL6	  are	  higher	  in	  patients	  with	  bone	  lesions	  than	  in	  patients	  without	  any	  
skeletal	  involvement.	  Many	  studies	  have	  suggested	  that	  this	  cytokine	  is	  produced	  not	  only	  by	  MM	  
PCs,	  but	  also	  by	  BMSCs,	  OC	  and	  OB	  75.	  
Pathogenesis	  of	  osteoblast	  inhibition	  
The	  physical	  interaction	  between	  MM	  PCs	  and	  OB	  and	  the	  elevated	  levels	  of	  cytokines	  inhibit	  the	  
maturation	   of	   OB	   precursors	   and	   activate	   apoptotic	   mechanism	   within	   the	   OB	   76.	   The	  
development	   of	  OB	   from	  pluripotent	  mesenchymal	   cells	   involves	   the	   activation	   of	   Runx2/Cbfa1	  
and	  Osterix,	  a	  zinc-­‐finger	  transcription	  factor	  of	  the	  Runx2	  signal	  cascade	  77.	  When	  MM	  cells	  are	  
co-­‐cultured	  with	  OB	  progenitors,	  a	  significant	  decrease	  in	  OB	  differentiation	  can	  be	  seen,	  due	  to	  
an	   inhibition	   of	   Runx2/Cbfa1	   through	   cell-­‐cell	   interaction	   78.	   This	   also	   translates	   in	   a	   reduced	  
production	  of	  OPG,	  misbalancing	  the	  RANKL/OPG	  ratio	  in	  favour	  of	  osteoclastogenesis.	  OB	  of	  MM	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patients	   also	   show	   a	   different	  GEP	   compared	   to	   their	   normal	   counterparts,	  with	   an	   increase	   in	  
angiopoietin	  and	  IL1β	  and	  reduced	  expression	  of	  WNT.	  
The	   Wnt	   signalling	   pathway	   has	   a	   major	   role	   in	   OB	   maturation	   and	   differentiation.	   The	  
glycoprotein	  Wnt	   binds	  with	   the	   co-­‐receptors	   LRP5	  or	   LRP6	   and	   the	   complex	   than	  binds	   to	   the	  
frizzled	  receptor;	  the	  signal	  transduction	  phosphorylates	  βcatenin,	  which	  is	  able	  to	  migrate	  in	  the	  
nucleus	   where	   it	   up	   regulates	   target	   genes	   for	   OB	   differentiation.	   In	   MM	   patients	   soluble	  
inhibitors	   such	   as	   Dickkopf-­‐1	   (DKK1)	   and	   secreted	   frizzled	   related	   proteins	   (sFRP)	   block	   this	  
pathway.	  DKK1	  binds	  to	  LRP,	  blocking	  the	  interaction	  with	  Wnt,	  and	  it	  has	  been	  shown	  that	  there	  
is	  a	  correlation	  between	  the	  levels	  of	  DKK1	  and	  the	  number	  of	  bone	  lesions	  79-­‐81.	  
DKK1	   is	  also	  able	   to	   increase	  OC	  activity,	   inhibiting	   the	  non-­‐canonical	  pathway	  of	  Wnt,	   reducing	  
the	  synthesis	  of	  OPG	  and	  increasing	  the	  one	  of	  RANKL.	  	  
The	   sFRP	   act	   as	   soluble	   receptors	   of	  Wnt,	   binding	   it	   before	   it	   can	   reach	   the	   frizzled	  membrane	  
receptor;	   sFRP-­‐2	   can	   inhibit	  OB	  differentiation	   in	  mice,	  whilst	   its	   role	   in	  humans	   is	   less	   clear	   82.	  
Other	  factors	  that	  can	  reduce	  OB	  activity	  in	  MM	  patients	  are	  IL3	  and	  IL7.	  
A	   better	   understanding	   of	   the	   mechanism	   underlining	   skeletal	   involvement	   has	   been	   useful	   in	  
identifying	  new	  therapeutics	  targets:	  	  
v RANKL	  →	  Human	  monoclonal	  antibody	  anti	  RANKL	  (Denosumab),	  actually	  in	  phase	  I,	  II	  and	  
III	  clinical	  studies	  
v MIP1α	  →	   Antagonist	   of	  MIP1α	   receptor	   (CCR1)	   tested	   in	   vitro	   and	   in	   vivo	   in	   preclinical	  
models	  (MLN	  3897)	  
v DKK1	   →	   Many	   antibodies	   targeting	   DKK1	   have	   been	   developed;	   of	   these	   BHQ880	   is	  
currently	  undergoing	  phase	  I	  clinical	  studies.	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Figure	  4.	  Pathogenesis	  of	  bone	  disease.	  Modified	  form	  Terpos	  et	  al.	  2009	  83	  	  
2.4	  GENETIC,	  CYTOGENETICS	  AND	  MOLECULAR	  CHARACTERISTICS	  OF	  MYELOMA	  
AND	  THEIR	  IMPACT	  ON	  PROGNOSIS2	  
2.4.1.	  GENETIC	  BASIS	  OF	  MYELOMA	  
As	  already	  stated,	  MM	  can	  be	  considered	  as	  being	  initiated	  via	  a	  MPC	  46.	  Such	  a	  cell	  is	  thought	  to	  
be	  the	  founding	  unit	  of	  the	  MM	  clone,	  and	  harbours	  the	  biological	  features	  of	  both	  self-­‐renewal	  
and	   proliferation.	   In	   the	   classical	   view	  MM	  progression	  was	   thought	   to	   follow	   a	   linear	   pattern,	  
from	  the	  initiating	  stage	  of	  monoclonal	  gammopathy	  of	  undetermined	  significance	  (MGUS)	  to	  the	  
final	   stages	   of	   extramedullary	   disease	   and	   plasma	   cell	   leukaemia.	   In	   this	   model	   following	   its	  
initiation,	   the	  MPC	   acquires	   additional	   genetic	   hits	   that	   further	   deregulate	   its	   behaviour,	   giving	  
rise	  to	  the	  clinical	  and	  biological	  feature	  of	  symptomatic	  myeloma.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2	  Contains	  quotes	  from	  “Biology	  and	  Treatment	  of	  Myeloma”	  Brioli	  A.	  et	  al,	  Clinical	  Lymphoma,	  
Myeloma	  and	  Leukemia	  2014	  (84.	   Brioli	  A,	  Melchor	  L,	  Walker	  BA,	  Davies	  FE,	  Morgan	  GJ.	  Biology	  
and	  Treatment	  of	  Myeloma.	  Clinical	  lymphoma,	  myeloma	  &	  leukemia.	  2014;14S.)	  
MM PC stimulates 
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Two	  of	  the	  main	  pathways	  that	  are	  traditionally	  thought	  to	  initiate	  the	  transformation	  of	  a	  normal	  
plasma	   cell	   into	   a	   MPC	   are	   translocations	   into	   the	   IGH	   locus	   and	   hyperdiploidy	   40.	   These	   two	  
distinct	   lesions,	   both	   ultimately	   leading	   to	   the	   deregulation	   of	   Cyclin	   D	   genes	   40,	   are	   mutually	  
exclusive	   in	   the	   majority	   of	   patients	   and	   are	   not	   linked	   to	   any	   specific	   phenotype.	   As	   already	  
stated,	   molecular	   archaeology	   using	   IgH	   rearrangements	   suggests	   that	   the	   germinal	   centre	  
reaction	  drives	  the	  origin	  of	  the	  disease	  35,38-­‐41,	  however,	  recent	  evidence	  suggests	  that,	  at	  least	  in	  
a	  proportion	  of	  patient,	  the	  transformating	  event	  can	  be	  attributable	  at	  a	  proB	  cell	  stage	  41.	  In	  this	  
respect	   a	   recently	   published	   genome	  wide	   association	   (GWAS)	   study	   has	   identified	   risk	   loci	   for	  
MM	   at	   chromosome	   3p22.1,	   7p15.3	   and	   2p23.3	   accounting	   for	   4%	   of	   familial	   risk	   in	   MM,	  
suggesting	   that	   alterations	  of	   genes	  mapping	   in	   these	   regions	   (such	  as	  ULK4,	  DNAH11,	  CDCA7L,	  
DNMT3A	   and	  DTNB)	  might	  precede	   IgH	   translocation	   leading	   to	  an	   increased	   risk	  of	  developing	  
MM	  21.	  Furthermore	  it	  has	  been	  shown	  that	  memory	  B	  cells	  of	  MM	  patients	  show	  involvement	  of	  
genes	  known	  to	  be	  deregulated	  by	  IgH	  translocations,	  such	  as	  FGFR3,	  IGH-­‐MMSET	  and	  CCDN1,	  but	  
lack	  the	  presence	  of	  “later”	  genetic	  events	  like	  mutation	  in	  the	  RAS	  genes,	  once	  more	  advocating	  
that	   the	   transformating	   events	   can	   occur	   also	   at	   a	   precursor	   B	   cell	   stage,	   despite	   probably	   not	  
being	  sufficient	  to	  maintain	  the	  MM	  clone	  85.	  
2.4.2	  CYTOGENETIC	  ALTERATIONS	  IN	  MYELOMA	  
The	  study	  of	  molecular	  and	  genetic	  alterations	  has	  a	  pivotal	   role	   in	  understanding	  the	  biological	  
mechanism	  that	  form	  the	  basis	  of	  MM	  pathogenesis	  and	  progression,	  and	  can	  be	  useful	  in	  clinical	  
practice	  to	  stratify	  patients	  according	  to	  their	  prognosis.	  	  
MM	   cells	   have	   a	   low	   proliferative	   index	   (PCLI	   1-­‐2%)	   and	   this	   leads	   to	   a	   low	   applicability	   of	  
conventional	  karyotyping.	  With	  this	  technique	  about	  30-­‐50%	  of	  newly	  diagnosed	  MM	  are	  shown	  
to	   have	   cytogenetic	   abnormalities	   (CA)	   at	   diagnosis.	   Fluorescent	   in	   situ	   hybridization	   (FISH),	  
allowing	   the	   study	   of	   cells	   in	   interphase,	   is	   able	   to	   identify	   CA	   in	   about	   80-­‐90%	   of	  M	   patients,	  
irrespective	  of	  disease	  stage	  and	  phase	  86.	  
On	   the	  basis	   of	   the	  number	   and	   type	  of	   CA	   two	  major	   categories	   of	  MM	  have	  been	   identified:	  
hyperdiploid	  and	  non	  hyperdiploid	  MM	  87:	  	  
v A	  hyperdiploid	  karyotype	   is	  generally	  made	  of	  48-­‐75	  chromosomes	  with	  trisomies	  of	   the	  
odd	  number	  chromosomes,	  3,	  5,	  7,	  9,	  11,	  15,	  19,	  and	  21.	  Translocations	  occur	  rarely.	  It	  is	  
associated	  with	  a	  better	  prognosis	  and	  with	  a	  disease	  that	  is	  more	  BMSCs-­‐dependent.	  It	  is	  
found	  in	  40-­‐60%	  of	  patients.	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v A	   non-­‐hyperdiploid	   karyotype,	   frequently	   associated	   with	   translocations	   involving	  
chromosome	   14(q32)	   and	   monosomy	   or	   deletion	   of	   chromosome	   13(q14).	   It	   is	   found	  
usually	  in	  more	  aggressive	  and	  more	  diffuse	  diseases.	  
As	   in	  other	  hematologic	  neoplasia	  deriving	   from	  the	  post	  germinal	  centre,	   in	  MM	  translocations	  
involving	  the	  IgH	  locus	  on	  chromosome	  14	  or	  IGL	  kappa	  and	  lambda	  loci	  on	  chromosomes	  2	  and	  
22	   are	   very	   common.	   These	   CA	   are	   linked	   to	  mistakes	   in	   DNA	  modification	   that	   physiologically	  
happen	  when	   a	  B	   cells	   go	   through	   the	   germinal	   centre	   of	   lymph	  nodes.	   These	  mechanisms	   are	  
normally	  switched	  off	  in	  normal	  and	  neoplastic	  plasma	  cells,	  and	  are	  likely	  to	  represent	  one	  of	  the	  
founding	  events	  of	  the	  MM	  clone	  88.	  
These	  translocations	  normally	  result	  in	  an	  oncogene	  being	  controlled	  by	  the	  strong	  Ig	  enhancers,	  
with	   its	   consequent	   over	   expression.	   A	   number	   of	   IgH	   translocations	   are	   recurrent	   in	   40%	   of	  
patients.	  The	  genes	  more	  commonly	   involved	  are:	  Cyclin	  D1,	  D2,	  D3	  (on	  11q13,	  12p13,	  6p21),	  c-­‐
MAF	  (on	  16q23),	  MAF-­‐B	  (on	  21q12),	  MAF-­‐A	  (on	  8q24),	  MMSET	  e	  FGFR3	  (on	  4p16)	  87,88.	  
t(11;14),	   can	   be	   found	   in	   15%	   of	   patients,	   and	   it	   leads	   to	   an	   up-­‐regulation	   of	   Cyclin	   D1;	   it	   is	  
common	  in	  IgM	  MM	  and	  in	  AL	  amyloidosis.	  It	  is	  associated	  with	  a	  good	  prognosis	  after	  high	  dose	  
chemotherapy	  but	  with	  a	  short	  survival	  after	  relapse	  89.	  	  
t(14;16),	   is	   present	   in	   5-­‐7%	   of	   patients.	   It	   leads	   to	   an	   overexpression	   of	   MAF	   and	   it’s	   an	  
unfavourable	  prognostic	  factor	  90,91.	  
t(4;14),	   is	   detected	   in	   15%	   of	   patients,	   where	   it	   leads	   to	   an	   increased	   expression	   of	   MMSET	  
(through	   the	   formation	   of	   a	   fusion	   gene	   IgH-­‐MMSET	   on	   chromosome	   4)	   and	   fibroblast	   growth	  
factor	   receptor	  3	   (FGFR3).	  However,	   in	  25%	  of	   the	  patients,	   the	   loss	  of	  derivative	  14	   leads	   to	  a	  
correspondent	   loss	   of	   FGFR3.	   t(4;14)	   is	   associated	   with	   a	   dismal	   prognosis	   after	   conventional	  
chemotherapy	   and	   autologous	   stem	   cell	   transplantation,	   a	   short	   duration	   of	   remission	   and	   an	  
early	  relapse	  91-­‐93.	  GEP	  analysis	  showed	  that	  patients	  with	  t(4;14)	  have	  an	  over	  expression	  of	  67	  
genes	  (including	  RAS	  GRP1,	  CDH2)	  and	  a	  lower	  expression	  of	  60	  genes	  (including	  MAPK14,	  CASP2,	  
HDCA1,	  DEED)	  compared	  to	  patients	  negative	  for	  this	  translocation.	  This	  partly	  explains	  the	  worst	  
prognosis	  of	   t(4;14)	  patients,	  although	  the	  French	  group	  showed	  that	  patients	  with	  t(4;14),	  high	  
haemoglobin	  and	  low	  β2microglobuline	  have	  a	  relatively	  good	  prognosis	  94.	  	  
Deletion	  of	   chromosome	  13	   (either	  monosomy	  of	  chromosome	  13	  or	   loss	  of	  13(q14)),	   involving	  
the	  RB1	  gene,	  is	  seen	  in	  50%	  of	  patients;	  in	  90%	  of	  the	  cases	  it	  is	  associated	  with	  t(4;14),	  and	  it	  has	  
been	  shown	  that	   the	  poor	  prognosis	  of	  patients	  positive	   for	  del(13q)	   is	  mainly	   linked	   to	   the	  co-­‐
occurrence	  of	  other	  cytogenetic	  abnormalities	  95-­‐97.	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Aberrations	  of	  chromosome	  1	  (gain	  of	  chromosome	  1(q)	  or	  loss	  of	  chromosome	  1(p))	  have	  a	  high	  
prevalence	   in	   MM.	   The	   gain	   of	   1(q21)	   is	   associated	   with	   an	   increase	   in	   of	   plasma	   cells	  
proliferation,	  due	  to	  an	  overexpression	  of	  CKS1B	  98.	  Loss	  of	  1(p31-­‐32)	  was	  found	  to	  be	  associated	  
to	  a	  significantly	  shorter	  OS	  in	  patients	  treated	  with	  autologous	  stem	  cell	  transplantation	  99.	  
Deletion	   of	   chromosome	   17(p13)	   is	   found	   in	   less	   than	   5%	   of	   patients	   at	   diagnosis,	   but	   its	  
prevalence	  increases	  at	  the	  time	  of	  relapse.	  It	  is	  associated	  with	  the	  loss	  of	  the	  tumour	  suppressor	  
gene	  p53,	  and	  it	  is	  associated	  with	  a	  dismal	  prognosis.	  With	  the	  loss	  of	  the	  pro-­‐apoptotic	  activity	  
of	  p53	  the	  neoplastic	  clone	  becomes	  independent	  from	  the	  bone	  marrow	  microenvironment,	  with	  
the	  development	  of	  plasma	  cell	  leukaemia	  or	  extramedullary	  MM	  100.	  
The	   oncogene	   c-­‐MYC,	   is	   hyperexpressed	   in	   the	   advanced	   phases	   of	   the	   disease.	   It	   is	   also	  
associated	  with	  the	  independence	  of	  the	  neoplastic	  clone	  from	  the	  microenvironment	  and	  with	  a	  
higher	  proliferating	  capacity,	  conferring	  poor	  prognosis	  to	  the	  disease	  87,88,101.	  
The	   constitutive	   activation	   of	   the	   NFkB	   pathway	   can	   be	   due	   both	   to	   mutation	   inactivating	  
inhibitors	  of	  the	  pathway	  (TRAF3,	  TRAF2,	  CYLD)	  or	  to	  amplification	  leading	  to	  an	  overexpression	  of	  
activating	  proteins	   (NIK,	  CD40,	  TACI,	  LTBR).	  This	  alteration	   is	  gaining	  always	  more	   importance	   in	  
MM	   taking	   into	   account	   the	   increasing	   use	   in	   clinical	   practice	   of	   the	   proteasome	   inhibitors	  
bortezomib	  and	  carfilzomib.	  	  
Mutations	  activating	  the	  RAS	  pathway	  (N-­‐RAS,	  K-­‐RAS,	  BRAF)	  are	  usually	  associated	  to	  an	  increase	  
in	  the	  levels	  of	  Cyclin	  D1	  and	  are	  though	  to	  be	  early	  events	  associated	  in	  the	  shift	  from	  MGUS	  to	  
MM.	   	  




Figure	  5.	  Genetic	  alterations	  in	  MM	  
	  
Table	  6.	  Cytogenetic-­‐molecular	  classification	  proposed	  by	  the	  IMWG	  87:	  
Type	  of	  myeloma	  	   Percentage	   Clinical	  and	  laboratory	  characteristics	  
Hyperdiploidy	   45	   Favourable,	  older	  pts,	  IgG/k	  
Non-­‐hyperdiploidy	   40	   Aggressive,	  IgA/l,	  younger	  pts	  
Translocations	  Cyclin	  D	   18	   	  
t(11;14)	   16	   CCND1,	  good	  prognosis,	  bone	  lesions	  
t(6;14)	   2	   CCND1,	  good	  prognosis,	  bone	  lesions	  
t(12;14)	   <	  1	   Extremely	  rare	  
Translocation	  of	  MMSET	  t(4;14)	   15	  
Unfavourable	  prognosis	  with	  
conventional	  chemo	  
Translocations	  of	  MAF	   8	   Aggressive	  disease	  
t(14;16)	   5	   Aggressive	  disease	  
t(14;20)	   2	   Aggressive	  disease	  
t(8;14)	   1	   Aggressive	  disease	  
Not	  classified	   15	   Various	  subtypes	  
	  
2.4.3	  MYELOMAS	  AS	  A	  DISEASE	  OF	  G1/S	  PHASE,	  RAS,	  MYC,	  AND	  NFKB	  	  
The	   overexpression	   of	   a	   D-­‐group	   cyclin	   is	   an	   early	   molecular	   abnormality	   in	  MM,	   leading	   to	   a	  
deregulation	   of	   the	   G1/S	   transition.	   Overexpression	   of	   cyclines	   of	   the	   D-­‐group	   can	   occur	   via	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such	   as	  MAF	   102,	   FGFR3	   and	  MMSET	   40.	   It	   seems,	   however,	   that	   this	   genetic	   alteration	   alone	   is	  
insufficient	  to	  give	  rise	  to	  the	  clinical	  hallmarks	  of	  MM	  and	  additional	  events	  are	  needed	  to	  enable	  
the	  disease	  to	  progress	  103.	  Mutations	  in	  the	  form	  of	  single	  nucleotide	  variants,	  chromosomal	  copy	  
number	  abnormalities	  and	  epigenetic	  changes	  are	  responsible	  for	  disease	  progression	  46,104.	  Such	  
secondary	   “hits”	   drive	   disease	   progression	   activating	   key	   oncogenic	   pathways	   that	  may	   include	  
the	  RAS/MAPK	  pathway	  87,105,106,	  MYC	  107	  or	  the	  NFkB	  pathway	  105,108.	  	  
The	  prevalence	  of	  activating	  mutations	  in	  one	  of	  the	  RAS	  genes	  (NRAS	  or	  KRAS)	   is	  about	  50	  %	  in	  
presenting	  MM	  87,106,	  and	  is	  higher	  in	  tumours	  that	  express	  CCND1	  108.	  There	  is	  increasing	  evidence	  
that	  MM	  depends	  on	  the	  continued	  expression	  of	  activated	  RAS	  109;	  mutations	  in	  the	  NRAS	  gene	  
have	  been	  found	  also	  in	  monoclonal	  gammopathy	  of	  undetermined	  significance	  (MGUS)	  patients,	  
although	  at	  a	  significantly	  lower	  frequency	  (7%)	  110.	  Recently	  BRAF	  mutations	  in	  approximately	  4%	  
of	  MM	  patients	  have	  also	  been	  described	  105.	  It	  is	  evident,	  however,	  that,	  even	  though	  mutations	  
in	  the	  RAS	  pathway	  are	  a	  driver	  event	  in	  the	  progression	  of	  MM,	  they	  are	  not	  present	  in	  all	  MM	  
cells,	   and	   can	  be	   found	  only	   in	   a	  minor	   clone.	  NRAS	   and	  KRAS	  mutations	  have	   similar	   but	  non-­‐
identical	  effects	  and	  this	  is	  strengthened	  by	  the	  finding	  that	  both	  mutations	  can	  be	  present	  in	  the	  
same	   patient	   111.	   Whether	   the	   same	   cell	   harbours	   both	   the	   mutations,	   or	   they	   are	   present	   in	  
different	   clones,	   in	   a	   parallel	   evolution	   pattern,	   is	   a	   question	   that	   still	   needs	   to	   be	   answered,	  
although	  recent	  evidence	  suggest	   the	  possibility	  of	  parallel	  evolution	  being	  a	   feature	  of	  MM	  111.	  
Recent	  biotechnological	  advances	  and	  the	  possibility	  of	  single	  cell	  analysis	  might	  further	  elucidate	  
this	  important	  question.	  
The	  deregulation	  of	  MYC	   is	  a	   central	   feature	  of	  MM,	  as	   is	   shown	  by	   the	   fact	   that	  MM	  cell	   lines	  
depend	  on	  MYC	   for	   their	   survival	   112.	   The	  MYC	   gene	   is	   located	   in	   chromosome	  8p14	   locus,	   and	  
abnormalities	   involving	  this	  genome	  region	  are	  frequent	  in	  MM	  patients.	   In	  presenting	  myeloma	  
abnormalities	  of	  8q	  are	  generally	   reported	   in	  15%	  of	   cases,	  while	   rearrangements	  at	  8q24	  have	  
been	   reported	   in	   up	   to	   47%	   of	   myeloma	   patients	   overall	   113-­‐115.	  MYC	   is	   also	   activated	   in	   the	  
transition	  from	  MGUS	  to	  myeloma,	  implicating	  it	  in	  disease	  progression	  116.	  MYC	  rearrangements	  
result	  overexpression	  on	  MYC	  due	  to	  the	  co-­‐localization	  of	  active	  super-­‐enhancers	  in	  the	  partner	  
loci;	  frequently	  the	  partner	  chromosome	  genes	  (for	  example	  FAM46C,	  XBP1	  or	   IGL)	  has	  a	  known	  
function	  in	  myeloma	  or	  B	  cell	  biology	  101.	  
NFkB	   is	  a	   transcription	   factor	   that	  was	   found	   to	  be	   important	   in	   the	  development	  of	  MM.	  Both	  
MGUS	  and	  MM	  highly	  express	  genes	  known	   to	  be	   targets	  of	  NFkB;	   this	   could	  partly	  explain	   the	  
dependency	  of	  MM	  cells	  on	  the	  BM	  microenvironment	  and	  suggests	  a	  continued	  role	  of	  extrinsic	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signalling	   in	  MM	   117,118.	   BM	   stromal	   cells	   produce	  extrinsic	   ligands	   such	   as	  APRIL	   and	  BAFF	   that	  
stimulates	   TACI,	   BCMA	   and	   BAFF	   receptors,	   ultimately	   activating	   NFkB	   pathways	   and	   providing	  
critical	   survival	   signals	   to	   plasma	   cells	   119.	   The	   importance	   of	   the	   NFkB	   pathway	   is	   further	  
highlighted	  by	  the	  finding	  that	  both	  activating	  and	  inactivating	  mutations	  in	  positive	  and	  negative	  
regulators	  of	  the	  non-­‐canonical	  NFkB	  pathway	  (such	  as	  TRAF2,	  TRAF3,	  CYLD,	  cIAP1/cIAP2	  and	  NIK)	  
have	  been	  identified	  in	  20%	  of	  patients	  and	  in	  myeloma	  cell	  lines	  117,118;	  mutations	  in	  these	  genes	  
can	  activate	  the	  NFkB	  pathway	  without	  the	  presence	  of	  a	   ligand	  105	  and	  might	  contribute	  to	  the	  
spread	  of	  extramedullary	  disease	  108,	  as	  well	  as	  being	  related	  to	  response	  to	  treatment	  117,118.	  	  
Other	  lesions	  that	  have	  a	  greater	  predisposition	  to	  occur	  late	  in	  the	  natural	  history	  of	  the	  disease	  
are	  gain	  of	  chromosome	  1q,	  mutation	  at	  TP53	  or	  deletion	  of	  chromosome	  17p87,107,108,114,120,121.	  
2.4.4	  IMPORTANCE	  OF	  BIOLOGY	  IN	  THE	  PROGNOSTIC	  STRATIFICATION	  AND	  TREATMENT	  OF	  
MYELOMA	  
Many	   attempts	   have	   been	   made	   to	   use	   biology	   to	   stratify	   risk	   in	   MM.	   Myeloma	   genetic	   was	  
initially	   assessed	   with	   metaphase	   karyotyping,	   however,	   the	   procedure	   is	   long	   and	   frequently	  
infeasible	   in	   a	   terminally	   differentiated	   cell	   such	   as	   a	   plasma	   cell.	   FISH	   assessment	   has	  
progressively	   taken	   the	   place	   of	   conventional	   karyotyping,	   and	   is	   now	   the	  most	   used	   and	  wide	  
spread	  technique	  for	  assessing	  the	  biological	  risk	  in	  MM	  patients.	  Single	  nucleotide	  polymorphism	  
(SNPs)	   analysis	   can	   be	   used	   as	   well	   to	   perform	   a	  molecular	   karyotyping	   in	  MM,	   and	   has	   been	  
proved	  to	  be	  able	  to	  identify	  biological	  risk	  in	  MM	  122.	  The	  classical	  approach	  to	  define	  biological	  
risk	   in	   myeloma	   is	   to	   classify	   patients	   as	   having	   standard	   risk	   if	   they	   have	   no	   FISH	   lesion,	   the	  
presence	   of	   t(11;14)	   or	   t(6;14).	   Patients	   with	   hyperdiploidy	   alone	   are	   known	   to	   have	   a	   good	  
prognosis,	   whilst	   the	   presences	   of	   translocations	   like	   t(4;14)	   (associated	   with	   deregulation	   of	  
FGFR3	  and	  MMSET)	  or	  t(14;20)	  and	  t(14;16)	  (both	  deregulating	  MAF),	  have	  been	  associated	  with	  a	  
poor	   outcome.	   Similarly	   amplification	   of	   chromosome	   1q	   and	   deletion	   of	   the	   short	   arm	   of	  
chromosome	   17	   are	   known	   to	   be	   negative	   prognostic	   factors	   108,122,123.	   The	   deletion	   of	  
chromosome	   13,	   which	   was	   thought	   to	   be	   a	   poor	   prognostic	   feature,	   has	   largely	   lost	   its	  
significance	   when	   it	   was	   shown	   that	   the	   negative	   impact	   on	   survival	   was	   mainly	   due	   to	   the	  
frequent	  association	  with	  the	  t(4;14)	  89.	  It	  has	  recently	  been	  demonstrated	  that	  not	  only	  the	  type	  
of	  genetic	  lesion	  is	  important,	  but	  also	  the	  number	  of	  genetic	  lesions	  present	  in	  a	  single	  patient	  124,	  
with	  the	  survival	  of	  patients	  being	  progressively	  shorter	  according	  to	  the	  number	  of	  adverse	  FISH	  
lesion	  co-­‐segregating	  in	  a	  single	  patient	  (1,	  2,	  3,	  more	  than	  3).	  This	  finding	  led	  to	  the	  definition	  of	  
new	   risk	   stratification	  based	  on	   the	  number	  of	   co-­‐segregating	   adverse	   FISH	   lesions	   (none,	   1,	   or	  
	   28	  
more	   than	  1),	  with	  patients	  harbouring	  more	   than	  one	  adverse	  FISH	   lesion	  being	  categorized	  as	  
ultrahigh-­‐risk	  124.	  However,	  no	  consensus	  still	  exist	  regarding	  the	   impact	  that	  the	  presence	  of	  an	  
adverse	   FISH	   lesion	   can	   have	   in	   patient	   known	   to	   have	   a	   good	   prognostic	   feature	   such	   as	  
hyperdiploid:	  some	  groups	  reported	  that	  the	  presence	  of	  hyperdiploidy	  can	  abrogate	  the	  adverse	  
prognostic	   impact	   of	   a	   t(4;14)	   translocation	   125,	   whilst	   other	   have	   shown	   the	   opposite	   126,127.	  
Integrating	   genetic	   with	   biological	   information,	   such	   as	   ISS,	   further	   improves	   risk	   stratification	  
124,128.	  
More	  recent	  GEP	  profiling	  has	  also	  been	  used	  to	  classify	  genetic	  risk	  in	  myeloma.	  GEP	  can	  be	  used	  
to	  classify	  MM	  patient	  into	  7	  to	  10	  major	  categories,	  characterized	  not	  only	  by	  different	  signalling	  
signatures,	   but	   also	   by	   distinct	   prognostic	   impact	   129,130.	   Interestingly,	   one	   of	   the	   subgroup	  
identified	   (corresponding	   to	   about	   12%	   of	   patients)	   was	   characterized	   by	   a	   high	   expression	   of	  
genes	   involved	   in	   the	   NFkB	   pathway,	   remarking	   the	   importance	   of	   the	   NFkB	   pathway	   in	   the	  
pathogenesis	  and	  development	  of	  MM	  130.	  The	  utility	  of	  GEP-­‐based	  risk	  classification	   in	  MM	  has	  
been	   independently	   demonstrated	   by	   different	   groups,	  which	   have	   shown	  how	  GEP	   signatures,	  
comprising	  70,	  15	  or	  6	  genes,	  could	  be	  associated	  with	  different	  outcomes	  123,131-­‐133.	  
Despite	   improving	  our	  knowledge	   in	   the	  biology	  of	  MM	  and	  developing	   tools	  and	  algorithms	   to	  
better	   stratify	   the	   risk	  of	  MM	  patients,	  we	  have	  made	   significant	  progress	  with	   the	  outcome	  of	  
standard	  and	  high-­‐risk	  disease	  but	  have	  had	  little	  impact	  on	  the	  outcome	  of	  ultrahigh-­‐risk	  disease	  
134,135.	   Therefore,	   if	   we	   are	   to	   improve	   the	   outcome	   of	   ultrahigh-­‐risk	   disease	   we	   have	   to	  
understand	   its	   biology	   and	   use	   this	   knowledge	   to	   develop	   targeted	   treatment	   strategies.	   This	  
approach	   requires	   us	   to	   understand	   the	   “actionable	   mutation”	   spectrum	   of	   myeloma	   and	   the	  
agents	  able	  to	  modulate	  the	  activity	  of	  the	  mutated	  genes.	  
3.THE	  CONCEPT	  OF	  INTRA-­‐CLONAL	  HETEROGENEITY3	  
Cancer	  is	  initiated	  and	  then	  progresses	  through	  a	  complex	  mechanism	  based	  on	  the	  acquisition	  of	  
genetic	  “hits”	  that	  change	  the	  biology	  of	  the	  target	  cell	  from	  normal	  to	  malignant.	  The	  “hits”	  can	  
be	   broadly	   divided	   into	   “driver”	   lesions	   contributing	   to	   a	   selective	   advantage,	   and	   “passenger”	  
lesions	   that	   are	   neutral	   in	   their	   effect	   1,2.	   It	   is	   important	   to	   understand	   the	   complex	   genetic	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3	  Contains	  quotes	  from	  “Biology	  and	  Treatment	  of	  Myeloma”	  and	  from	  “The	  Impact	  of	  Intra-­‐Clonal	  
Heterogeneity	  on	  the	  Treatment	  of	  Multiple	  Myeloma”	  (43.	   Brioli	  A,	  Melchor	  L,	  Cavo	  M,	  
Morgan	  GJ.	  The	  impact	  of	  intra-­‐clonal	  heterogeneity	  on	  the	  treatment	  of	  multiple	  myeloma.	  
British	  journal	  of	  haematology.	  2014;165(4):441-­‐454,	  84.	   Brioli	  A,	  Melchor	  L,	  Walker	  BA,	  Davies	  
FE,	  Morgan	  GJ.	  Biology	  and	  Treatment	  of	  Myeloma.	  Clinical	  lymphoma,	  myeloma	  &	  leukemia.	  
2014;14S.)	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landscape	  of	  cancer	  not	  only	  because	   it	  can	   inform	  us	  on	  how	  individual	  genetic	   lesions	   interact	  
leading	   to	  disease	  progression,	  but	  also	  because	  of	   its	   impact	  on	   treatment	   3-­‐5.	   Studies	  both	  on	  
solid	  and	  haematological	   tumours	  have	  shown	  that	  cancer	  comprises	  a	  collection	  of	   related	  but	  
subtly	  different	  clones,	  a	  feature	  that	  has	  been	  termed	  “intra-­‐clonal	  heterogeneity”	  (see	  Table	  7)	  6-­‐
9.	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Table	  7.	  Intra-­‐clonal	  heterogeneity	  in	  cancer	  and	  MM	  
Author	   Disease	   N	  of	  
patients	  





21	   Presentation	   NGS	  (WGS)	   Prominent	  sub-­‐clonal	  diversification	  was	  identified	  
with	  a	  dominant	  sub-­‐clonal	  lineage	  found	  in	  every	  
tumour	  sample.	  Existence	  of	  long-­‐lived,	  quiescent	  
cell	  lineages	  capable	  of	  substantial	  proliferation	  upon	  
acquisition	  of	  enabling	  genomic	  changes	  is	  






4	   Relapse	   NGS	  (WES)	   Phylogenetic	  reconstruction	  revealed	  branched	  
evolutionary	  tumour	  growth.	  Mutational	  intra-­‐
tumour	  heterogeneity	  was	  seen	  for	  multiple	  genes	  
converging	  on	  loss	  of	  function,	  suggesting	  
convergent	  phenotypic	  evolution	  
Anderson,	  
2011	  8	  
ALL	   30	   Presentation	  
(Presentation/Relapse	  
in	  5	  cases)	  
FISH/CNA	   Enumeration	  of	  CNA	  in	  single-­‐cells	  identified	  
distinctive	  genetic	  signatures	  of	  sub-­‐clones	  and	  their	  
relative	  frequencies.	  The	  more	  common	  feature	  was	  
sub-­‐clonal	  heterogeneity	  (up	  to	  ten	  sub-­‐clones)	  
related	  via	  a	  branching	  tree	  
Ding,	  2012	  9	   AML	   8	   Presentation/Relapse	   NGS	  (WGS)	   AML	   relapses	  are	  characterized	  by	   two	  major	  clonal	  
evolution	   patterns:	   (1)	   the	   founding	   clone	   in	   the	  
primary	   tumour	   gained	   mutations	   and	   evolved	  
following	  a	   linear	  pathway,	  or	  (2)	  a	  sub-­‐clone	  of	  the	  
founding	   clone	   survived	   initial	   therapy,	   gained	  




MM	   28	   Presentation/relapse	   CGH	   Three	   major	   tumour	   types	   identifiable	   in	   MM	  
patients:	   (1)	   genetically	   stable,	   (2)	   linearly	   evolving,	  




MM	   22	   Presentation	   NGS	  (WES)	   Intra-­‐tumour	   heterogeneity	   identified	   by	   the	  
presence	  of	  clonal	  and	  sub-­‐clonal	  mutations	  (e.g.	  RAS	  
mutations).	   Intra-­‐clonal	   heterogeneity	   was	  
confirmed	  at	  a	  single-­‐cell	  level	  
Walker,	  
2013	  136	  
MM	   36	   Presentation	  
(SMM/presentation	  
MM	  in	  4	  cases)	  
NGS	  
(WES/WGS)	  
Intra-­‐clonal	   heterogeneity	   is	   present	   at	   all	   stages	  of	  
MM	   from	   the	  MGUS	   stage.	   Paired	   analysis	   of	   SMM	  
transformed	   to	   MM	   show	   that	   intra-­‐clonal	  
heterogeneity	  is	  a	  typical	  feature	  of	  MM.	  	  
Magrangeas,	  
2013	  137	  
MM	   24	   Presentation/Relapse	   SNP	  array	   A	  branching	  pattern	  of	  relapse	  is	  present	  in	  1/3	  of	  
MM	  patients.	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This	  intra-­‐clonal	  heterogeneity	  is	  likely,	  from	  a	  “Darwinian”	  natural	  selection	  perspective,	  to	  be	  the	  
essential	   substrate	   for	   cancer	   evolution,	   disease	   progression	   and	   relapse.	   These	   ideas	   derived	  
from	   evolutionary	   biology	   are	   teaching	   us	   that	   cancer	   progression	   is	   driven	   via	   branching	  
evolutionary	  patterns,	  rather	  than	  following	  a	  linear	  multistep	  process	  as	  was	  thought	  previously	  
4,6,10-­‐12.	   In	   this	   context	   the	   critical	   mechanism	   for	   tumour	   progression	   is	   competition	   between	  
individual	   clones	   for	   the	   same	   micro	   environmental	   “niche”,	   combined	   with	   the	   process	   of	  
adaptation	  and	  natural	  selection	  4,10.	  According	  to	  this	  hypothesis,	  following	  the	  immortalization	  of	  
a	   single	   cancer	   stem	   cell	   and	   based	   on	   the	   random	   acquisition	   of	   distinct	  mutations,	   different	  
cancer	   stem	   cell	   populations	   are	   generated,	   each	   with	   different	   genotypic	   and	   phenotypic	  
characteristics	  but	  all	  sharing	  the	  features	  of	  self-­‐renewal	  and	  proliferation.	  These	  different	  cancer	  
stem	  cells	  compete	  for	  access	  to	  limited	  resources,	  and	  the	  acquisition	  of	  “driver”	  mutations	  gives	  
them	   a	   survival	   advantage,	   leading	   to	   clonal	   dominance	   138.	   A	   metastatic	   site	   that	   is	   spatially	  
different	   from	   the	   original	   tumour	   could,	   therefore,	   be	   colonized	   by	   a	   cancer	   stem	   cell	   with	   a	  
unique	  set	  of	  features,	  further	  modifying	  disease	  evolution	  and	  increasing	  the	  genetic	  complexity	  
of	  the	  disease	  4,6.	  In	  addition	  to	  micro-­‐environmental	  pressure,	  therapy	  itself	  can	  act	  as	  a	  selective	  
bottleneck	  facilitating	  the	  death	  or	  survival	  of	  a	  different	  set	  of	  tumour	  clones;	  distinct	  clones	  will	  
therefore	   dominate	   at	   different	   time	   points	   of	   the	   natural	   history	   of	   conditions	   with	   a	  
relapsing/remitting	  behaviour,	  such	  as	  the	  indolent	  lymphoproliferative	  diseases	  11.	  This	  feature	  of	  
intra-­‐clonal	   heterogeneity	   also	   has	   a	   significant	   impact	   on	   how	   cancer	   therapy	   should	   be	  
delivered,	  and	  its	  therapeutic	  effects	  should	  now	  be	  considered	  in	  the	  context	  of	  the	  ideas	  implicit	  
in	  evolutionary	  biology.	  
3.1	  INTRA-­‐CLONAL	  HETEROGENEITY	  AND	  ITS	  IMPACT	  ON	  MYELOMA	  TREATMENT	  
Newer	   techniques,	   such	   as	   massive	   parallel	   sequencing,	   have	   significantly	   changed	   our	  
understanding	   of	   MM	   biology.	   It	   has	   become	   evident	   from	   recent	   studies	   that	   MM	   is	   not	  
composed	   of	   a	   single	   neoplastic	   clone,	   but	   is	   rather	   a	   collection	   of	   multiple	   sub-­‐clones	   that	  
compete	   for	   the	   same	   resources	   11,12,136.	   This	   knowledge	   has	   also	   changed	   our	   view	   on	   the	  
progression	  of	  MM	   from	  his	   premalignant	   condition	  of	  MGUS	   to	   the	   final	   stages	   of	   plasma	   cell	  
leukaemia	  and	  extramedullary	  myeloma.	  The	  progression	  of	  MM	  was	  historically	  thought	  to	  follow	  
a	  multistep	  linear	  process	  in	  which	  “genetic	  hits”	  are	  acquired	  in	  a	  sequential	  way	  deregulating	  the	  
behaviour	  of	  a	  normal	  plasma	  cell	  46,139.	  Next	  generation	  sequencing	  (NGS)	  techniques	  have	  shown	  
that	  mutations	   are	   not	   homogeneously	   distributed	   in	   all	  MM	  cells,	   but	   are	   present	   at	   different	  
frequencies	   within	   a	   tumour	   sample.	   This	   finding	   is	   consistent	   with	   intra-­‐clonal	   heterogeneity	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being	  a	  relevant	  feature	  of	  myeloma	  136.	  In	  this	  model	  disease	  progression	  is	  based	  on	  the	  random	  
acquisition	  of	  genetic	  hits	  followed	  by	  Darwinian	  selection	  of	  the	  fittest	  clone(s).	  On	  average	  3	  to	  6	  
different	   major	   sub-­‐clones	   can	   be	   detected	   at	   presentation	   in	   MM	   12,111,	   and	   serial	   genomic	  
analyses	  of	  samples	  collected	  at	  different	  points	  during	  disease	  progression	  have	  shown	  that	  MM	  
can	   progress	   via	   both	   linear	   and	   branching	   evolution	   11,137.	   However,	   clonal	   heterogeneity	   is	  
present	  since	  the	  earlier	  stages	  of	  MM	  development	  136,	  and,	  if	  3	  to	  6	  clones	  are	  already	  present	  
form	   when	   the	   disease	   becomes	   symptomatic,	   than	   the	   branching	   evolutionary	   patterns	  
represents	   the	   best	   unifying	   mechanism	   able	   to	   explain	   the	   biology	   and	   progression	   of	   the	  
disease.	  	  
A	  sample	   from	  a	  MM	  patient	  has	  on	  average	  35	  mutations	  105,	  a	  number	   intermediate	  between	  
that	   seen	   in	   acute	   lymphoblastic	   leukaemia	   (ALL)	   140,	   a	   less	   complex	   and	   more	   homogeneous	  
disease,	  and	  the	  hundreds	  of	  mutations	  reported	  to	  be	  present	   in	  solid	  cancers	  141.	   If	  Darwinian	  
evolution	   theory	   is	   to	   be	   applied	   at	   the	   biology	   and	   evolution	   of	   MM,	   the	   disease	   can	   be	  
considered	   as	   being	   derived	   from	   an	   initially	   immortalised	  MPC.	   As	   seen	   in	   other	   cancers,	   the	  
diversity	  of	  the	  MPC	  supports	  the	  evolution	  of	  the	  fittest	  clone,	  leading	  to	  disease	  progression	  142;	  
adaptation	  of	   the	  MPC	   to	  adverse	  conditions	   can	   further	   lead	   to	  drug	   resistance	  and	   treatment	  
failure	  143,144.	  If	  a	  MM	  sample	  is	  composed	  of	  different	  clones	  each	  of	  which	  has	  a	  different	  fitness	  
for	   different	   environments,	   then	   it	   is	   likely	   that	   sites	   of	   disease	   within	   a	   patient	   will	   evolve	  
independently,	   with	   mutation	   present	   in	   one	   site	   but	   not	   in	   another	   one,	   a	   process	   that	   will	  
ultimately	  lead	  to	  metastasis	  145,146.	  In	  Darwinian	  terms	  it	  is	  likely	  that	  different	  clones	  compete	  for	  
the	  same	  stem	  cell	  niche,	  and	  this	  is	  an	  important	  concept	  that	  has	  to	  be	  taken	  into	  account	  when	  
considering	  disease	  progression.	  Clonal	  dominance	  can	  change	  over	  time,	  and	  the	  different	  clonal	  
tides	  will	   lead	   to	   differential	   responses	   to	   treatment.	   It	   is	   therefore	   important	   to	   consider	   how	  
modification	  of	  treatment	  strategies	  can	  impact	  on	  how	  clones	  are	  selected	  and	  progress.	  	  
3.2	  HOW	  BIOLOGICAL	  KNOWLEDGE	  CAN	  CHANGE	  MYELOMA	  TREATMENT	  
Considering	  the	  rate	  at	  which	  evolution	  and	  disease	  progression	  is	  likely	  to	  happen,	  the	  genomes	  
of	  standard-­‐risk	  patients	  show	  fewer	  changes	  over	  time	  compared	  to	  high-­‐risk	  patients	  who	  have	  
significantly	  more	  variation	   11.	   Interestingly	  however,	   it	  has	  been	  shown	  that	   response	  rates	  are	  
the	  same	  in	  high-­‐	  and	  standard-­‐risk	  disease	  124,135,	  but,	  due	  to	  their	  biology,	  high-­‐risk	  patients	  have	  
a	  significantly	  shorter	  progression	  free	  survival	  (PFS)	  and	  overall	  survival	  (OS)	  135.	  This	  notion	  could	  
allow	   us	   to	   postulate	   a	   model	   in	   which	   treatment	   can	   be	   personalised	   after	   remission	   post-­‐
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induction	  has	  been	  achieved.	  The	  ability	  to	  distinguish	  indolent	  from	  more	  aggressive	  clones	  and	  
tailor	  therapy	  accordingly	  is	  therefore	  of	  primary	  importance	  in	  clinical	  practice	  going	  forward.	  
The	  introduction	  of	  novel	  agents	  into	  upfront	  therapy	  has	  dramatically	  improved	  the	  outcomes	  of	  
symptomatic	  MM	  134,147-­‐157.	  Modern	  treatment	  strategy	  of	  MM	  involves	  the	  concept	  of	  sequential	  
blocks	  of	  therapy	  given	  as	  an	  induction	  followed	  by	  consolidation	  and	  maintenance.	  The	  induction	  
phase	  aims	  at	  de-­‐bulking	  the	  disease,	  reducing	   it	  to	  the	  smallest	  amount	  possible.	  Consolidation	  
therapy	   further	   reduces	   tumour	   bulk,	   potentially	   eradicating	   some	   sub-­‐clonal	   populations.	  
Maintenance	  treatment	  is	  given	  to	  modify	  selective	  pressure	  and	  is	  aimed	  at	  keeping	  tumour	  cells	  
under	   control	   selecting	   for	   the	  most	   indolent	   clones	   and	   potentially	   leading	   to	   a	   cure.	   Even	   if	  
treatment	  approaches	  change	  according	  to	  patients’	  age	  and	  to	  their	  eligibility	  or	  not	  to	  receive	  
high	  dose	  treatment	  followed	  by	  autologous	  stem	  cell	  transplantation,	  the	  concept	  of	  disease	  de-­‐
bulk	   followed	   by	   a	   continuous	   treatment	   is	   becoming	   the	  mainstay	   of	  MM	   treatment	   protocol	  
irrespective	  of	  patients’	  age	  151,157-­‐161.	  
In	  the	   light	  of	  a	  Darwinian	  evolution	  theory	  applied	  to	  cancer	  and	  based	  on	  the	   ideas	   implicit	   in	  
terms	  of	  evolutionary	  biology,	  it	  is	  important	  to	  consider	  the	  composition	  of	  such	  treatments	  and	  
how	  they	  are	  delivered.	  The	  use	  of	  combination	  of	  agents	  with	  different	  modes	  of	  actions	  will	  kill	  
different	   cell	   population	   according	   to	   their	   susceptibility	   to	   the	   different	   drugs	   present	   in	   the	  
combination,	  maximising	  the	  chances	  of	  a	  cure.	  It	  is	  likely	  that	  the	  more	  proliferative	  clones	  will	  be	  
totally	  eradicated	  by	  such	  an	  approach.	  Maximising	  the	  de-­‐bulk	  of	  the	  disease	  in	  the	  initial	  phases	  
of	   treatment,	   revolving	   patients	   to	   a	   premalignant	   disease	   state,	   will	   translate	   into	   minimal	  
numbers	  of	  cells	  at	  risk	  of	  transformation,	  reducing	  the	  risk	  of	  an	  aggressive	  relapse.	  Alternating	  
chemotherapy	  with	  different	  modes	  of	  action	  will	  also	  lead	  to	  a	  cross	  kill	  of	  the	  different	  clones,	  
reducing	  the	  risk	  of	  developing	  treatment	  resistance.	  	  
However,	  if	  we	  really	  want	  to	  cure	  MM	  it	  is	  important	  to	  take	  advantage	  of	  what	  we	  know	  about	  
its	   biology.	   An	   important	   concept	   in	   the	   new	   treatment	   strategies	   for	   MM	   is	   the	   one	   of	  
maintenance	  treatment.	  The	  aim	  of	  a	  maintenance	  therapy	  is	  to	  modify	  residual	  disease	  biology,	  
selecting	  for	   less	  aggressive	  clones	  thus	  stabilising	  the	  disease.	  Maintenance	  acts	  as	  a	  Darwinian	  
selective	  pressure,	  adjusting	  pressure	   to	   select	   for	   indolent	  clones.	   It	   is	   important,	   therefore,	   to	  
use	   agents	   that	   affect	   the	   biology	   of	   the	   stem	   cell,	   such	   as	   the	   novel	   drugs	   that	   have	   the	  
characteristics	   of	   selecting	   for	   good	   performing	   clones.	   Maintenance	   treatment	   should	   be	  
continued	  until	  disease	  progression,	  to	  apply	  a	  constant	  selective	  pressure	  to	  residual	  clones.	  It	  is	  
also	   important	   to	   alternate	   the	   use	   of	   available	   agents	   to	   prevent	   emergence	   of	   treatment	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resistance,	   alternating	   the	   selective	   pressure	   on	   the	  MPC	   and	   to	   avoid	   using	   chemotherapeutic	  
agents	   that	   are	   known	   to	   have	   a	  mutagenic	   effect.	   In	   the	   future	   it	  might	   prove	   important	   the	  
ability	  of	  utilizing	   the	   immune	   system	   to	  augment	   the	  anti-­‐tumour	  activity	  of	  maintenance.	  The	  
immune	  system	  requires	  specific	  and	  balanced	  responses	  to	  clear	  pathogens	  and	  tumours	  and	  yet	  
maintain	   tolerance.	   In	   this	   respect	   the	   use	   of	   monoclonal	   antibodies,	   bi-­‐specific	   antibodies	   or	  
programmed	  death	  1	  (PD-­‐1)	  and	  its	  ligands,	  PD-­‐L1	  and	  PD-­‐L2,	  can	  be	  important.	  PD-­‐1,	  for	  instance	  
deliver	   inhibitory	   signals	   that	   regulate	   the	   balance	   between	   T	   cell	   activation,	   tolerance,	   and	  
immunopathology	  162.	  
Another	   important	   new	   concept	   in	   the	   treatment	   of	   MM	   is	   that	   of	   targeted	   treatment.	   Small	  
molecules	   that	   inhibit	   extrinsic	   NFkB	   signalling,	   such	   as	   inhibitors	   of	   TACI.Fc,	   IKKb	   and	   NIK	  
(MAP3K14)	   are	   being	   developed	   as	   potential	   therapeutic	   agents	   163,164.	   There	   is	   also	   some	  
evidence	  suggesting	  that	  some	  cells	  can	  be	  particularly	  sensitive	  to	  proteasome	  inhibitors,	  such	  as	  
those	  cells	  harbouring	  TRAF3	  mutation	  and	  that	  are	  addicted	  to	  constitutive	  NFkB	  activation	   for	  
their	  survival	  118.	  
As	   already	   stated	   mutations	   in	   the	   RAS	   pathway	   are	   present	   in	   50%	   of	   MM	   samples	   at	  
presentation,	  and	  even	  if	  no	  prognostic	  relevance	  for	  these	  mutations	  have	  been	  demonstrated,	  
specific	  inhibitors	  of	  this	  pathway	  might	  prove	  to	  be	  important	  in	  clinic.	  An	  example	  of	  this	  is	  the	  
BRAF	  mutation	  V600E	  that	  has	  been	  demonstrated	  in	  4%	  of	  MM	  patients	  and	  that	  has	  been	  shown	  
to	   be	   sensitive	   to	   the	   specific	   inhibitor	   Vemurafenib	   165.	   From	   all	   this	   it	   does	   not	   seem	  
unreasonable	   that	   in	   the	   future	   the	   strategy	   for	   MM	   treatment	   will	   comprise	   a	   mutational	  
screening	  and	  detection	  followed	  by	  targeted	  treatment.	  	  
It	  is	  also	  important,	  however,	  to	  consider	  the	  potential	  hazards	  of	  chemotherapy	  delivered	  with	  a	  
Darwinian	   approach.	   Treatment	   that	   modifies	   the	   immune	   system	   and	   the	   biology	   of	   the	  
microenvironment	   might	   have	   off-­‐target	   effects,	   such	   as	   an	   increased	   rate	   of	   second	   primary	  
malignancies	   (SPMs).	   In	   fact	   studies	   with	   maintenance	   lenalidomide	   reported	   an	   increased	  
incidence	   of	   developing	   SPMs	   in	   patients	   receiving	   the	   study	   drugs	   compared	   to	   patients	  
randomised	  to	  placebo	  151,159,161.	  Despite	  other	  trials	  didn’t	  confirm	  these	  results	  157,166,	  it	  is	  clear	  
that	  additional	   research	  on	   the	  biological	  mechanism	   that	  might	   trigger	   for	   the	  development	  of	  
SPMs	  is	  warranted	  before	  any	  definite	  conclusion	  can	  be	  drawn,	  whilst	  clinicians	  should	  carefully	  
inform	  patients	  regarding	  the	  potential	  risks	  and	  benefit	  of	  a	  maintenance	  treatment.	  Applying	  a	  
selective	  pressure	  could	  also	  select	  for	  more	  resistant	  clones,	  allowing	  the	  outgrowth	  of	  aggressive	  
clones	  and	  effectively	  decreasing	   survival	  post	   relapse.	   It	   is	  obvious	   that	   the	  negative	   impact	  of	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these	   off-­‐target	   effects	   needs	   to	   be	   balanced	   against	   the	   positive	   effect	   on	   long-­‐term	   disease	  
control	  and	  the	  potential	  for	  cure.	  
4.	  THERAPY	  
Treatment	  of	  MM	  formally	  began	  in	  the	  50s	  and	  60s,	  with	  the	  introduction	  in	  clinical	  practice	  of	  
alkylating	  agents	  (such	  as	  melphalan	  and	  cyclophosphamide),	  of	  nitrosurea,	  of	  the	  vinca	  alkaloids	  
(such	   as	   vincristine)	   and	   anthracyclins	   (such	   as	   doxorubicin)	   167.	   These	  drugs	  have	  proven	   to	  be	  
effective	  in	  MM	  when	  used	  as	  single	  agent,	  and	  it	  was	  later	  shown	  that	  their	  effect	  is	  increased	  by	  
the	  concomitant	  use	  of	  dexamethasone	  and	  the	  combination	  of	  melphalan	  and	  prednisone	  (MP)	  
was	   considered	   the	   standard	  of	   care	   for	  many	   years.	  With	   this	   combination	  50-­‐60%	  of	  patients	  
achieved	  a	  response,	  however	  only	  5-­‐10%	  achieved	  a	  complete	  remission	  (CR);	  median	  duration	  of	  
response	  was	  1-­‐2	  years,	  and	  only	  5-­‐10%	  of	  the	  patients	  became	  long	  term	  survivor	  168,169.	  	  
At	   the	   beginning	   of	   the	   80s	   the	   addition	   to	   the	   therapeutic	   armamentarium	   of	   high	   dose	  
melphalan	  followed	  by	  stem	  cell	  rescue	  opened	  a	  new	  way	  in	  the	  treatment	  of	  younger	  patients	  
170-­‐172,	   but	   it	   is	   in	   the	   last	   decade	   that	   a	   real	   “revolution”	   began	   in	   MM	   treatment,	   with	   the	  
introduction	   of	   the	   so	   called	   “novel	   agents”.	   These	   “novel	   agents”	   are	   non-­‐antiblastic	   drugs	  
showing	  a	  high	  activity	  against	  the	  plasma	  cell	  clone	  and	  its	  microenvironment.	  The	  crucial	  role	  of	  
the	  microenvironment	  in	  promoting	  the	  growth,	  progression	  and	  development	  of	  drug	  resistance	  
in	  the	  MM	  clone	  has	  already	  been	  discussed.	  These	  drugs	  were	  proven	  to	  be	  highly	  effective	  in	  the	  
treatment	  of	  advance	  relapsed/refractory	  MM,	  and	  were	  subsequently	  added	  to	  the	  treatment	  of	  
newly	  diagnosed	  patients,	  both	  transplant	  eligible	  (both	  as	   induction	  pre	  and	  consolidation	  after	  
transplantation)	   and	   transplant	   ineligible.	   The	   main	   “novel	   agents”	   that	   are	   currently	   used	   in	  
clinical	   practice	   are:	   the	   immunomodulatory	   drugs	   (IMiDs),	   Thalidomide	   and	   its	   analogues	  
(Lenalidomide	  and	  Pomalidomide)	  and	  proteasome	   inhibitors	   (PI),	  Bortezomib	   (Velcade)	  and	  the	  
second	  generation	  PI,	  such	  as	  Carfilzomib	  and	  Ixazomib.	  Other	  new	  drugs	  of	  different	  classes	  and	  
with	   different	   mechanisms	   of	   action	   are	   currently	   under	   evaluation	   in	   pre-­‐clinical	   and	   clinical	  
trials.	  This	  drugs,	  such	  as	  histone	  deacetilase	  inhibitors,	  kinesin	  spindle	  inhibitors,	  AKT	  inhibitors,	  
mTOR	  inhibitors	  and	  monoclonal	  antibodies	  are	  further	  expanding	  the	  treatment	  landscape.	  
Currently,	  to	  evaluate	  the	  efficacy	  of	  a	  treatment	  the	  2006	  Uniform	  Response	  Criteria	  of	  the	  IMW	  
are	  used	  (Table	  2)	  (109).	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Table	  8.	  Uniform	  Response	  Criteria	  IMWG	  2006,	  modified	  from	  Durie	  et	  al	  and	  Kyle	  et	  al	  14,173:	  
Complete	  response	  (CR)	  *	  
Negative	  serum	  and	  urine	  immunofixation,	  disappearance	  of	  soft	  tissue	  plasmocytoma	  and	  BMPC	  
<5%	  
Stringent	  complete	  response	  (sCR)	  
CR	  defined	   as	   above	   plus	   normal	   FLC	   ratio	   plus	   absence	   of	   clonal	   plasma	   cells	  by	   IHC	   or	   flow	  
cytometry	  (2-­‐4	  colours)	  
Near	  Complete	  Response	  (nCR)	  
No	  paraprotein	  at	  electrophoresis,	  but	  positive	  immunofixation.	  This	  response	  criteria	  is	  absent	  in	  
the	  IMWG	  classification	  
Very	  Good	  Partial	  Response	  (VGPR)	  *	  
Negative	  paraprotein	  in	  serum	  or	  urine	  but	  immunofixation	  positive	  or	  reduction	  in	  paraprotein	  of	  
≥	  90%	  for	  serum	  paraprotein	  and	  <	  100	  mg/24h	  for	  urine	  paraprotein	  
Partial	  Response	  (PR)	  
Decrease	  in	  serum	  paraprotein	  ≥	  50%	  and	  reduction	  in	  urine	  paraprotein	  ≥	  90%	  or	  <	  200	  mg/24h	  
If	   serum	   and	   urine	   paraprotein	   are	   not	   evaluable	   a	   reduction	  ≥50%	   in	   the	   difference	   between	  
involved	  and	  uninvolved	  FLC	  is	  required	  	  
If	  also	  FLC	  are	  not	  measurable	  a	  reduction	  ≥50%	  of	  BMPC	  is	  required	  (proven	  that	  at	  baseline	  the	  
percentage	  was	  ≥30%	  
If	  soft	  tissue	  plasmocytoma,	  decrease	  of	  ≥50%	  	  
Stable	  Disease	  (SD)	  
Not	  fulfilled	  criteria	  for	  CR,	  VGPR,	  PR	  or	  PD	  
Progressive	  disease	  (PD)	  †	  
Increase	  ≥25%	  from	  nadir	  of:	  
-­‐serum	  paraprotein	  (absolute	  increase	  must	  be	  ≥	  500	  mg/dl)	  and/or	  
-­‐urine	  paraprotein	  (absolute	  increase	  must	  be	  ≥	  200	  mg/24	  h)	  and/or	  
-­‐if	   paraprotein	   not	  measurable,	   difference	  between	   involved	   and	  uninvolved	   (absolute	   increase	  
must	  be	  >10	  mg/dL)	  
-­‐if	  also	  FLC	  are	  not	  measurable,	  percentage	  of	  BMPC	  (absolute	  increase	  must	  be	  ≥10%)	  
Appearance	  of	  new	  bone	  lesions	  or	  soft	  tissue	  plasmocytoma	  or	  increase	  of	  a	  pre-­‐existing	  lesions	  
Hypercalcemia	  (Corrected	  serum	  Ca2+	  >11.5	  mg/dL)	  only	  due	  to	  MM	  
Additional	  criteria	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Minimal	  response	  (MR)	  (EBMT	  classification)	  174	  
Decrease	  in	  serum	  paraprotein	  ≥	  25%	  but	  ≤49%	  and	  decrease	  in	  urine	  paraprotein	  of	  50%-­‐89%	  
If	  plasmocytoma,	  reduction	  of	  dimension	  of	  25%-­‐49%	  
Not	  increase	  in	  dimension	  and	  number	  of	  lytic	  bone	  lesions	  (an	  increase	  in	  a	  compression	  fracture	  
does	  not	  exclude	  the	  response)	  
All	   the	   responses	   categories	   require	   at	   least	   2	   consecutive	   measurements.	   Additional	   imaging	   is	   not	   required.	  
Sequential	   biopsies	   to	   confirm	   responses	   are	   not	   required.	   VGPR	   and	   CR	   requires	   both	   serum	   and	   urine	  
measurements,	   irrespective	  of	   the	   fact	   that	   the	  disease	   at	   baseline	  was	  measurable	  only	   in	   the	   serum,	  only	   in	   the	  
urine,	   in	   both	   or	   in	   none.	   For	   PD	   assessment	   an	   increase	   in	   serum	  paraprotein	   ≥	   1	   g/dL	   it	   is	   sufficient	   to	   define	   a	  
relapse	  if	  CM	  at	  baseline	  was	  ≥	  5	  g/dL.	  
BMPC:	  bone	  marrow	  plasma	  cells;	  FLC:	  free	  light	  chains;	  IHC:	  immunohistochemistry	  
*IMWG	  criteria	   for	  CR	  and	  VGPR	  when	  the	  disease	   is	  measurable	  only	  with	  serum	  FLC:	  CR	   is	  defined	  by	  a	  FLC	  ratio	  
between	  0.25-­‐1.65.	  VGPR	  requires	  a	  decrease	  in	  the	  difference	  between	  involved	  and	  uninvolved	  FLC	  ≥90%	  
†	  PD:	  BM	  criteria	  are	  to	  be	  used	  only	  in	  patients	  in	  whom	  the	  disease	  is	  not	  measurable	  with	  serum	  paraprotein,	  urine	  
paraprotein	  of	  FLC	  levels	  
EBMT:	  European	  Group	  for	  Blood	  and	  Marrow	  Transplantation	  
4.1	  THERAPY	  FOR	  NEWLY	  DIAGNOSED	  PATIENTS	  
Nowadays	   MM	   treatment	   is	   started	   only	   in	   the	   case	   of	   symptomatic	   MM,	   identified	   by	   the	  
presence	  of	  the	  CRAB	  criteria.	  Patients	  with	  SMM	  require,	  at	  present,	  only	  follow-­‐up.	  It	  has	  to	  be	  
noted,	  however,	  that	  recent	  evidences	  suggest	  a	  role	  of	  early	  treatment	  of	  SMM	  175,	  and	  that	  the	  
recent	   updated	   criteria	   for	   the	   diagnosis	   of	  MM	   identify	   as	   a	  MM	   that	   requires	   treatment	   also	  
those	   cases	   with	   a	   BMPC	   infiltration	   higher	   than	   60%,	   a	   FLC	   ratio	   higher	   than	   100	   and	   the	  
presence	  of	  more	  the	  one	  focal	  lesion	  at	  the	  MRI	  scan	  27.	  	  
The	  choice	  of	  the	  treatment	  for	  newly	  diagnosed	  MM	  has	  to	  be	  based	  on	  available	  evidences	  and	  
on	  patients’	  characteristics,	  such	  as	  age,	  performance	  status	  and	  comorbidities.	  	  
Generally	   patients	   younger	   than	   65	   years	   and	   without	   relevant	   comorbidities	   receive	   a	   short	  
induction	   therapy	   (usually	   3	   to	   4	   cycles)	   with	   “novel	   agents”	   (occasionally	   associated	   with	  
chemotherapy),	   followed	  by	   high	   dose	   chemotherapy	  with	  melphalan	   and	   autologous	   stem	   cell	  
rescue.	   A	   consolidation	   or	   maintenance	   treatment	   can	   be	   added	   to	   this	   therapeutic	   program.	  
Patients	  between	  the	  age	  of	  65	  and	  70	  can	  also	  receive	  an	  autologous	  transplantation,	  proven	  that	  
they	   are	   fit	   and	   with	   no	   relevant	   comorbidities.	   In	   these	   cases	   a	   reduced	   intensity	   of	  
chemotherapy	  is	  usually	  applied	  (melphalan	  100-­‐140	  mg/m2).	  The	  standard	  for	  patients	  older	  that	  
70	  or	  not	  transplant	  eligible	  is	  conventional	  chemotherapy	  associated	  with	  new	  drugs,	  even	  if	  new	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data	   are	   emerging	   regarding	   the	   possibility	   of	   treating	   these	   patients	   with	   chemotherapy	   free	  
regimens	  including	  only	  new	  drugs	  157.	  	  
4.1.1	  FIRST	  LINE	  TREATMENT	  FOR	  TRANSPLANT	  ELEGIBLE	  PATIENTS	  
High	  dose	  chemotherapy	  with	  autologous	  stem	  cell	  support	  (autologous	  transplantation,	  ASCT)	  is	  
one	  of	  the	  corner	  stone	  of	  MM	  treatment	  for	  patients	  ≤65	  years.	  It	  has	  a	  treatment	  mortality	  rate	  
of	  about	  1-­‐2%	  and	  is	  able	  to	  increase	  significantly	  the	  rates	  of	  CR	  (20-­‐30%)	  and	  the	  duration	  of	  PFS	  
and	  OS	  (median	  values	  4-­‐5	  years)	   171,172,176.	  High	  dose	  melphalan	  (HDM)	   is	  currently	  regarded	  as	  
the	  best	  conditioning	  treatment	  for	  ASCT	  (Melphalan	  200	  mg/m2;	  if	  the	  patient	  age	  is	  between	  65	  
and	  70	  years	  old,	  or	  in	  special	  situations	  a	  reduced	  dose	  of	  100-­‐140	  mg/m2	  can	  be	  used).	  
In	   order	   to	   increase	   the	   probability	   of	   attainment	   of	   a	   CR	   and	   to	   prolong	   PFS	   and	   OS,	   at	   the	  
beginning	  of	  the	  90s	  the	  administration	  of	  2	  sequential	  courses	  of	  HDM	  was	  introduced	  in	  clinical	  
practice	  (double	  ASCT)	  170,177.	  	  
In	  Table	  9	  the	  major	  randomised	  trials	  of	  conventional	  chemotherapy	  vs.	  ASCT	  and	  of	  double	  vs.	  
single	  ASCT	  are	  reported.	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Table	  9.	  Major	  studies	  on	  ASCT	  before	  the	  advent	  of	  new	  drugs.	  
Author	   Random	  	   N°	  pts	   ORR%	   CR%	   PFS	   OS	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Notes:	  pts	  patients,	  CCT	  conventional	  chemotherapy,	  ASCT	  autologous	  stem	  cell	  transplantation,	  ORR	  overall	  response	  rate,	  CR	  complete	  remission,	  
PFS	   progression	   free	   survival,	  OS	   overall	   survival,	   TT1	   total	   therapy	   I,	   IFM	   Intergroupe	   francophone	   du	  myèlome,	  MRC	  medical	   research	   council,	  
PETHEMA	  programma	  para	  el	  estudio	  y	  tratamiento	  de	  las	  hemopatìas	  malignas,	  SWOG	  South	  west	  oncology	  group,	  HOVON	  Hemato-­‐oncologie	  voor	  
volwassen	  nederland,	  BO	  Bologna,	  MAG	  Myèlome	  autogreffe,	  NA	  not	  assessed,	  NR	  not	  reached,	  NS	  not	  significant,	  nCR	  near	  CR.	  *:	  ≥	  nCR,	  y	  years,	  m	  
months	  
	  
Many	  studies	  have	   identified	  prognostic	   factors	  associated	  with	  a	   longer	  OS	   in	  patients	  receiving	  
ASCT,	  such	  as	  absence	  of	  cytogenetic	  abnormalities	  (deletion	  on	  chromosome	  13	  or	  hypodiploidy),	  
low	   levels	   of	   C	   reactive	   protein	   (CRP),	  non	   IgA	   isotype,	   ISS	   stage	   I-­‐II,	   low	   levels	   of	   plasma	   cells	  
infiltration	  at	  diagnosis	  (<30%)	  and	  achievement	  of	  a	  good	  response	  to	  induction	  treatment	  184-­‐191.	  
The	  quality	  of	  response	  after	  ASCT	  is	  also	  an	  important	  prognostic	  factor	  for	  an	  extended	  survival	  
187,188,192,193.	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As	  previously	  said,	  since	  2000	  the	  therapeutic	  armamentarium	  of	  MM	  has	  been	  increased	  by	  the	  
discovery	  of	  new	  molecules,	  such	  as	  Thalidomide,	  Lenalidomide	  and	  Bortezomib.	  These	  drugs	  have	  
been	  inserted	  in	  the	  treatment	  schema	  of	  young	  patients	  with	  MM,	  post	  as	  induction	  therapy	  pre	  
and	  as	  consolidation	  or	  maintenance	  therapy	  post	  ASCT,	  and	  have	  significantly	  increased	  the	  rate	  
of	  at	  least	  a	  VGPR	  and	  CR	  after	  the	  first	  ASCT	  (rate	  of	  VGPR	  between	  54	  and	  79%)	  147,149,160,194,	  thus	  
increasing	  PFS.	  At	  present	  however	  the	  benefit	  in	  terms	  of	  long	  term	  OS	  are	  still	  not	  known	  and	  a	  
longer	  follow	  up	  is	  needed	  187.	  	  
Thalidomide	  has	  been	  one	  of	  the	  first	  drugs	  studied	  in	  the	  context	  of	  ASCT	  due	  to	  the	  impressive	  
results	   obtained	   in	   the	   relapsed/refractory	   setting.	   The	   combination	   of	   Thalidomide	   and	  
Dexamethasone	   (TD)	   incorporated	   into	  double	  ASCT	   resulted	   in	  a	   very	  good	   rate	  of	  high	  quality	  
responses	  (CR/nCR	  14%	  after	   induction	  and	  36%	  after	  ASCT)	  and	  an	   improvement	   in	  PFS	  and	  OS	  
(median	  PFS	  48	  months,	  OS	  65%	  at	  5	  years)	  195.	  The	  major	  prognostic	  negative	  prognostic	  factors	  
were	  del(17p),	  t(4;14)	  and	  high	  levels	  of	  β2microglobulin.	  
The	   inclusion	   of	   thalidomide	   in	   an	   intensified	   chemotherapeutic	   program	   with	   an	   induction	  
followed	  by	  ASCT	  and	  consolidation	  chemotherapy	  (Total	  Therapy	  2:	  TT2)	  resulted	  in	  a	  rate	  of	  CR	  of	  
62%	  (235)	  and	  in	  a	  significantly	  extension	  of	  OS	  (even	  in	  patients	  with	  unfavourable	  prognosis	  due	  
to	   the	  presence	  of	   cytogenetic	  abnormalities)	   196;	   the	   estimated	  OS	   at	   10	   years	  was	  of	  50%	   197.	  
Thalidomide	  associated	  with	  cyclophosphamide	  and	  dexamethasone	  was	  superior	  to	  conventional	  
chemotherapy	  in	  terms	  of	  response	  rate	  both	  after	  induction	  and	  after	  ASCT	  134.	  
There	  is	  a	  large	  agreement	  of	  data	  on	  the	  superiority,	  in	  terms	  of	  rates	  of	  responses,	  offered	  by	  the	  
combination	   TD	   or	   thalidomide	   associated	   with	   conventional	   chemotherapy	   in	   comparison	   to	  
conventional	  chemotherapy	  such	  ad	  VAD	  or	  VAD-­‐like	  194,195,198,199.	  The	  insertion	  of	  thalidomide	  in	  
the	  context	  of	  ASCT	  resulted	  in	  an	  increase	  of	  PFS	  after	  ASCT;	  more	  controversy	  exists	  regarding	  a	  
possible	  improvement	  of	  OS.	  
Similarly	  to	  thalidomide,	  the	  efficacy	  of	  Bortezomib	  in	  relapsed/refractory	  patients	  paved	  the	  way	  
for	   its	   testing	   in	   first	   line	   treatment.	   Results	   from	   the	   studies	   so	   far	   available	   confirm	   the	   high	  
efficacy	  of	  bortezomib	  when	  administered	   in	  combination	  with	  other	  agents	   in	  newly	  diagnosed	  
MM	   patients.	   The	   combination	   of	   Bortezomib-­‐Dexamethasone	   (VD)	   was	   shown	   to	   be	   very	  
effective	   149,	   and	   association	   with	   chemotherapeutic	   drugs	   such	   has	   doxorubicin	   (PAD)	   or	  
cyclophosphamide	  (VCD),	  further	  incremented	  the	  possibility	  of	  achieving	  a	  good	  quality	  response	  
160,200-­‐202.	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One	   of	   the	   most	   interesting	   combinations	   is	   that	   of	   Bortezomib-­‐Thalidomide-­‐Dexamethasone	  
(VTD).	  The	  superiority	  of	  VTD	  was	  seen	  both	  in	  terms	  of	  response	  rate	  and	  of	  PFS;	  this	  three	  drug	  
combination	   was	   also	   able	   to	   improve	   the	   poor	   prognosis	   given	   by	   the	   presence	   of	   a	   t(4;14)	  
translocation	  147,203.	  To	  reduce	  bortezomib	  associated	  side	  effects	  (mainly	  peripheral	  neuropathy),	  
low	  doses	  of	  bortezomib	  and	   thalidomide	  associated	  with	  dexamethasone	   (vtD)	  have	  also	  been	  
tested,	  showing	  good	  rate	  of	  responses	  with	  a	  better	  toxicity	  profile	  204.	  The	  addition	  of	  a	  fourth	  
drug	   such	   as	   cyclophosphamide	   results	   in	   higher	   toxicity	   without	   a	   significant	   increase	   in	  
responses	  205.	  
In	  the	  Total	  Therapy	  approach	  bortezomib	  was	  added	  in	  the	  therapeutic	  protocol	  TT3,	  resulting	  in	  
an	  EFS	  and	  OS	  of	  71%	  and	  78%	  respectively,	  with	  a	  median	  follow	  up	  of	  39	  months.	  The	  addition	  of	  
bortezomib	  to	  a	  thalidomide	  containing	  approach	  (TT2	  thalidomide	  arm	  versus	  TT3)	  resulted	  in	  a	  
longer	  duration	  of	  CR	  (2-­‐year	  sustained	  CR	  TT3	  92%	  vs.	  81%	  TT2	  thalidomide	  arm)	  and	  in	  a	  trend	  
towards	  a	  longer	  OS	  in	  patients	  with	  a	  high-­‐risk	  disease	  (GEP	  high	  risk,	  t(4;14)	  positive)	  206.	  Despite	  
these	  encouraging	  results,	  with	  a	  median	  follow	  up	  of	  3.9	  years	  the	  survival	  post	  relapse	  (SPR)	  was	  
relatively	   short	   (14%	   at	   5	   years)	   due	   to	   a	   higher	   aggressiveness	   of	   the	   disease	   associated	  with	  
increased	  drug	  resistance	  197.	  	  
Even	   more	   promising	   than	   the	   VTD	   combination	   seem	   the	   association	   of	   Bortezomib,	  
Lenalidomide	  and	  Dexamethasone	  (VRD).	  The	  VRD	  combination	  seems	  to	  be	  well	  tolerated,	  with	  
an	  unprecedented	  response	  rate	  of	  100%,	  and	  a	  40%	  CR/nCR	  rate	  207.	  The	  same	  combination	  with	  
lower	   doses	   of	   dexamethasone	   (VRd)	   is	   now	   being	   tested.	   Similarly	   to	   what	   already	   seen	  with	  
thalidomide	  and	  bortezomib,	  several	  studies	  have	  also	  evaluated	  the	  addition	  of	  chemotherapy	  to	  
the	   VRD	   regimen.	   Both	   doxorubicin	   and	   cyclophosphamide	   have	   been	   used	   in	   association	  with	  
VRD,	  showing	  a	  good	  response	  rate	  208	  but	  at	  the	  price	  of	  an	  increased	  toxicity	  209.	  	  
The	   second	   generation	   PI	   Carfilzomib	   is	   also	   being	   tested	   in	   the	   first	   line	   treatment	   of	   MM	  
patients	   in	   association	   with	   Cyclophosphamide	   and	   IMiDs.	   The	   combination	   of	   Carfilzomib-­‐
thalidomide-­‐dexamethasone	  (CarTaDex)	  resulted	  in	  an	  ORR	  of	  91%	  (CR+VGPR	  of	  18%	  and	  60%	  pre	  
and	   post	   ASCT,	   respectively)	   210.	   The	   association	   of	   carfilzomib	   with	   lenalidomide	   and	  
dexamethasone	  achieved	  a	  rate	  of	  nCR	  of	  38%	  after	  4	  cycles	  211.	  	  
The	  unprecedented	  results	  seen	  with	  the	  use	  of	  new	  drugs	  have	  raised	  the	  question	  whether	  HDM	  
and	   ASCT	   is	   still	   needed	   in	   the	   treatment	   of	   young	   patients	   with	   MM.	   A	   chemotherapeutic	  
regimen	   with	   Melphalan,	   Prednisone	   and	   Lenalidomide	   (MPR)	   has	   been	   compared	   to	   HDM	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followed	  by	  ASCT,	  showing	  an	  advantage	  of	  the	  ASCT	  arm	  both	  in	  terms	  of	  PFS	  (43	  vs.	  22	  months,	  
p<0.001)	  and	  of	  OS	  (82%	  vs.	  65%	  at	  4	  years,	  p=0.02)	  212.	  
Therapy	  after	  ASCT	  
Treatment	   strategy	   after	   ASCT	   is	   at	   present	   a	   matter	   of	   debate.	   Patients	   can	   be	   offered	   a	  
consolidation	  treatment,	  a	  maintenance	  approach	  or	  both,	  with	  the	  aim	  of	   increasing	  responses	  
and	  improving	  PFS	  and	  OS.	  Consolidation	  is	  normally	  a	  highly	  effective	  regimen	  given	  for	  a	  short	  
period	  of	  time.	  A	  second	  ASCT	  can	  also	  be	  considered	  a	  consolidation	  strategy,	  and	  it	  is	  of	  higher	  
benefit	   in	   those	  patients	   that	  have	  not	   achieved	  a	  CR	  or	  VGPR	  after	   the	   first	  ASCT.	  By	   contrast	  
maintenance	  treatment	  consists	  of	  low	  dose	  drugs	  given	  fro	  a	  prolonged	  period	  of	  time,	  with	  the	  
aim	  of	  maintaining	  the	  response	  achieved.	  	  
Thalidomide	  was	   the	   first	  of	   the	  new	  drugs	  used	  as	  a	  consolidation	  or	  maintenance	   therapy.	  All	  
studies	   showed	   a	   benefit	   in	   terms	   of	   PFS,	   whilst	   an	   improvement	   on	   OS	   was	   seldom	   reported	  
158,197,199,213,214.	  The	  benefit	  of	  thalidomide	  in	  terms	  of	  OS	  seems	  to	  be	  abrogated	  by	  the	  use	  of	  the	  
same	  drug	  in	  the	  induction	  regimen	  158,199,215;	  furthermore	  caution	  is	  warranted	  due	  to	  the	  possible	  
emergence	   of	   resistant	   clones	   and	   an	   unfavourable	   outcome	   seen	   in	   patients	   with	   high	   risk	  
cytogenetic	   126,158.	  The	  unfavourable	   toxicity	  profile	   (mainly	  peripheral	  neuropathy)	   further	   limits	  
the	  use	  of	  thalidomide	  in	  the	  maintenance	  setting	  216.	  
Bortezomib	  has	  been	  inserted	  in	  consolidation	  and	  maintenance	  regimen	  (usually	  with	  as	  part	  of	  a	  
2	   or	   3	   drugs	   combination),	   administered	   for	   2	   to	   3	   cycles	   after	   ASCT	   160,203,217,218.	   Bortezomib	  
consolidation	   was	   also	   compared	   to	   observation,	   showing	   an	   improvement	   in	   responses	   for	  
patients	  receiving	  treatment	  (51%	  vs.	  32%,	  p=0.007)	  and	  a	  significative	  advantage	  in	  terms	  of	  PFS	  
(median	   27	   vs.	   20	   months	   for	   treated	   and	   observation	   patients	   respectively,	   p	   =0.05)	   219.	   A	  
consolidation	   treatment	  with	   the	   combination	  VTD	  was	   also	   shown	   to	   significantly	   improve	   the	  
outcome	   (in	   terms	   of	   %	   of	   CR+VGPR	   and	   of	   PFS)	   of	   patients	   receiving	   bortezomib	   217,218.	   A	  
consolidation	   treatment	   with	   VTD	   has	   also	   a	   role	   in	   inducing	   molecular	   remission	   220,221.	   By	  
contrast	   data	  on	  bortezomib	  maintenance	   are	   currently	   limited	   and	  not	   conclusive,	   and	   further	  
trials	  are	  needed	  to	  better	  address	  the	  role	  of	  bortezomib	  in	  this	  setting	  160,203,216.	  
Lenalidomide	   seems	   to	   be	   the	   perfect	   drug	   for	   a	   maintenance	   treatment	   due	   to	   its	   oral	  
administration	  and	  its	  favourable	  toxicity	  profile.	  Many	  trials	  are	  ongoing	  to	  better	  define	  the	  role	  
of	   lenalidomide	   as	   a	   long-­‐term	   treatment.	   Patients	   receiving	   lenalidomide	   maintenance	   (10-­‐15	  
mg)	  after	  ASCT	  had	  a	  significantly	   longer	  PFS,	  with	  one	  trial	  also	  showing	  a	  significant	  benefit	   in	  
terms	  of	  OS	  159,161,212.	  Despite	  these	  encouraging	  results	  concerns	  have	  been	  raised	  regarding	  the	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possibility	  that	  a	   long-­‐term	  treatment	  with	   lenalidomide	  after	  melphalan	  therapy	  might	   increase	  
the	   risk	   of	   developing	   second	   primary	  malignancies	   159,161,222.	   A	   longer	   follow	   up	   together	   with	  
studies	   designed	   to	   address	   the	   biological	   reasons	   for	   this	   increased	   risks	   are	   needed	   to	   better	  
understand	  the	  exact	  role	  and	  timing	  of	  lenalidomide	  as	  a	  maintenance	  treatment	  216.	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Table	  10.	  Studies	  with	  new	  drugs	  in	  newly	  diagnosed	  MM	  patients	  receiving	  ASCT	  
THALIDOMIDE	  PRE-­‐ASCT	  
Author	   Random	  	   DVT	  
(%)	  
N°	  pts	   ≥	  VGRP	  (%)	  
preASCT	  
≥	  VGPR	  (%)	  
postASCT	  
Rajkumar	  198	   ®TDvsD	   17	   200	   63vs41	  (≥PR)	   n.r.	  
Cavo	  194	   TDvsVAD	   13	   270	   30vs15	   68vs49	  
Morgan	  134	   ®CTDvsC-­‐VAD	   n.r.	   1111	   85vs71	   90vs92	  
Lokhorst	  199	   ®TADvsVAD	   10	   402	   32vs15	   49vs32	  
THALIDOMIDE	  MAINTENANCE	  
Author	   Therapy	   N°	  pts	   PFS	   OS	  
Morgan	  158	   ®Induction	   (CVAD	   o	   CTD	  
+	  ASCT	  vs.	  MP	  o	  CTDa)	  +	  
®maint	  Thal	  vs.	  no	  maint	  
818	   (induction	  
in	  1970)	  
23%	  vs.	  15%	   n.s.	  
LENALIDOMIDE	  PRE-­‐ASCT	  









VRD	  phase	  II	  	  207	  
35	   100	   74	   57	   NR	  


















PFS	  22.4	  m	  
OS	  81.6%,	  
PFS	  43	  m	  















OS	  88%	  PFS	  
41.9	  m	  
OS	  79%	  PFS	  
21.6	  m	  
LENALIDOMIDE	  MAINTENANCE	  
Author	   N°	  pts	   PFS	   OS	  
McCarthy	  159	  
Lenalidomide	  vs.	  placebo	  





OS	  at	  3	  y	  	  
88	  %vs.	  80%	  
	  Attal	  161	  
Lenalidomide	  vs.	  placebo	  	  
	  




OS	  at	  4	  y	  	  
73%	  vs.	  75%	  
BORTEZOMIB	  PRE-­‐ASCT	  AND/OR	  CONSOLIDATION	  
Author	   Therapy	   N°	  pts	   ≥	  VGPR	  
(%)	  
preASCT	  
≥	  VGPR	  (%)	  	  
postASCT	  
PFS	  
Harousseau	  149	   ®	  VD	  vs.	  VAD	   482	   38	  vs.	  15	   54	  vs.	  37	   36	  m	  vs.	  27	  
	   45	  
m	  
Sonneveld	  160	   ®	  induction	  PAD	  +	  maint	  
VEL	  vs.	  induction	  VAD	  +	  
maint	  Thal	  
626	   n.r.	   75	  vs.	  61	   46%	  vs.	  42%	  
at	  3	  y	  
Cavo	  147	   ®	  VTD	  vs.	  TD	  induction	  
and	  consolid	  
480	   62	  vs.	  28	   82	  vs.	  64	   68%	  vs.	  56%	  
at	  3	  y	  




82%	  at	  2	  y	  
(OS)	  
Moreau	  204	   ®	  VD	  vs.	  vtD	   199	   49	  vs.	  39	   74	  vs.	  58	   30	  m	  vs.	  26	  
m	  
Leleu	  218	   VTd-­‐ASCT	  +	  consolid	  VTd	  
vs.	  VTd-­‐ASCT	  
217	   After	  treatment:	  83	  vs.	  
64	  
TTP:	  62%	  vs.	  
29%	  at	  4	  y	  
CARFILZOMIB	  
Author	   Therapy	   N°	  pts	   PN	  gr	  1-­‐
2	  (%)	  
ORR	  (%)	   DOR	  
Jakubowiak	  211	   CRd	  	   53	   24	   100%	  (≥	  
VGPR)	  
n.r.	  
Sonneveld	  210	   CARTHADEX	   20	   35	   68%	  (≥	  
VGPR)	  
n.r.	  
Notes:	   RP	   partial	   response,	   VGPR	   very	   good	   partial	   response,	   TTP	   time	   to	   progression,	   PFS	   progression	   free	   survival,	   n.r.	   not	   reported	   Thal	  
thalidomide,	   Dex	   dexamethasone,	   pts	   patients,	   TD	   thalidomide	   dexamethasone,	   VAD	   vincristine	   adriamycin	   dexamethasone,	   CTD	   thalidomide	  
cyclophosphamide	  dexamethasone,	  TAD	  thalidomide	  adriamycin	  dexamethasone,	  CARTHADEX	  Carfilzomib-­‐Thalidomide-­‐Dexamethasone,	  DVT	  deep	  
vein	   thrombosis,	   MP	   melphalan	   prednisone,	    	   randomisation,	   y	   years,	   m	   months,	   ASCT	   autologous	   transplantation.	   *no	   prophylaxis,	   consolid	  
consolidation,	  mant	  maintenance	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4.1.2	  FIRST	  LINE	  TREATMENT	  IN	  PATIENTS	  NOT	  SUITABLE	  FOR	  ASCT	  
Many	   options	   are	   nowadays	   available	   for	   elderly	   patients	   not	   suitable	   for	   ASCT.	   In	   patients	  
younger	  than	  85	  years,	  when	  possible,	  experimental	  protocols	  are	  preferred.	  If	  that	  is	  not	  possible	  
the	  preferred	  treatment	  should	  include	  a	  Pi	  or	  an	  IMiDs,	  in	  association	  or	  combined	  with	  steroids	  
and	   low	  dose	  chemotherapy.	   In	   very	  old	  patients	   (>85	  years),	  or	   in	  particularly	   fragile	  and	  unfit	  
patients,	   the	   old	   schema	   MP	   (Melphalan	   +	   Prednisone)	   or	   alternatively	   Dexamethasone	   are	  
usually	  used,	  in	  association	  with	  new	  drugs	  if	  the	  performance	  status	  is	  acceptable.	  	  
Melphalan-­‐prednisone	  (MP)	  has	  for	  many	  years	  been	  the	  standard	  of	  care	  in	  elderly	  patients,	  and	  
is	  still	  used	  as	  a	  backbone	  for	  combination	  therapy	  in	  this	  category.	  The	  ORR	  with	  MP	  is	  of	  about	  
53%,	  with	  only	  5%	  of	  cases	  achieving	  a	  CR,	  the	  PFS	  is	  18	  months	  and	  OS	  is	  36.5	  months	  168,169.	  	  
The	  first	  drug	  to	  be	  added	  to	  the	  classic	  MP	  schema	  was	  Thalidomide,	  at	  doses	  ranging	  from	  100	  
mg	  to	  400mg).	  Some	  studies	  showed	  no	  significant	  improvement	  in	  ORR	  for	  MPT	  compared	  to	  MP,	  
but	  a	  better	  PFS	  and	  OS	  223,224.	  Conversely	  other	  groups	  found	  a	  better	  ORR	  and	  a	  higher	  PFS,	  but	  
no	   differences	   in	   OS	   225,226.	   A	   meta-­‐analysis	   of	   six	   randomised	   trials	   comparing	   MP	   vs.	   MPT	  
demonstrated	  that	  the	  addition	  of	  Thalidomide	  the	  MP	  significantly	  increases	  PFS	  and	  OS	  of	  about	  
20%,	  thus	  showing	  a	  superiority	  of	  MPT	  compared	  to	  MP	  227.	  	  
Lenalidomide,	   in	   association	   with	   dexamethasone	   was	   founds	   superior	   to	   high	   dose	  
dexamethasone	  both	  in	  terms	  of	  a	  higher	  response	  rate	  (ORR	  of	  78%	  with	  63%	  ≥	  VGPR)	  and	  of	  a	  
longer	  PFS	  228.	  Lenalidomide	  with	  high	  dose	  Dexamethasone	  (LD)	  was	  compared	  to	  Lenalidomide	  
with	   low	   dose	   dexamethasone	   (Ld)	   showing	   higher	   response	   rate	   for	   patients	   receiving	   higher	  
doses	   of	   dexamethasone,	   but	   a	   better	   OS	   for	   patients	   treated	   with	   Ld	   due	   to	   an	   increased	  
mortality	  in	  patients	  receiving	  LD	  148.	  Results	  from	  this	  study	  made	  Ld	  as	  the	  treatment	  of	  choice	  
both	  for	  young	  and	  older	  patients.	  Continuous	  treatment	  with	  Ld	  was	  found	  to	  be	  superior	  to	  Ld	  
for	  18	  cycles	  and	  to	  MPT,	  significantly	  reducing	  the	  risk	  of	  death	  (HR=0.78;	  p=0.02)	  157.	  For	  the	  first	  
time	  a	  regimen	  not	  containing	  any	  chemotherapeutic	  agent	  was	  identified	  as	  one	  of	  the	  standard	  
of	   care	   for	   the	   treatment	   of	   MM	   patients.	   Similarly	   to	   thalidomide,	   lenalidomide	   was	   also	  
associated	  with	  MP,	  with	   (MPR-­‐R)	  or	  without	   (MPR)	   lenalidomide	  maintenance.	   The	  association	  
MPR	  was	  not	  superior	  to	  MP	  in	  terms	  of	  PFS	  (14	  months,	  HR:	  0.49,	  <0.001	  vs.	  13	  months,	  HR:	  0.40,	  
p<0.001),	  but	  the	  addition	  of	  lenalidomide	  maintenance	  significantly	  improved	  the	  outcomes	  (PFS	  
31	  months)	  151.	  Further	  studies	  with	  lenalidomide	  in	  elderly	  patients	  are	  summarised	  in	  table	  11.	  
Similarly	  to	  what	  has	  been	  seen	  in	  young	  patients,	  one	  of	  the	  most	  interesting	  combinations	  is	  the	  
association	  of	  Lenalidomide-­‐Bortezomib	  207,229.	  Preliminary	  results	   testing	  this	  combination	  show	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that	   results	   can	   improve	   prolonging	   therapy	   from	   4	   to	   8	   cycles,	   making	   this	   combination	  
interesting	  also	  in	  the	  non-­‐transplant	  setting	  207.	  The	  addition	  of	  doxorubicin	  the	  VRD	  regimen	  is	  
also	  under	  study	  208.	  	  
The	  association	  Ld	  is	  currently	  undergoing	  evaluation	  in	  association	  with	  the	  monoclonal	  antibody	  
anti	  CS-­‐1	  Elotuzumab.	  
As	   already	   seen	   with	   thalidomide	   and	   lenalidomide,	   Bortezomib	   has	   been	   added	   to	   the	   MP	  
schema,	  showing	  a	  higher	  ORR	  and	  CR	  rate	  and	  a	  longer	  TTP	  and	  OS	  (24	  vs.	  16.6	  months,	  p<0.001	  
and	   56.4	   vs.	   43.1	   months,	   p=0.0004,	   respectively),	   compared	   to	   the	   standard	   MP	   150.	   In	  
consideration	  of	   these	   impressive	   results,	   the	  VMP	  regimen	  has	  become	  one	  of	   the	  standard	  of	  
care	   for	   patients	   older	   than	   65	   years	   not	   suitable	   for	   ASCT.	   The	   same	   combination	   with	   once	  
weekly	  bortezomib	  showed	  that	  a	  weekly	  administration	  of	  bortezomib	  is	  better	  tolerated	  in	  the	  
elderly	   population,	   with	   a	   reduced	   rate	   of	   adverse	   events,	   in	   particularly	   a	   reduced	   risk	   of	  
developing	   peripheral	   neuropathy	   230.	   VMP	   has	   also	   been	   compared	   to	   VD	   and	   VTD:	   the	   three	  
regimens	  showed	  similar	   response	  rates,	  but	  a	  higher	   toxicity	   in	   the	  VTD	  arm	  231.	  Similar	   results	  
were	  seen	  with	  the	  combination	  VMP	  vs.	  VTP	  confirming	  a	  better	  toxicity	  profile	  for	  VMP	  regimen	  
232.	   The	   comparison	   between	   VCD,	   VRD	   and	   VDCR	   is	   also	   under	   evaluation	   in	   the	   elderly	  
population	  209.	  For	  patients	  between	  65	  and	  75	  years	  of	  age	  a	  4	  drugs	  combination	  of	  Bortezomib-­‐
Melphalan-­‐Prednisone-­‐Thalidomide	  (VMPT)	  can	  also	  be	  considered.	  The	  VMPT	  combination	  has	  a	  
higher	   rate	  of	  neuropathy,	  but	   increases	   significantly	   the	   rate	  of	  CR	  compared	   to	  VMP	   (38%	  vs.	  
24%,	  p	  <0.001)	  and	  improves	  OS	  (59.3%	  vs.	  45.9%	  at	  5	  years,	  respectively,	  p=0.04)	  230,233.	  	  
The	  association	  of	  Cyclophosphamide,	  Dexamethasone	  and	  Carfilzomib,	   followed	  by	  Carfilzomib	  
maintenance	  has	  currently	  been	  tested,	  showing	  an	  ORR	  after	  induction	  of	  96%	  (76%	  VGPR,	  64%	  
CR/nCR,	   24%	   sCR)	   and	   a	   PFS	   and	   OS	   at	   1	   year	   of	   86%	   and	   87%,	   respectively.	   Six	   months	   of	  
Carfilzomib	  maintenance	  increased	  the	  rate	  of	  PR	  to	  100%	  (68%	  CR/nCR)	  234.	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Table	  11.	  Clinical	  studies	  in	  patients	  not	  suitable	  for	  ASCT	  
THALIDOMIDE	  
Author	   N°	  pts	   Therapy	   ≥PR	   CR/nCR	   PFS	  
OS	  




76%	  vs.	  35%	  
vs.	  65%	  
13%	  vs.	  2%	  vs.	  
18%	  
PFS:	  /	  
OS:	  	  51.6	  vs.	  
33,2	  vs.	  
38,8	  m	  
Hulin	  224	  	   232	   MPT	  vs.	  
MP-­‐
placebo	  
62%	  vs.	  31%	   7%	  vs.	  1%	   PFS:	  24.1	  
vs.	  18.5	  m	  
OS:	  44.0	  vs.	  
29.1	  m	  
Palumbo	  225	   255	   MPT	  vs.	  
MP	  
76%	  vs.	  47.6%	   27.9%	  vs.	  7.2%	   EFS:	  54%	  vs.	  
27%	  (at	  2	  y)	  
OS:	  80%	  vs.	  
64%	  (at	  3	  y)	  
Wijermans	  226	   333	   MPT-­‐T	  vs.	  
MP	  
65%	  vs.	  45%	   n.r.	   PFS:	  15	  vs.	  
11	  m	  
OS:	  40	  vs.	  
31	  m	  
Fayers	  227	   1685	   MPT	  vs.	  
MP	  
59%	  vs.	  37%	   n.r.	   PFS:	  20.3	  
vs.	  14.9	  m	  
OS:	  39.3	  vs.	  
32.7	  m	  
Kapoor	  152	  	   1568	   MP	  vs.	  
MPT	  
66%	  vs.	  45%	   3%	  vs.	  13%	   n.r.	  
LENALIDOMIDE	  







CR/nCR	  %	   PFS	  
OS	  
Rajkumar	  	  
RD	  phase	  II	  235	  
34	   91	  	   56	  	   18	  	   PFS	  83%	  and	  
OS	  92%	  at	  2	  y	  
Kumar	  	  
CRd	  236	  	  
53	   83	   40	   2	   n.r.	  
Rajkumar	  	  
RD	  vs.	  Rd	  148	  
445	   79vs68	   51vs40	   17vs14	   OS	  87%	  vs.	  96%	  
P=0.0002	  
Zonder	  	  
RD	  vs.	  Dex	  228	  
198	   78vs48	   63vs16	   26vs4	   OS	  79%	  vs.	  73%	  at	  
3	  y	  
Niesvizky	  	  
BiRD	  237	  	  
72	   90	   74	   46	   n.r.	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Kumar	  	  
EVOLUTION	  
VDCR	  phase	  I	  238	  
25	  
	  




Kumar	  	  EVOLUTION	  phase	  II	  209	   140	   	   	   	   OS	  n.r.	  
PFS	  at	  1	  y:	  
VDRC	   	   n.r.	   58	   25	   86	  
VDR	   	   n.r.	   51	   24	   83	  
VDC	   	   n.r.	   41	   22	   93	  





RD	  until	  PD	  (A)	  vs.	  RD	  (B)	  vs.	  
MPT	  (C)	  157	  
1623	   75%	  (A)	  
vs.	  62%	  
(C)	  
n.r.	   n.r.	   PFS:	  reduction	  of	  
risk	  of	  death	  or	  PD	  
28%	  (A	  vs.	  C)	  
OS:	  reduction	  of	  
risk	  of	  death	  22%	  
(A	  vs.	  C)	  
LENALIDOMIDE	  MAINTENANCE	  
Author	   N°	  
pts	  
PFS	   OS	  
Palumbo	  
MPR-­‐R	  vs.	  MPR	  vs.	  MP	  
(MM015)	  151	  
459	   31	  vs.	  14	  
vs.	  13	  m	  
70%	  vs.	  62%	  vs.	  66%	  
BORTEZOMIB	  
Author	   Therapy	   N°	  pts	   ORR	   OS	   SAEs	  
San	  Miguel	  150	   ®	  VMP	  vs.	  
MP	  	  
682	   >for	  VMP	   46%	  vs.	  
34%	  a	  5	  y	  
n.r.	  
Niesvizky	  231	   ®	  VMP	  vs.	  
VD	  vs.	  VTD	  




86.1%	  at	  1	  
y	  
>for	  VTD	  
Mateos	  232	   ®	  VMP	  vs.	  
VTP	  
260	   No	  
differences	  
n.r.	   >for	  VTP	  
Richardson	  207	  	   VRD	  phase	  
II	  
35	   96%	   Nr	  at	  1	  y	   n.r.	  
Kumar	  209	   ®	  VRD	  vs.	  
VRDC	  vs.	  
140	   >for	  VRDC	   Nr	  at	  1	  y	   >for	  VRDC	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VDC	  
Palumbo	  230	   ®	  VMPT	  vs.	  
VMP	  
511	   >for	  VMPT	   No	  
differences	  
	  	  >for	  VMPT	  
CARFILZOMIB	  
Author	   Therapy	   N°	  pts	   ORR	   OS	   SAEs	  
Brighen	  234	   CFZ-­‐Ciclo-­‐
Dex	  
25	   96%	   87%	   n.r.	  
M=Melphalan;	   P=Prednisone;	   T=Thalidomide;	   V=Bortezomib;	   D=Dexamethasone;	   C=Cyclophosphamide;	   R=Lenalidomide;	  
ELO=Elotuzumab	  
®=randomization;	  nr	  =not	  reached;	  n.r.=	  not	  reported	  
PR=partial	   response;	  CR=	  complete	   response;	  nCR=	  near	   complete	   response;	  VGPR=very	  good	  partial	   response;	  PFS=progression	  
free	  survival;	  OS=overall	  survival	  
	  
4.2	  THERAPY	  FOR	  RELAPSED/REFRACTORY	  PATIENTS	  
Despite	   the	  advantages	   in	   terms	  of	   response	   rate	  and	   survival	  obtained	  after	   the	  advent	  of	   the	  
new	  drugs,	  the	  history	  of	  MM	  is	  still	  characterised	  by	  phases	  of	  remission	  and	  relapses.	  At	  every	  
relapse	   responses	   are	   less	   profound	   and	   shorter,	   until	   drug	   resistance	   is	   developed	   and	   the	  
disease	  enter	  in	  the	  so-­‐called	  relapsed/refractory	  phase,	  eventually	  leading	  to	  patient’s	  death.	  The	  
new	   drugs	   such	   as	   PI	   and	   IMiDs	   have	   proven	   their	   efficacy	   also	   in	   this	   subset	   of	   patients,	  
significantly	  increasing	  OS	  compared	  to	  high	  dose	  dexamethasone	  239.	  	  
A	  wide	  variety	  of	  options	  are	  nowadays	  available	   for	   relapsed	  patients.	   If	   the	  patient	  has	  never	  
received	  a	  PI	  or	  an	  IMiD,	  treatment	  with	  these	  drugs	  (especially	  Bortezomib	  and	  Lenalidomide)	  is	  a	  
good	  option;	  an	  alternative,	   in	  case	  of	  a	   long	  duration	  of	  the	  first	  remission,	   is	  a	  retreatment	  or	  
rechallenge	  with	  the	  same	  molecule	  or	  the	  same	  class	  of	  molecules	  previously	  used.	  In	  fit	  patients	  
below	  65-­‐70	  years	  of	  age	  a	  salvage	  treatment	  with	  ASCT	  can	  be	  applied,	  proven	  that	  the	  duration	  
of	  response	  after	  the	  first	  ASCT	  was	  long	  enough.	  Enrolment	  in	  clinical	  trials	  gives	  the	  possibility	  to	  
use	  new	  molecules	  not	  yet	  approved,	  such	  as	  the	  monoclonal	  antibody	  Elotuzumab,	  Daratumuab	  
(anti	  CD38)	  or	  second	  generation	  PI	  such	  as	  MLN.	  
When	  choosing	   the	  salvage	   treatment	   to	  use,	  different	   factors	  have	   to	  be	   taken	   into	  account	   in	  
order	   to	   obtain	   a	   good	   balance	   between	   efficacy	   and	   side	   effects.	   There	   are	   disease-­‐related	  
factors:	   quality	   and	   duration	   of	   the	   previous	   remission,	   aggressive	   or	   indolent	   relapse,	   the	  
presence	  or	  absence	  of	  negative	  prognostic	  factors	  (del(17p),	  t(4;14),	  ampl(1q21)),	  the	  presence	  of	  
extramedullary	   disease	   or	   plasma	   cell	   leukaemia;	   and	   patients-­‐related	   risk	   factors:	   age,	  
performance	  status,	  renal	  function,	  precedent	  treatments,	  residual	  toxicity,	  presence	  of	  peripheral	  
neuropathy,	  risk	  of	  DVT	  240,241.	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For	   very	   advanced	  patients,	   already	   exposed	   and	   resistant	   to	   both	   IMiDs	   (Lenalidomide)	   and	  PI	  
(Bortezomib)	  (double	  refractory	  patients)	  the	  prognosis	  is	  extremely	  poor,	  with	  an	  OS	  and	  a	  PFS	  of	  
9	   and	   5	   months,	   respectively	   242;	   for	   this	   group	   of	   patients	   no	   standard	   of	   care	   is	   at	   present	  
available,	  and	  several	  clinical	  trials	  are	  ongoing	  to	  find	  the	  most	  effective	  drug	  combination.	  The	  
FDA	  (Food	  and	  Drug	  Administration)	  has	   recently	  approved	  Carfilzomib	   (a	  second	  generation	  PI)	  
for	  the	  treatment	  of	  patients	  previously	  exposed	  to	  Bortezomib	  and	   IMiDs	  and	  refractory	  to	  the	  
last	  line	  of	  treatment	  received.	  Pomalidomide	  (a	  third	  generation	  IMiDs)	  has	  also	  been	  approved	  
for	   the	   treatment	   of	   patients	   previously	   exposed	   to	   Bortezomib	   and	   Lenalidomide.	   Other	  
compounds	  currently	  under	  evaluation	  are	  the	  kinesine	  spindle	  protein	  (KSP)	  inhibitor	  (ARRY-­‐520).	  
The	  major	  studies	  in	  relapsed/refractory	  patients	  are	  summarised	  in	  table	  12.	  Among	  the	  different	  
possibilities	   for	   relapsed/refractory	   patients,	   the	   more	   interesting	   at	   present	   seem	   to	   be	   a	  
retreatment	  and	  the	  new	  molecules	  already	  available	  Carfilzomib	  and	  Pomalidomide.	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Table	  12.	  Clinical	  studies	  in	  relapsed/refractory	  MM	  patients	  
THALIDOMIDE	  ±	  dexamethasone	  
Author	   Dose	  Thal	   Dex	   N°	  
pts	  
≥PR	  (%)	   TTP/PFS	  
Barlogie	  243	   200-­‐800	   /	   169	   33	   20%	  at	  2	  
y	  
Tosi	  244	  	   400	  
(median)	  
/	   65	   28	   8	  m	  
Schey	  245	   300	  
(median)	  
/	   69	   39.5	   14	  m	  
Dimopoulos	  246	  
	  
400	   DEX	   44	   55	   ≥10	  m	  
Anagnostopoulos	  247	  	   200-­‐800	   DEX	   47	   47	   n.a.	  
Zamagni	  248	   100-­‐200	   DEX	   100	   46	   22	  m	  
THALIDOMIDE	  +	  chemotherapy	  
Author	   Therapy	   DVT	  (%)	   N°	  
pts	  
≥	  PR	  (%)	   TTP/PFS	  
Palumbo	  225	  	   MP+T	   0.04	   24	   42	   9	  m	  
LENALIDOMIDE	  
Author	   N°	  pts	   ORR	  %	   TTP	   OS	  
Dimopoulos	  249	  
MM010	  












28	   82%	   NR	   NR	  
Siegel	  252	  	  
RD+Vorinostat	  dose	  escalation	  	  




Therapy	   N°	  pts	   ≥	  PR	  
(%)	  
OS	  (m)	   TTP	  (m)	  
Richardson	  253	   VEL	  1.31	   202	   27	   16	  
(median)	  
7	  in	  pts	  
with	  ≥	  
PR	  
Jagannath	  254	   VEL	  1.02	  vs.	  VEL	  
1.3	  
27	  vs.	  26	   30	  vs.	  
38	  
n.a.	   7	  vs.	  11	  
Richardson	  255	   ®	  VEL	  1.3	  vs.	  
DEX3	  
336	  vs.	  333	   38	  vs.	  
18	  
80%	  vs.	  




Ludwig	  256	   VEL	  1.3-­‐Dex-­‐
Bendamustine	  
79	   61	   25.6	   9.7	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Petrucci	  257	  	   VEL	  1.0	  o	  1.3	   132	   40	   n.r.	   8.5	  in	  pts	  
with	  ≥	  
PR	  
Richardson	  258	  	   VEL	  1.0-­‐	  Len-­‐	  
Dex	  
64	   64	   30	   9.5	  
Berenson	  259	   DVD-­‐R	   40	   49	   n.r.	   9	  
CARFILZOMIB	  
Author	   Therapy	   N°	  pts	   PN	  gr	  
1-­‐2	  (%)	  
ORR	  (%)	   DOR	  
Siegel	  260	   Carfilzomib1	   266	   77	   24	  (≥	  PR)	   7.4	  m	  
Vij	  261	   Carfilzomib5	  	   129	   16	   52	  (≥	  PR)	   NR	  
Vij	  262	   Carfilzomib	   35	   14.3	   17.1	   >10.6	  m	  
Badros	  263	  	   Carfilzomib	   50	  (RI)	   10	   26	   7.9	  m	  
Niesvizky	  264	   Carfilzomib-­‐	  
Len-­‐Dex	  
40	   50	   62.5	   11.8	  m	  
(pts	  with	  
≥	  PR)	  	  
Lendvai	  265	   Carfilzomib	  
high-­‐dose	  ±	  
Dex	  























65	   13	   76%	  at	  2	  
y	  


























67%	  at	  6	  
months	  
























































Thal=Thalidomide;	   Len=Lenalidomide;	   Dex=Dexamethasone;	   VEL=Bortezomib;	   DVD-­‐R=Dexamethasone	   Bortezomib	   Doxorubicin	  
Lenalidomide;	  NR=not	  reached;	  n.r.=not	  reported;	  ®=randomisation;	  *=no	  prophylaxis;	  **=no	  dex;	  §=with	  dex;	  y=years;	  m=months;	  
1pts	  with	  more	  than	  2	  previous	  lines	  of	  therapy;	  2pts	  with	  ≤3	  lines	  of	  therapy,	  not	  refractory	  to	  Dex;	  3pts	  after	  1	  line	  of	  therapy;	  4	  
median	   4	   lines	   of	   therapy;	   5bortezomib	   naive;	   aPatients	   refractory	   to	   Lenalidomide;	   bPatients	   refractory	   to	   Lenalidomide	   and	  
Bortezomib;	  PR=partial	  response;	  SD=stable	  disease;	  MR=minimal	  response;	  PN=polyneuropathy;	  DVT=deep	  vein	  thrombosis;	  RI=	  
renal	   impairment;	   TTP=time	   to	   progression;	   PFS=progression	   free	   survival;	   DOR=duration	   of	   response;	   OS=overall	   survival;	  
ORR=overall	  response	  rate 
	  
• Retreatment	  with	  Lenalidomide	  or	  Bortezomib	  
Many	   studies	   are	   available	   regarding	   the	   retreatment	   with	   Bortezomib	   or	   Lenalidomide.	   The	  
combination	   DVD-­‐R	   (Doxorubicin-­‐Bortezomib-­‐Dexamethasone-­‐Lenalidomide)	   has	   shown	   the	  
efficacy	  of	  Bortezomib	  retreatment	  in	  a	  group	  of	  patients	  previously	  exposed	  to	  Bortezomib	  (82%),	  
and	  Lenalidomide	  (47.5%).	  The	  ORR	  of	  the	  DVD-­‐R	  combination	  was	  of	  48.7%,	  and	  it	  was	  high	  also	  
in	  patients	  previously	  treated	  with	  Bortezomib	  (≥MR	  81.8%)	  or	  Lenalidomide	  (≥MR:	  63.1%)	  or	  that	  
had	   failed	   both	   (≥MR	   60%)	   259.	   The	   combination	   BLD	   (Bendamustine-­‐Lenalidomide-­‐
Dexamethasone)	  was	  used	   in	  relapsed/refractory	  MM	  (RRMM)	  patients,	  of	  which	  66%	  had	  been	  
previously	  treated	  with	  Bortezomib	  and	  45%	  with	  Lenalidomide.	  The	  ORR	  was	  76%,	  with	  a	  median	  
PFS	   of	   6.1	   months	   in	   patients	   previously	   exposed	   to	   Bortezomib,	   and	   not	   reached	   in	   patients	  
previously	   exposed	   to	   Lenalidomide	   270.	   Bortezomib	   plus	   Bendamustine	  was	   effective	   in	   heavily	  
pre-­‐treated	  patients	  who	  had	   already	   received	  Bortezomib	   256.	   Retreatment	  with	  Bortezomib	   in	  
patients	  that	  had	  received	  Bortezomib	  and	  had	  obtained	  a	  response	  for	  more	  than	  6	  months	  was	  
specifically	  evaluated	  showing	  an	  ORR	  of	  40%	  and	  a	  TTP	  of	  8.5	  months	  for	  those	  patients	  achieving	  
at	  least	  a	  PR	  257.	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• Carfilzomib	  
The	   second-­‐generation	   proteasome	   inhibitor	   Carfilzomib	   has	   recently	   been	   approved	   for	   the	  
treatment	  of	  RRMM	  patients.	  Carfilzomib	  was	   shown	   to	  have	  a	  prolonged	  anti-­‐tumour	  effect	   in	  
RRMM,	   irrespective	  of	  previous	  Bortezomib	  treatment.	   In	  patients	  never	  exposed	  to	  Bortezomib	  
the	   ORR	   was	   of	   48%,	   and	   it	   was	   higher	   for	   those	   patients	   that	   received	   a	   dose	   escalation	   of	  
Carfilzomib	  (up	  to	  27	  mg/m2)	  (52%	  vs.	  42%	  respectively);	  median	  DOR	  was	  13.1	  months,	  with	  a	  PFS	  
of	   8	   months.	   The	   risk	   of	   peripheral	   neuropathy	   was	   relatively	   small,	   considering	   that	   50%	   of	  
patients	   had	   pre-­‐existent	   neuropathy	   at	   study	   entry	   262.	   In	   patients	   previously	   exposed	   to	  
Bortezomib,	  including	  14	  patients	  refractory	  to	  the	  most	  recent	  line	  of	  therapy,	  the	  ORR	  was	  17%,	  
with	  a	  DOR	  of	  9	  months	  and	  a	  TTP	  of	  5.3	  months	  262.	  	  
The	  major	   grade	  ≥3	  adverse	  events,	   evaluated	  on	  526	  patients,	  were:	   thrombocytopenia	   (23%),	  
anaemia	   (22%),	   lymphopenia	   (18%),	   pneumonia	   (11%)	   and	   neutropenia	   (10%).	   Peripheral	  
neuropathy	  was	  reported	  only	  in	  14%	  of	  cases,	  and	  it	  was	  generally	  mild	  or	  moderate,	  despite	  72%	  
of	  patients	  having	  a	  ≥	  grade	  2	  neuropathy	  at	  trial	  entry	  271.	  	  
In	  a	  different	  phase	  II	  trial	  266	  patients	  already	  exposed	  to	  IMiDs	  e	  PI	  were	  evaluated;	  95%	  were	  
refractory	   to	   the	   last	   line	   of	   treatment,	   80%	   were	   refractory	   or	   intolerant	   to	   Bortezomib	   or	  
Lenalidomide.	  The	  ORR	  with	  Carfilzomib	  monotherapy	  was	  of	  23.7%	  (28%	  in	  patients	  with	  adverse	  
cytogenetic);	  median	  DOR	  was	  7.8	  months	  and	  median	  OS	  was	  15.6	  months.	  The	  most	  common	  
adverse	   events	   were	   fatigue	   (49%),	   anaemia	   (46%),	   nausea	   (45%),	   e	   thrombocytopenia	   (39%);	  
12.4%	  of	  patients	  developed	  a	  peripheral	   neuropathy	   grade	  1-­‐2	   260.	  A	  possible	   activity	  of	   single	  
agent	  Carfilzomib	  in	  high-­‐risk	  patients	  harbouring	  adverse	  cytogenetic	  abnormalities	  has	  also	  been	  
suggested.	  	  
Based	   on	   the	   favourable	   results	   of	   single	   agent	   Carfilzomib,	   its	   activity	   in	   combination	   has	   also	  
been	  explored.	  Carfilzomib	  associated	  with	  Lenalidomide	  and	  low	  dose	  Dexamethasone	  obtained	  
a	  rate	  of	  responses	  of	  62.5%	  (2.5%	  sCR,	  32.5%	  VGPR,	  27.5%	  PR);	  the	  most	  frequent	  adverse	  events	  
≥	  grade	  3	  were	  neutropenia,	  anaemia	  and	  thrombocytopenia	  264.	  
High	  doses	  of	  Carfilzomib	  (up	  to	  56	  mg/m2),	  with	  the	  optional	  addition	  of	  Dexamethasone	  in	  case	  
of	   unsatisfactory	   response	   after	   2	   cycles,	   showed	   an	   ORR	   of	   47%	   in	   patients	   refractory	   to	  
Bortezomib	  (77%),	  suggesting	  that	  a	  higher	  dose	  might	  be	  more	  effective;	  with	  a	  follow	  up	  of	  18.4	  
months	  the	  median	  PFS	  was	  4.1	  months	  and	  the	  median	  OS	  was	  20.3	  months	  265.	  	  
Several	   phase	   III	   trials	   are	   currently	   ongoing:	   the	   ASPIRE	   study,	   comparing	   Carfilzomib-­‐
Lenalidomide-­‐Dexamethasone	   vs.	   Lenalidomide-­‐Dexamethasone;	   the	   FOCUS	   study,	   comparing	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Carfilzomib	  monotherapy	  vs.	  best	   supportive	  care;	   the	  ENDEAVOR	  study	  comparing	  Carfilzomib-­‐
Dexamethasone	  vs.	  Bortezomib-­‐Dexamethasone.	  
• Pomalidomide	  
The	  third	  generation	  IMiD	  Pomalidomide	  has	  been	  evaluated	  in	  a	   large	  number	  of	  phase	  I	  and	  II	  
clinical	  trials;	  these	  trials	  have	  identified	  the	  dose	  of	  4	  mg	  for	  21	  days	  over	  a	  28	  days	  period	  as	  the	  
dose	  to	  bring	  forward	  in	  the	  clinic	  266-­‐268,272,273.	  	  
In	  patients	  refractory	  to	  Lenalidomide	  treatment	  with	  Pomalidomide	  (at	  different	  dose	  ranges)	  in	  
association	  with	  weekly	  Dexamethasone	  achieved	  at	  least	  a	  PR	  in	  21-­‐32%	  267,272.	  Preliminary	  data	  
suggests	   that	   Pomalidomide	   might	   have	   a	   role	   in	   the	   treatment	   of	   high-­‐risk	   patients.	  
Pomalidomide	  was	  evaluated	   in	  patients	  positive	   for	   t(4;14)	  and/or	  del(17p)	   showing	  an	  ORR	  of	  
22%.	  Interestingly	  both	  responses	  and	  DOR	  were	  higher	  in	  patients	  with	  del(17p)	  than	  in	  patients	  
with	   t(4;14)	   (ORR	   32%	   vs.	   15%,	   DOR	   8.3	  months	   vs.	   2.4	  months,	   respectively),	   suggesting	   that	  
treatment	  with	  pomalidomide	  might	  improve	  the	  outcome	  of	  this	  very	  high-­‐risk	  group	  274.	  
Based	   on	   the	   results	   of	   a	   recently	   published	   phase	   III	   trial,	   comparing	   Pomalidomide	   ad	  
Dexamethasone	  versus	  high	  dose	  Dexamethasone,	  Pomalidomide	  has	  been	  approved	  by	  FDA	  and	  
EMA	   for	   the	   treatment	   of	   relapsed/refractory	   patients	   that	   have	   previously	   received	   both	  
Bortezomib	  and	  Lenalidomide	  and	  are	  refractory	  to	  at	  least	  one	  of	  those.	  With	  a	  median	  follow	  up	  
of	  10	  months	  the	  trial	  showed	  that,	  in	  a	  heavily	  pre-­‐treated	  population	  (median	  5	  lines	  of	  previous	  
treatment,	   75%	   refractory	   to	   Bortezomib	   and	   Lenalidomide),	   the	   PFS	   was	   double	   in	   patients	  
receiving	   Pomalidomide	   compared	   to	   the	   control	   arm	   (4.0	   months	   vs.	   1.9	   months,	   HR:0.48;	  
p<0.0001).	  An	  advantage	  in	  OS	  could	  also	  be	  seen	  (12.8	  vs.	  8.1	  months,	  HR=0.74;	  p=0.028)	  269.	  	  
Pomalidomide	  has	   also	   been	   tested	   in	   association	  with	   proteasome	   inhibitors	   and	   conventional	  
chemotherapy	  275,276.	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STUDY	  OBJECTIVES	  
The	   presence	   of	   intra-­‐clonal	   heterogeneity	   has	   been	   postulated	   in	   a	   variety	   of	   solid	   and	  
haematological	   tumour,	   including	  Multiple	  Myeloma.	  Furthermore	   the	  advent	  of	  new	  drugs	  and	  
the	  new	  treatment	  concept	  including	  a	  maintenance	  treatment	  following	  ASCT	  for	  young	  patients,	  
and	   a	   continuous	   treatment	   for	   elderly	   patients	   not	   suitable	   for	   ASCT,	   have	   raised	   concerns	  
regarding	  the	  possible	  side	  effects	  of	  new	  drugs	  and	  their	  long-­‐term	  impact	  on	  the	  bone	  marrow	  
of	  MM	  patients.	  	  
In	  the	  light	  of	  these	  concepts,	  the	  main	  objectives	  of	  the	  present	  research	  project	  were	  to:	  
1.	  Confirm	  the	  presence	  of	  intra-­‐clonal	  heterogeneity	  in	  Multiple	  Myeloma,	  both	  at	  a	  general	  level	  
(with	   the	   use	   of	  whole	   exome	   sequencing)	   and	   at	   a	  more	   profound	   single-­‐cell	   level	   in	   primary	  
samples	  of	  patients	  receiving	  IMiDs	  or	  PI.	  
2.	  Assess	  the	  presence	  of	  intra-­‐clonal	  heterogeneity	  at	  a	  clinical	  level,	  and	  evaluate	  its	  impact	  on	  
treatment	  outcomes	  
3.	  Evaluate	  the	  possible	  long-­‐term	  effect	  of	  Lenalidomide	  on	  the	  bone	  marrow	  of	  MM	  patients.	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MATHERIALS	  AND	  METHODS	  
1.	  EVALUATION	  OF	  INTRA-­‐CLONAL	  HETEROGENEITY	  IN	  PRIMARY	  
SAMPLES	  OF	  MYELOMA	  PATIENTS	  
1.1	  WHOLE	  EXOME	  SEQUENCING	  
CD138-­‐positive	   bone	   marrow	   plasma	   cells	   were	   selected	   to	   a	   purity	   >95%,	   as	   determined	   by	  
cytospin,	   using	  magnetic-­‐assisted	   cell	   sorting	   (Miltenyi	   Biotec,	   Bisley,	   Surrey,	   UK).	   Tumour	   DNA	  
was	  extracted	  using	  the	  AllPrep	  kit	   (QIAGEN,	  Manchester,	  UK);	  DNA	  concentration	  was	  assessed	  
using	  Pico-­‐green	  (Life	  Technologies,	  Pailsey,	  UK).	  Non-­‐tumour	  DNA	  was	  isolated	  from	  white	  blood	  
cells	   using	   the	   FlexiGene	   kit	   (QIAGEN).	   Approximately	   50	   to	   100	   ng	   of	   DNA	   underwent	   whole-­‐
genome	  sequencing	  using	  120-­‐bp	  paired-­‐end	  reads	  on	  a	  GAIIx	  (Illumina,	  Saffron	  Walden,	  UK)	  to	  a	  
median	  depth	  of	  44x	  to	  59	  x	  according	  to	  the	  study,	  with	  96%	  to	  82%	  >20x	  coverage.	  Paired	  reads	  
were	  aligned	  to	  the	  human	  genome	  (GRCh37)	  using	  Stampy	  277	  and	  BWA	  278,	  and	  duplicate	  reads	  
were	   removed	   using	   Picard.	   Sequence	   recalibration,	   local	   realignment	   and	   single-­‐nucleotide	  
variant	   (SNV)	   calling	  were	   all	   undertaken	  using	   the	  GATK	   279	   or	  MuTect	   280.	   SnpEff	  was	   used	   to	  
functionally	  annotate	  all	  variants.	  Further	  filtering	  of	  variants	  and	  comparisons	  between	  samples	  
were	  performed	  using	  code	  written	  in	  R.	  Variants	  present	  in	  both	  the	  peripheral	  blood	  and	  tumour	  
samples	  were	  discarded.	  Only	  variants	  sequenced	  to	  a	  minimum	  depth	  of	  10x	  in	  both	  the	  tumour	  
and	  matched	   normal	   sample,	   as	   well	   as	   having	   a	  minimum	   genotype	   score	   of	   greater	   than	   50	  
(representing	  a	  1	  in	  100	  000	  error	  rate)	  and	  no	  more	  than	  one	  variant	  read	  in	  the	  normal	  sample	  
were	  retained.	  Variants	  were	  determined	  to	  be	  unique	  to	  a	  disease	  stage	  or	  present	  in	  both	  stages	  
by	  comparing	  the	  base	  calls	  at	  the	  location	  of	  the	  SNV	  in	  both	  samples.	  Finally,	  an	  additional	  filter	  
was	  applied	  for	  C>A|G>T	  SNVs	  to	  take	  into	  account	  somatic	  change	  artefacts	  reported	  by	  Costello	  
et	   al.	  Whole-­‐genome	   copy	   number	  was	   called	   using	   a	   combination	   of	   the	   R	   package	   BICseq	   to	  
perform	  segmentation	  of	  the	  log	  ratio	  of	  the	  read	  depth	  between	  matched	  peripheral	  blood	  and	  
tumour	  samples	  and	  the	  R	  package	  CGHcall	   to	  produce	   integer	  copy	  calls	  within	   the	  segmented	  
regions.	  Copy	  number	  in	  exome	  samples	  was	  similarly	  determined	  using	  the	  R	  package	  ExomeCNV.	  
The	  proportion	  of	  cells	  containing	  a	  variant	  was	  estimated	  using	  the	  following	  equation:	  	  𝑝 = min(1, 𝑟𝐶𝑅 )	  
Where	   p	   is	   the	   proportion	   of	   cells	   containing	   the	   variant,	   C	   is	   the	   integer	   copy	   number	   at	   that	  
position,	  r	  is	  the	  number	  of	  reads	  containing	  the	  variant	  and	  R	  is	  the	  total	  number	  of	  reads.	  Note	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that	  this	  method	  assumes	  that	  the	  tumour	  cell	  population	  is	  free	  from	  normal	  cell	  contamination	  
and	  that	  detected	  copy	  number	  changes	  are	  not	  sub-­‐clonal.	  
Owing	  to	  the	  high	  identity	  between	  the	  human	  and	  mouse	  genomes,	  two	  strict	  precautions	  were	  
taken	   to	   avoid	   false	   positives	   in	   the	   xeno-­‐transplanted	   samples.	   First,	   aligned	   xeno-­‐transplant	  
BAMs	  were	  filtered	  to	  remove	  any	  reads	  containing	  more	  than	  a	  single	  mismatch	  to	  the	  reference	  
genome.	  Second,	  private	  SNVs	  in	  xenograft	  samples	  were	  treated	  as	  artefacts	  and	  removed.	  As	  a	  
result	  of	  this	  filtering,	  the	  median	  depth	  for	  xenograft	  samples	  after	  deduplication	  was	  31x	  (range	  
15-­‐47)	  with	  an	  average	  of	  58.4%	  of	  the	  targeted	  exome	  covered	  at	  a	  minimum	  depth	  of	  20x.	  All	  
SNVs	   were	   manually	   inspected	   using	   IGV	   to	   verify	   that	   they	   were	   both	   correctly	   called	   and	  
correctly	  annotated	  as	  being	  present	  or	  absent	  in	  each	  of	  the	  tumour	  samples.	  	  
1.2	  SINGLE	  CELL	  ANALYSIS	  
Archival	   methanol:acetic-­‐acid-­‐fixed	   single-­‐cells	   and	   tumour/normal	   DNA	   were	   obtained.	   Fixed	  
single-­‐cells	   from	  each	  patient	  were	  sorted	   in	  a	  FACSAria	  cell	   sorter	   (BD	  Biosciences,	  Oxford,	  UK)	  
using	  Propidium	  Iodide	  (PI)	  nuclei	  staining.	  Depending	  on	  cell	  availability,	  we	  sorted	  73-­‐243	  single-­‐
cells	   into	  DNA-­‐lysis	  buffer	   in	  one	  to	  three	  96-­‐well	  plates	  (84	  cells/plate).	   In	  parallel,	   lymphocytes	  
from	  a	  healthy	  donor	  were	  sorted	  as	  wild	  type	  and	  normal	  copy	  number	  controls	  (10	  cells/plate).	  
Finally,	  2	  wells/plate	  were	  left	  empty	  to	  add	  bulk	  tumour	  and	  peripheral	  blood	  DNA	  from	  the	  same	  
patient	  (positive	  and	  negative	  controls	  for	  mutation	  detection).	  Additionally,	  60	  fixed-­‐lymphocytes	  
from	  a	  healthy	  donor	  were	  sorted	  in	  a	  separate	  96-­‐well	  plate	  as	  reference	  cells	  for	  the	  definition	  
of	   copy	   number	   thresholds	   across	   all	   interrogated	   genomic	   regions.	   Assay	   efficiency	   was	  
calculated	  using	  five	  2x	  dilutions	  for	  the	  amplified	  DNA	  of	  six	  lymphocytes.	  	  
A	  novel	  approach	  for	  single-­‐cell	  multiplex	  qPCR	  analysis	  was	  performed	  (Fluidigm	  UK,	  London,	  UK)	  
281.	  Briefly,	  single-­‐cells	  were	  sorted	  into	  lysis	  buffer	  followed	  by	  specific	  (DNA)	  target	  amplification	  
(STA).	  This	  multiplex	  STA	   reaction	  comprises	   the	   simultaneous	  amplification	  of	   target	   regions	  of	  
interest	   using	   TaqMan	   PreAmp	   Master	   Mix	   and	   assays	   (Life	   Technologies).	   Mutation-­‐specific	  
genotyping	   assays	   were	   custom-­‐designed	   following	   manufacturer’s	   guidelines.	   Pre-­‐designed	  
genotyping	  assays	  for	  locus	  known	  to	  be	  in	  heterozygosis	  in	  all	  tumour	  samples	  114,282	  were	  used	  as	  
reference	   (rs346172	   and	   rs909895).	   Three	  different	   TaqMan	   copy	  number	   assays	   covering	   each	  
chromosomal	  region	  of	  interest	  were	  used	  for	  copy	  number	  analysis.	  The	  STA	  product	  was	  diluted	  
and	   qPCR	   was	   performed	   using	   the	   96.96	   dynamic	   microfluidic	   arrays	   and	   the	   BioMark	   HD	  
(Fluidigm).	   Genotyping	   assays	   were	   present	   in	   replicates	   (2-­‐4),	   whereas	   each	   multiple	   copy	  
number	  assay	  per	  region	  was	  used	  in	  quadruplicates	  to	  ensure	  enough	  replicates	  for	  accuracy	  in	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copy	  number	  calling	  283.	  Translocations,	  mutations,	  and	  copy	  number	  aberrations	  were	  assessed	  at	  
the	   single-­‐cell	   level.	   Genotyping	   and	   copy	   number	   analyses	  were	   assessed	   using	   Fluidigm	   Real-­‐
Time	  PCR	  Analysis	  v.3.0.2	  software	  (Fluidigm).	  To	  estimate	  copy	  number	  values,	  CopyCaller	  v.1.0	  
software	  (Life	  Technologies)	  was	  used	  and	  weighted	  means	  of	  the	  calculated	  copy	  number	  values	  
for	   each	   experimental	   replicate	   were	   determined.	   Hierarchical	   clustering	   was	   achieved	   using	  
Pearson	  correlation	  and	  average	  linkage	  on	  the	  Rock	  platform284	  and	  further	  customized	  with	  R.	  A	  
filtering	  strategy	  for	  wells	  with	  low-­‐quality	  DNA	  amplification	  and	  sub-­‐clones	  without	  a	  minimum	  
cell	  number	  was	  applied.	  To	  define	   tumour	  sub-­‐clones	  and	  the	  most	  plausible	  clonal	  phylogeny,	  
we	  used	  minor	  modifications	  to	  the	  filtering	  strategy	  for	  wells	  with	  low	  quality	  DNA	  amplification	  
and	  sub-­‐clones	  without	  a	  minimum	  number	  of	  cells,	  used	  elsewhere	  281.	  We	  removed	  from	  further	  
analysis	  all	  those	  cells/rows	  that	  failed	  to	  amplify	  in	  at	  least	  one	  of	  the	  reference	  SNP	  assays	  (for	  
mutation	   call)	   or	   in	   any	   of	   the	   reference	   copy	   number	   assays	   (for	   copy	   number	   calling).	  
Additionally,	  Ct	  values	  >30	  cycles	  were	  flagged	  as	  not	  assessable	  (NA).	  
For	  mutation	  and	  translocation	  calling,	  we	  transformed	  Ct	  results	  for	  mutation	  and	  translocation	  
assays	  into	  binary	  (1,	  presence	  of	  mutation;	  0	  wild	  type)	  considering	  the	  assay	  replicates	  per	  cell	  
(2-­‐4	  replicates).	  Results	  from	  all	  the	  interrogated	  mutations	  per	  cell	  were	  combined	  and	  cells	  with	  
NA	   values	   were	   removed	   from	   subsequent	   analyses.	   The	   total	   number	   of	   sorted	   analysable	  
tumour	  single-­‐cells	  was	  calculated.	  The	  threshold	  to	  define	  sub-­‐clonal	  populations	  was	  established	  
in	  at	   least	  5%	  of	  the	  total	  of	  analysable	  tumour	  cells.	  All	  cells	   in	  fractions	  below	  such	  thresholds	  
were	  removed	  from	  further	  analysis.	  	  
For	  copy	  number	  aberrations,	  cells	  were	  initially	  filtered	  out	  if	  normal	  reference	  regions	  failed	  to	  
amplify.	   CopyCaller	   software	   was	   used	   to	   estimate	   the	   calculated	   copy	   number	   values	   (cCNV).	  
Nine	  comparisons	  were	  performed	  in	  Copycaller,	  comparing	  the	  3	  reference	  control	  region	  assays	  
versus	  the	  3	  test	  region	  assays.	  This	  provided	  a	  total	  of	  nine	  cCNVs	  for	  each	  tested	  region	  in	  any	  of	  
the	   analysed	   cell	   per	   patient.	   cCNVs	   were	   removed	   if	   confidence	   intervals	   were	   below	   0.5.	  
Additionally,	  cCNV>4.5	  were	  not	  considered,	  as	  the	  number	  of	  replicates	  did	  not	  ensure	  statistical	  
accuracy	   for	   copy	   number	   estimation	   283.	   The	   weighted	   mean	   of	   the	   cCNVs	   (weighted	   copy	  
number	  values,	  wCNV)	  was	  calculated	  only	  when	  at	  least	  3/9	  replicates	  were	  available.	  If	  less	  than	  
3,	   such	   region	   was	   considered	   NA	   in	   that	   specific	   cell.	   wCNV	   below	   1.5	   and	   above	   2.5	   were	  
considered	  as	  genomic	   loss	   (-­‐1)	  and	  gain	   (1)	   respectively,	  whereas	   intermediate	  values	  mean	  no	  
change	  (0).	  Then,	  we	  plotted	  histograms	  with	  the	  wCNV	  for	  each	  cell	  in	  all	  plates.	  Reference	  array	  
histogram	  was	   characterized	   for	   the	   accumulation	   of	   cells	  within	   the	   normal	   parameters,	   but	   a	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group	   of	   cells	   provided	  wCNV	   >2.5	   and	   <1.5	   as	   a	   consequence	   of	   the	   qPCR	   technical	   variation	  
283,285.	  For	  each	  region,	  we	  calculated	  the	  percentage	  of	  normal	  cells	  misleadingly	  displaying	  gains	  
or	   losses	   and	   used	   the	   highest	   frequency	   as	   a	   threshold	   to	   set	   the	   minimum	   number	   of	   cells	  
required	  to	  be	  considered	  sub-­‐clone	  in	  copy	  number	  aberration	  analyses	  (sub-­‐clonal	  thresholds).	  
Qualitative	  values	  for	  each	  region	  and	  cell	  (loss,	  no	  change,	  gain)	  were	  combined	  and	  cells	  with	  NA	  
value	  for	  any	  region	  were	  removed	  from	  further	  analysis.	  The	  total	  number	  of	  analysable	  tumour	  
single-­‐cells	   for	  copy	  number	  aberrations	  was	   then	  calculated	  and	  sub-­‐clonal	   thresholds	   for	  each	  
tested	   chromosomal	   region	   were	   applied.	   Hierarchical	   clustering	   illustrated	   the	   different	  
aberration	   patterns	   in	   clonal	   populations.	   Copy	   number	   aberrant	   sub-­‐clonal	   populations	   were	  
considered	  when	   cells	  were	   grouped	   in	   numbers	   higher	   than	   each	   of	   the	   sub-­‐clonal	   thresholds	  
established	  per	  chromosomal	  region.	  All	  cells	  not	  fulfilling	  the	  criteria	  were	  filtered	  out.	  We	  then	  
combined	   both	   filtered	  mutation	   and	   copy	   number	   information	   for	   each	   cell,	   and	   followed	   an	  
additional	   filtering	   process	  with	   the	   same	   criteria	   for	   both	   features.	   A	   total	   number	   of	   filtered-­‐
analysable	   tumour	   cells	   were	   estimated	   and	   clonal	   phylogenies	   and	   percentages	   could	   be	  
accurately	  established.	  
1.3	  NOD-­‐SCID	  MOUSE	  TRANSPLANTATION	  
Presentantion-­‐	  and	  relapse-­‐samples	  from	  a	  PCL-­‐patient	  were	  studied	  by	  WES.	   In	  parallel,	   female	  
NOD/SCID	  IL2Rγnull	  mice	  approximately	  6	  weeks	  old	  were	  inoculated	  with	  1x106	  CD138+cells	  from	  
the	  PCL-­‐patient	  at	  diagnosis	   in	  20	  µl	   complete	  RPMI-­‐1640	  GlutaMAXTM	  medium,	  and	  monitored	  
for	   myeloma	   development	   over	   5	   months	   as	   before	   286.	   Mice	   were	   then	   culled	   and	  myeloma-­‐
xenograft	  samples	  were	  purified	  for	  human	  CD138+	  cells.	  	  
1.4	  GENETIC	  ALGORITHM	  IN	  THE	  MULTI-­‐SAMPLE	  EXOME	  SEQUENCING	  ANALYSIS	  	  
Xenograft-­‐tumour	  DNA	  was	   analysed	  by	  WES	  using	   a	  modified	  pipeline	   and	   compared	  with	   the	  
tumour	   exomes	   from	   presentation	   and	   relapse	   patient-­‐samples.	   A	   genetic	   algorithm	   was	  
implemented	  using	   the	  GA	  package	   for	  R	   287	   to	  calculate	   the	  most	  parsimonious	  assignments	  of	  
mutations	   to	   clonal	   lineages.	   Custom	   population	   generation,	   fitness,	   mutation,	   and	   crossover	  
functions	   were	   written.	   The	   population	   being	   optimised	   consisted	   of	   a	   series	   of	   vectors,	   each	  
composed	  of	  three	  parts.	  The	  first	  n	  elements	  (where	  n	  is	  a	  predicted	  number	  of	  lineages	  present	  
in	   the	   sample)	   are	   integers	   identifying	   the	   parent	   of	   the	   lineage	   ni,	   with	   0	   indicating	   that	   this	  
lineage	  is	  the	  root	   lineage.	  The	  next	  n	  x	  m	  elements	  (where	  m	   is	  the	  number	  of	  cases	  observed)	  
are	   integers,	   initialized	   between	   0	   and	   5,	   but	   with	   no	   upper	   bound	   following	   mutation,	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representing	  the	  relative	  abundance	  of	  lineage	  ni	  in	  case	  mj.	  The	  remaining	  l	  elements	  (where	  l	  is	  
the	  number	  of	  mutations	  observed)	  are	   integers	   from	  1	  to	  n	  representing	  the	  earliest	   lineage	   in	  
which	  each	  mutation	   li	  occurs.	  The	  population	  generation	  function	  produces	  vectors	  with	  exactly	  
one	   root	   lineage,	  where	   the	   lineages	  can	  be	   represented	  as	  a	  directed	  acyclic	  graph	   (DAG),	  and	  
with	   all	   remaining	   elements	   assigned	   randomly.	   The	   fitness	   function	   calculates	   the	   predicted	  
proportion	  of	  the	  total	  sample	  that	  should	  contain	  each	  mutation	  based	  around	  the	  assumption	  
that	  a	  mutation	  should	  appear	  in	  the	  lineage	  it	  first	  occurs	  in	  and	  all	  children	  of	  that	  lineage.	  The	  
proportion	  of	  each	   lineage	   in	  case	  mj	  is	  computed	  first	  as	  the	  relative	  abundance	  of	   lineage	  ni	  in	  
case	  mj	  divided	   by	   the	   sum	   of	   all	   ni	   in	   case	  mj.	   Then	   for	   each	   mutation	   the	   proportions	   of	   all	  
lineages	  containing	  that	  mutation	  are	  summed.	  The	  absolute	  value	  of	  the	  difference	  between	  the	  
predicted	  proportion	  and	  the	  experimentally	  observed	  proportion	  of	  each	  mutation	  in	  each	  case	  is	  
summed.	   The	   fitness	   function	   then	   returns	   -­‐1	   times	   the	   sum	   of	   these	   values	   as	   a	   score	   to	   be	  
optimized.	  The	  mutation	   function	  assumes	   that	   the	  predicted	   lineages,	  abundances	  or	  mutation	  
calls	  can	  change	  with	  equal	  probability.	   In	  the	  case	  that	   lineages	  are	  changed,	  a	  completely	  new	  
DAG	  for	  the	   lineages	   is	  produced	  and	  replaces	  the	  original.	   In	  the	  case	  that	  relative	  abundances	  
are	  changed,	  a	  random	  relative	  abundance	  is	  incremented	  or	  decremented	  by	  1	  (in	  the	  case	  that	  a	  
decrement	  would	  reduce	  abundance	  below	  0,	  the	  abundance	  is	  incremented	  instead).	  In	  the	  case	  
that	   a	   mutation	   is	   changed,	   a	   random	   mutation	   is	   assigned	   a	   new	   lineage	   at	   random.	   The	  
crossover	   function	   uses	   single	   point	   crossover.	   However,	   to	   ensure	   that	   lineages	   are	   always	  
representable	   as	   a	  DAG	   the	   crossover	   cannot	   occur	   during	   the	   first	  n	  elements	   of	   a	   vector.	   The	  
remaining	  parameters	  required	  for	  the	  GA	  function	  were	  selected	  as	  follows:	  population	  size:	  100,	  
elitism:	  2,	  mutation	   rate:	   0.8,	   tournament	   selection,	   iterations:	   1000,	   type:	  binary.	   The	   function	  
was	  iterated	  over	  n=5:12	  predicted	  lineages,	  and	  the	  best	  scoring	  individual	  was	  selected.	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2.	  CLINICAL	  ASSESSMENT	  OF	  INTRA-­‐CLONAL	  HETEROGENEITY	  IN	  
PATIENTS	  TREATED	  WITH	  NEW	  DRUGS	  
2.1	  PATIENTS	  
Patients	   from	   the	  MRC	  Myeloma	   XI	   trial	   for	  which	   complete	   clinical	   and	   laboratory	   value	  were	  
available	  were	  selected.	  The	  MRC	  Myeloma	  IX	  trial	  (ISRCTN68454111)	  enrolled	  1960	  patients	  and	  
the	   full	   design	   and	   primary	   results	   of	   the	   trial	   have	   been	   reported	   288,289.	   In	   summary,	   the	   trial	  
randomised	   newly	   diagnosed	   multiple	   myeloma	   patients	   to	   receive	   thalidomide	   versus	   non-­‐
thalidomide	   containing	   therapy;	   thalidomide	   could	   be	   given	   both	   as	   an	   induction	   and/or	   as	   a	  
maintenance	  regimen.	  Patients	  were	  divided	  between	  an	   intensive	  and	  a	  non-­‐intensive	  pathway	  
based	  on	  their	  eligibility	  for	  ASCT.	  Primary	  end-­‐points	  included	  PFS,	  OS	  and	  response.	  Centralised	  
laboratory	  results	  were	  available	  for	  647	  patients.	  
2.2	  FLC	  EVALUATION	  AND	  RESPONSE	  ASSESSMENT	  
FLC	   and	   paraprotein	   levels	   were	   evaluated	   at	   diagnosis,	   post	   induction,	   and	   at	   relapse	   in	   all	  
patients.	   The	   International	  Myeloma	  Working	  Group	   (IMWG)	  uniform	   response	   criteria	   173	  were	  
used	   to	   assess	   response	   and	   relapse	   in	   this	  manuscript	   based	   on	   central	   laboratory	   analysis	   of	  
serial	  blood	  and	  urine	  samples.	  Patients	  were	  classified	  as	  relapsing	  with	  free	  light	  chain	  only	  (FLC)	  
escape	  if	  they	  failed	  to	  meet	  the	  IMWG	  criteria	  for	  change	  in	  paraprotein	  levels	  that	  define	  relapse	  
but	  satisfied	  IMWG	  criteria	  for	  changes	  in	  FLC	  levels	  (Table	  1).	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Table	   1.	   Relapse	   criteria	   used	   to	   define	   the	   type	   of	   relapse	   (modified	   from	  Durie	   et	   al.	   173	   and	  
Rajkumar	  et	  al.	  290)	  
iFLC=involved	  serum	  free	   light	  chain	   level.	  dFLC=difference	  between	   involved	  and	  uninvolved	  serum	  free	   light	  chain	  
levels	  
3.	  IMPACT	  OF	  LENALIDOMIDE	  ON	  THE	  BONE	  MARROW	  OF	  MYELOMA	  
PATIENTS	  
3.1	  PATIENTS	  
A	  total	  of	  18	  patients	  diagnosed	  with	  MM	  and	  treated	  at	  the	  Royal	  Marsden	  Hospital	   in	  London	  
were	   included.	   All	   patients	   were	   receiving	   treatment	   with	   lenalidomide,	   either	   alone	   or	   in	  
association	   with	   steroids	   and	   had	   received	   0	   to	   4	   prior	   lines	   of	   treatment;	   14/18	   patients	   had	  
received	  ASCT.	  Patients	  were	   categorized	  according	   to	   the	   time	   they	  had	  been	  on	   lenalidomide	  
treatment:	   eleven	   patients	   that	   had	   received	   lenalidomide	   for	   less	   than	   one	   year	   (median	   9	  
months,	   range	   4-­‐12)	   where	   categorised	   as	   “short-­‐term	   lenalidomide”	   (STL),	   whilst	   the	   seven	  
patients	   that	   had	   received	   lenalidomide	   for	   more	   than	   one	   year	   were	   defined	   as	   “long-­‐term	  





Change in FLC Levels Between Maximum 
Response and Relapse 
Paraprotein only 
PO 
 ≥5g/L and an 
increase ≥25% 
Urine FLC <200mg/24hr and 
iFLC <100mg/L and dFLC <100mg/L  
Paraprotein and light 
chain 
PLC 
 ≥5g/L and an 
increase ≥25% 
 iFLC must have increased by ≥ 100mg/L 
and the increase must be ≥25% and 
dFLC≥100mg/L and the FLC ratio must be 
abnormal  
Free light chain escape 
FLC escape 
<5g/L iFLC must have increased by ≥ 100mg/L 
and the increase must be ≥25% and 
dFLC≥100mg/L and the FLC ratio must be 
abnormal 
Clinical relapse <5g/L iFLC <100mg/L and  
dFLC<100mg/L  
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lenalidomide”	  (LTL)	  (median	  65	  months,	  range	  22-­‐82).	  Seven	  additional	  patients	  who	  had	  received	  
ASCT,	  but	  were	  never	  treated	  with	  lenalidomide,	  where	  used	  as	  control	  group.	  
3.2.	  FLOW	  CYTOMETRY	  ANALYSIS	  
MPF	  analysis	  was	  performed	  using	  the	  EuroFlow	  antibody	  panels	  291;	  three,	  8	  colour,	  combinations	  
(Pacific	   Blue;	   Pacific	   Orange;	   Fluorescin	   Isothiocyanate,	   FITC;	   Phycoerythrin,	   PE;	   Peridinin	  
Chlorophyll	  Protein	  Cyanin	  5,	  PerCP-­‐Cy	  5.5;	  Phycoerythrin-­‐cyanin	  7,	  PE-­‐Cy7;	  Allophycocyanin,	  APC;	  
Allophycocyanin	  hilite	  7,	  APC-­‐H7)	  were	  used	  with	  the	  aim	  of	  investigating	  relative	  percentages	  of	  
the	  different	  BM	  populations	  (CD3,	  CD45,	  MPO7,	  CD79a,	  CD34,	  CD19,	  CD7,	  HLADR),	  B	  cells	  (CD20,	  
CD45,	  TdT,	  CD10,	  CD34,	  CD19,	  CD123,	  CD38)	  and	  myeloid	  cells	  (CD16,	  CD45,	  HLADR,	  CD13,	  CD34,	  
CD117,	  CD11b,	  CD10).	  EDTA-­‐anticoagulated	  fresh	  bone	  marrow	  (BM)	  samples	  (approximately	  0.5	  
mL)	   were	   collected	   and	   analysed	   within	   24	   hours	   from	   collection;	   a	   total	   of	   19	   samples	   were	  
analysed	   (one	   patient	   provided	   samples	   from	   both	   iliac	   crests	   at	   the	   same	   time	   point).	  Whole	  
bone	  marrow	  samples	  were	  stained	  for	  cell	  surface	  markers	  using	  the	  stain-­‐lyse-­‐and-­‐wash	  direct	  
immunofluorescence	  technique	  (myeloid	  panel),	  while	  for	  those	  panels	  including	  both	  surface	  and	  
intracellular	  markers	  (BM	  populations	  and	  B	  panel),	  staining	  was	  performed	  after	  cell	  fixation	  and	  
permeabilization,	   using	   the	   ADG	   Fix&Perm®	   kit	   (An	   Der	   Grub	   Bio	   Research	   GmbH,	   Austria).	  
Following	  staining,	  samples	  were	  measured	  using	  a	  BD	  LSR	  II	  flow	  cytometer	  (BD	  Bioscience,	  San	  
Jose,	  CA)	  with	  the	  EuroFlow	  instrument	  setup	  data	  acquisition	  standard	  operating	  procedures	  292.	  
Minimum	   number	   of	   events	   analysed	   was	   30.000	   cells/tube,	   with	   a	   median	   number	   of	  
mononuclear	  cells	  acquired	  of	  50.000/test.	  Data	  were	  analysed	  with	  BD	  FACSDiva	  software	  version	  
6.1.3	  and	  SPSS	  version	  20.0.	  Mononuclear	  and	  lymphocytic	  cells	  were	  first	  identified	  based	  on	  light	  
scatter	  characteristics	  (sideward	  scatter,	  SSC	  and	  forward	  scatter,	  FSC),	  then	  confirmed	  as	  CD45+	  
and	  gated	  accordingly.	  For	  the	  lymphoid	  populations	  both	  CD45+	  and	  CD45dim	  cells	  were	  taken	  into	  
account.	  
4.	  STATISTICAL	  ANALYSIS	  
Statistical	  analysis	  was	  performed	  using	  SPSS	  version	  20.0	  (SPSS	  Inc.,	  Chicago,	  USA)	  and	  GraphPad	  
Prism	  6.	  Statistical	  significance	  of	  the	  differences	  between	  light	  chain	  and	  paraprotein	  levels	  were	  
assessed	   using	  Mann-­‐Whitney	   U	   tests.	   Significance	   between	   the	   different	   BM	   populations	   was	  
assessed	   with	   the	   Mann-­‐Whitney	   U	   or	   the	   Kruskall-­‐Wallis	   test,	   as	   appropriate.	   Survival	   curves	  
were	   plotted	   using	   the	   Kaplan-­‐Meier	   method.	   Differences	   between	   curves	   were	   tested	   for	  
statistical	  significance	  using	  the	  log-­‐rank	  test.	  Statistical	  significance	  was	  set	  at	  p=0.05.	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RESULTS	  
1.	  EVALUATION	  OF	  INTRA-­‐CLONAL	  HETEROGENEITY	  IN	  PRIMARY	  
SAMPLES	  OF	  MYELOMA	  PATIENTS	  
The	   evaluation	   of	   intra-­‐clonal	   heterogeneity	   in	   primary	   samples	   of	   MM	   patients	   followed	   two	  
different	  approaches.	  On	  one	  hand	  we	  were	  interested	  in	  assessing	  intra-­‐clonal	  heterogeneity	  at	  a	  
single	  cell	  level,	  while	  on	  the	  other	  hand	  the	  evolution	  of	  myeloma	  with	  WES	  was	  also	  evaluated.	  
MM	   evolution	   was	   evaluated	   in	   two	   different	   ways,	   searching	   for	   differences	   at	   the	   different	  
stages	   of	  MM	   (including	   4	   paired	   samples	   SMM-­‐MM)	   and	   looking	   at	   the	   clonal	   dynamics	   after	  
treatment	  (one	  SMM-­‐MM	  paired	  sample)	  and	  in	  a	  xenograft	  model.	  	  
1.1	  SINGLE	  CELL	  ANALYSIS	  OF	  PRIMARY	  MYELOMA	  SAMPLES	  
Using	   a	   single	   cell	   approach	  we	  examined	  6	   cases	  of	  MM	  of	  which	   fixed	   cells	  were	   available	   at	  
diagnosis,	  and	  we	  were	  able	  to	  detect	  both	  a	  linear	  and	  a	  branching	  evolution	  pattern.	  In	  the	  first	  
sample	   5–6	   tumour	   sub-­‐clones	   could	   be	   distinguished,	   wherein	   each	   mutation	   and	   genomic	  
aberration	  was	  acquired	  in	  a	  stepwise	  linear	  fashion.	  Briefly,	  mutations	  in	  5	  genes	  were	  analysed	  
in	  the	  89.6%	  (216/241)	  of	  sorted	  fixed	  single	  cells	  that	  passed	  all	   filtering	  thresholds	  (Figure	  1a).	  
The	   most	   recurrent	   mutation	   was	   ATM	   c.428A4G	   (100%	   of	   tumour	   cells)	   followed	   by	   KLK8	  
c.356A4G	   (94.4%),	   GMEB1	   c.478A4T	   and	   POLE	   c.776G4A	   (44.4%),	   and	   lastly	   KRAS	   c.182A4G	  
(24.5%).	   The	   presence	   of	   +8q	   and	   +21q	   at	   sub-­‐clonal	   levels	   was	   also	   seen	   with	   the	   single-­‐cell	  
analyses.	   When	   considering	   cells	   with	   mutations	   and	   copy	   number	   aberration	   data,	   86.7%	  
(137/158)	  displayed	  +8q	  and	  63.9%	  (101/158)	  had	  +21q	  (Figures	  1b	  and	  c).	  Hierarchical	  clustering	  
defined	  five	  clones	  (Figure	  1b)	  and	  allowed	  to	  delineate	  the	  most	  plausible	  tumour	  phylogeny.	  In	  
this	  case	  genetic	  mutations	  and	  genomic	  aberrations	  were	  acquired	   in	  a	   linear	  sequence,	  where	  
ATM/KLK8	  mutations	   preceded	   +8q	   and	   +21q,	  which	  were	   followed	   by	  GMEB1/POLE	   and	   KRAS	  
mutations	  (Figure	  1c).	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Figure	   1.	   Linear	   evolutionary	  pattern.	   (a)	   Thumbnail	  heatmap	  of	  a	  Fluidigm	  array	  used	   for	   the	   study	  of	   this	  
case.	   Each	   column	   shows	   the	   interrogated	   genotyping	   (left)	   or	   copy	   number	   (right)	   assay.	   Each	   row	   represents	   a	  
sorted	   single-­‐cell,	   which	   DNA	   is	   interrogated	   for	   mutation	   presence/absence	   and	   copy	   number	   values.	   Rows	   are	  
sorted	  to	  group	  cells	  with	  the	  same	  genetic	  pattern	  (clones).	  Bulk	  tumour	  and	  peripheral	  blood	  DNA	  from	  the	  same	  
case,	   and	   normal	   donor	   lymphocytes,	   are	   interrogated	   below.	   Amplification	   intensity	   is	   colour	   scale-­‐based,	   from	  
yellow	  (high	  DNA	  content)	  to	  blue	  (low	  DNA	  content).	  Black	  means	  no	  amplification.	  Zoomed	  images	  to	  cell	  patterns	  
are	  shown	  on	  the	  right.	  Clone	  2	  has	  mutations	   in	  ATM/KLK8,	  clone	  4	  further	  carries	  mutations	  in	  GMEB1/POLE,	  and	  
clone	   5	   has	   an	   additional	   KRAS	   mutation.	   (b)	   Hierarchical	   clustering	   of	   158	   single-­‐cells	   which	   passed	   quality	   and	  
thresholds	  criteria.	  Grey	  means	  no	  change;	  red,	  mutation;	  blue,	  gain.	  Cells	  are	  clustered	  according	  to	  their	  pattern	  for	  
mutations	   and	   genomic	   aberrations	   (+8q/+21q)	   in	   five	   clones.	   N	   means	   cells	   with	   a	   normal	   pattern.	   (c)	   Clonal	  
phylogeny.	   Clones	   evolve	   via	   a	   linear	   evolutionary	   pattern	   where	   mutations	   (coloured	   stars)	   and	   copy	   number	  
aberrations	  (+8q/+21q)	  are	  acquired	  in	  a	  stepwise	  process.	  KRAS	  c.182A>G	  (p.Q61R)	  is	  the	  most	  recent	  mutation	  and	  
generates	  clone	  5.	  Clonal	  frequencies	  are	  depicted	  in	  absolute	  numbers	  and	  percentages.	  	  
	  
Two	  additional	  cases	  displayed	  a	  similar	  pattern	  of	  linear	  evolution,	  although	  with	  a	  lower	  clonal	  
diversity	   (2	   and	   3	   clones	   identified,	   respectively).	  Mutations	   in	   the	   RAS	   pathway	   were	   seen	   to	  
occur	  later	  in	  tumour	  development	  in	  our	  series.	  The	  genetic	  architecture	  of	  the	  remaining	  three	  
samples	   had	   4–6	   clones	   detected	   at	   presentation,	   but	   in	   these	   cases	   clones	  were	   related	   via	   a	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branching	  phylogeny	  (Figure	  2).	  In	  one	  of	  the	  samples	  analysed	  del(13q)	  was	  detected	  with	  FISH.	  
As	  a	  mutation	  in	  STK4	  was	  present	  at	  a	  sub-­‐clonal	  level	  and	  the	  STK24	  locus	  is	  at	  13q31.2-­‐q32.3,	  
we	  aimed	  to	  define	  whether	  del(13q)	  preceded	  or	  followed	  STK24	  mutation.	  Using	  qPCR	  analysis	  
of	  the	  RB1	  locus	  on	  chr13,	  del(13q)	  was	  shown	  in	  66–87%	  of	  the	  filtered	  tumour	  cells	  (Figure	  2a).	  
Combined	   analysis	   of	   both	   wild-­‐type/mutant	   STK24	   alleles	   and	   del(13q)	   copy	   number	   data	  
demonstrated	  that	  del(13q)	  preceded	  STK24	  mutation.	  It	  occurred	  in	  a	  sub-­‐clone	  of	  clone	  1	  (clone	  
1.1),	  after	  PCDH15	  and	  TRPA	  were	  mutated	  but	  before	  the	  acquisition	  of	  the	  remaining	  mutations	  
and	  the	  emergence	  of	  the	  most	  recent	  clones	  (Figures	  2b	  and	  c).	  Clone	  1.1	  is	  the	  ancestor	  for	  both	  
clone	  2,	  which	  mutated	  the	  STK24	  allele	   located	   in	   the	  single	  copy	  of	  chr13,	  and	  clone	  3,	  which	  
instead	  retained	  the	  wild-­‐type	  STK24	  allele	  but	  acquired	  ACAD10	  and	  NRAS	  mutations	  (Figure	  2c).	  
These	   branching	   evolutionary	   patterns	   are	   a	   characteristic	   feature	   of	   myeloma	   and	   resemble	  
those	  described	  in	  other	  cancers	  6-­‐8.	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Figure	   2.	  Branching	  evolutionary	  pattern.	   (a)	  Thumbnail	  heatmap	  of	  a	  Fluidigm	  array	  used	  for	  this	  analysis.	  
Zoom	  image	  to	  cell	  patterns	  are	  shown	  (right).	  Clone	  2	  and	  clone	  3	  have	  common	  mutations	  in	  TRPA/PCDH15	  to	  clone	  
1	   but	   further	   accumulate	   independent	   mutations	   in	   NRAS/ACAD10	   (clone	   2)	   or	   STK24	   (clone	   3).	   (b)	   Hierarchical	  
clustering	  of	  the	  135	  filtered	  single-­‐cells.	  Grey	  means	  no	  change;	  red,	  mutation	  or	  wild-­‐type	  allele	  (for	  STK24	  wt);	  deep	  
red,	  loss	  of	  13q.	  Four	  tumour	  sub-­‐clones	  are	  distinguished,	  with	  mutations	  present	  in	  clone	  3	  (NRAS	  and	  ACAD10)	  but	  
not	  in	  clone	  2	  (STK24).	  N	  means	  cells	  with	  a	  normal	  and	  reference	  pattern.	  (c)	  Clonal	  branching	  phylogeny	  considering	  
both	  mutations	  (coloured	  stars)	  and	  13q	  copy	  number	  data.	  Clone	  1,	  which	  already	  has	  TRPA	  and	  PCDH15	  mutations,	  
further	  acquires	  del(13q),	  producing	  clone	  1.1.	  This	   clone	  generates	   two	   lineages:	   clone	  2,	  with	  mutation	   in	  STK24;	  
and	  clone	  3,	  with	  wild	  type	  STK24	  and	  mutations	  in	  ACAD10	  and	  NRAS.	  NRAS	  c.182A>G	  (p.Q61R)	  mutation	  occurs	  in	  
an	   independent	   branch	   and	   relatively	   recently	   in	   myeloma	   development.	   Asterisks	   mean	   PCHD15	  
c.2272_2273delinsTA.	  Clonal	  frequencies	  are	  depicted	  in	  absolute	  numbers	  and	  percentages.	  	  
	  
Having	  shown	  the	  myeloma	  phylogeny,	  we	  analysed	  the	  putative	  founder	  clone	  as	  defined	  by	  the	  
initiating	   genetic	   lesion,	   the	   chromosomal	   translocation	   t(11:14).	   All	   patients	   analysed	   had	   a	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t(11;14),	  which	  hypothetically	  served	  as	  a	  marker	  of	  the	   initially	   immortalized	  clone.	  To	  test	  this	  
theory,	   we	   defined	   the	   translocation	   breakpoint	   using	   massively	   parallel	   sequencing	   combined	  
with	  targeted	  pull	  down	  of	  the	  Ig	  regions	  and	  designed	  translocation-­‐detection	  PCR-­‐based	  assays	  
applicable	  to	  single-­‐cell	  assays	  for	  three	  of	  the	  six	  cases.	  For	  all	  three	  cases,	  we	  demonstrated	  that	  
the	   t(11;14)	   was	   present	   in	   91–100%	   of	   tumour	   cells.	   Remarkably,	   we	   identified	   an	   ancestral	  
myeloma	  clone	  showing	  only	  t(11;14)	  in	  two	  of	  the	  three	  samples	  with	  a	  frequency	  of	  27.5%	  and	  
7%,	   respectively	   (clone	  1,	  Figures	  3a	  and	  b).	  None	  of	   the	   remaining	   interrogated	  mutations	  was	  
present	  in	  these	  sub-­‐clones,	  suggesting	  these	  may	  be	  the	  initiating	  founders.	  However,	  we	  cannot	  
dismiss	   the	   potential	   presence	   of	   other	  mutations/alterations	   that	   we	   could	   not	   detect	   due	   to	  
technical	   issues	  or	   that	  were	  not	   included	   in	   the	  analysis.	  Conversely,	   the	  ancestral	  clone	   in	   the	  
remaining	  case	  carried	  the	  t(11;14)	  and	  4	  genetic	  mutations	  (clone	  1,	  Figures	  3c	  and	  d).	  The	  exact	  
timeline	  of	  the	  events	   leading	  to	  this	  clone	  seems	  untraceable,	  as	  mutations	  may	  have	  followed	  
initial	  immortalization	  by	  t(11;14),	  occurred	  simultaneously	  to	  translocation	  or	  preceded	  t(11;14).	  
Three	  cases	  had	  double	  hits	  in	  the	  RAS/MAPK	  pathway	  either	  in	  the	  same	  gene,	  KRAS	  (two	  cases),	  
or	  in	  different	  genes	  such	  as	  KRAS	  and	  NRAS	  (one	  case).	  To	  determine	  whether	  these	  double	  hits	  
occurred	  in	  the	  same	  or	  in	  independent	  sub-­‐clones,	  we	  interrogated	  both	  mutations	  together	  with	  
other	   altered	   genes	   at	   the	   single-­‐cell	   level.	   The	   first	   case	   had	   KRAS	   c.183A4C	   (p.Q61H)	   and	  
c.199A4C	   (p.M67L)	   mutations	   at	   similar	   frequencies	   (92%	   and	   83%,	   respectively),	   and	   these	  
followed	  a	  linear	  sequence.	  KRAS	  p.Q61H	  occurred	  earlier	  than	  p.M67L,	  which	  was	  acquired	  soon	  
after	  clonal	  expansion,	  as	  clone	  3	  carries	  both	  mutations	  and	  is	  present	  in	  83.2%	  of	  tumour	  cells.	  
Although	   the	   presence	   of	   both	   mutations	   seemed	   to	   improve	   clonal	   fitness	   due	   to	   the	  
predominance	  of	  clone	  3,	  the	  extent	  to	  which	  p.M67L	  was	  responsible	  for	  this	  benefit	  is	  uncertain.	  
p.M67L	   is	   not	   a	   known	   activating	   mutation	   and	   may	   simply	   be	   a	   passenger	   mutation	   in	   a	  
proliferative	  clone	  defined	  by	  the	  activating	  mutation	  p.Q61H.	  Conversely,	  the	  double	  RAS	  hits	  in	  
the	  remaining	  cases	  occurred	  in	  different	  clones	  related	  via	  a	  branching	  pattern.	  The	  second	  case	  
had	   6	   sub-­‐clones	   (Figure	   3a)	   and	   we	   confirmed	   the	   independent	   acquisition	   of	   2	   KRAS/NRAS	  
mutations.	   The	   founding	   clone	   that	   only	   carried	   t(11;14)	   (clone	   1,	   27.5%	   frequency)	   acquired	  
ABCA4	  c.3294C4T,	  and	   it	  was	  this	  clone	  2	   (5.0%)	  that	  generated	  two	  divergent	   lineages:	  clone	  3	  
(40.0%)	  carrying	  both	  FAT	  c.6080T4G	  and	  NRAS	  c.182A4G	  (p.Q61R)	  mutations,	  and	  clone	  4	  (5.0%)	  
that	  had	  KRAS	  c.183A4C	   (p.Q61H).	  The	   latter	  gave	   rise	   to	  a	   lineage	  where	  PCSK6	  c.463G4A	  was	  
accumulated	   in	   clone	   5	   (7.5%),	   which	   subsequently	   originated	   clone	   6	   after	   the	   IRF4	   c.368A4G	  
mutation	   (15.0%;	   Figure	   3b).	   In	   the	   last	   case	   we	   described	   five	   clones	   and	   confirmed	   the	   co-­‐
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occurrence	  of	   two	  KRAS	  mutations	   (Figure	  3c).	   Clonal	   phylogeny	   identified	   the	  earliest	   clones	  1	  
and	   2	   (4.0%	   and	   34.0%,	   respectively)	   with	   t(11;14)	   and	   a	   range	   of	   mutations,	   including	   IRF4	  
c.368A4G	  and	  EGR1	  c.1169A4G,	  the	  latter	  being	  specific	  of	  clone	  2.	  Two	  divergent	  clonal	  lineages	  
derived	   from	   clone	   2,	   both	   acquiring	   KRAS-­‐activating	   mutations.	   Clone	   3	   accumulated	   KRAS	  
c.182A4G	   (p.Q61R)	  and	  accounted	   for	  26.0%	  of	   tumour	  cells,	  whereas	  clones	  4	  and	  5	  had	  KRAS	  
c.34G4C	  (p.G12R)	  representing	  24.0%	  and	  12.0%,	  respectively,	  of	  tumour	  cells	  (Figure	  4d).	  These	  2	  
cases	  acquired	  the	  same	  convergent	  phenotype,	  that	  is,	  activation	  of	  the	  RAS/MAPK	  pathway,	  in	  2	  
divergent	   clonal	   lineages	   derived	   from	   the	   same	   clonal	   ancestor,	   which	   subsequently	   evolved	  
independently.	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Figure	  3.	  Putative	  founding	  role	  of	  t(11;14)	  and	  parallel	  evolution	  in	  myeloma.	  Close	  examination	  
of	   two	   cases	   with	   branching	   evolutionary	   patterns	   illustrates	   how	   independent	   clones,	   but	  
originated	   from	   the	   same	   ancestor,	   acquire	   activating	  mutations	   in	   the	   same	   gene	   or	   in	   genes	  
from	  the	  same	  pathway.	  (a-­‐b)	  Single-­‐cell	  analysis	  of	  the	  first	  case.	  (a)	  Results	  from	  the	  used	  Fluidigm	  array.	  Four	  
columns	  per	  genotyping	  assay	  were	  interrogated.	  No	  copy	  number	  assays	  were	  used.	  Clone	  1	  only	  shows	  positivity	  for	  
t(11;14),	  representing	  the	  most	  likely	  founding	  myeloma	  clone	  in	  this	  sample.	  White	  arrows	  point	  out	  NRAS	  c.182A>G	  
mutations	   (clone	   3)	   are	   recognized	   in	   different	   cells	   that	   those	   displaying	   KRAS	   c.183A>C	   (clones	   4-­‐6).	   (b)	   Clonal	  
phylogeny	   considering	   t(11;14)	   and	   mutations.	   Divergent	   clonal	   lineages	   emerged	   from	   clone	   2	   with	   activating	  
mutations	  in	  NRAS	  (clone	  3)	  or	  KRAS	  (clone	  4).	  Clone	  4	  further	  evolves	  independently	  acquiring	  first	  PCSK6	  c.463G>A	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(clone	  5),	  and	   later	   IRF4	  c.368A>G	  (clone	  6)	  as	  additional	  hits.	   (c-­‐d)	  Single-­‐cell	  analysis	  of	   the	  second	  case.	   (c)	  Array	  
heatmap	  obtained	  for	  this	  case.	  White	  arrows	  point	  out	  cells	  with	  KRAS	  c.182A>G	  (clone	  3)	  do	  not	  have	  KRAS	  c.34G>C	  
(shown	   in	   clones	   4-­‐5).	   (d)	   Tumour	   phylogeny	   reveals	   a	   common	   ancestor	   (clone	   2)	   carrying	   t(11;14)	   and	   other	  
mutations	   (including	   IRF4	   c.368A>G).	   Two	   independent	   clonal	   lineages	   arise	   from	   clone	   2	   and	   acquire	   different	  
activating	  mutations	  in	  KRAS:	  clones	  3-­‐4.	  The	  latter	  clone	  further	  evolves	  mutating	  C7ORF23.	  
1.2	  INTRA-­‐CLONAL	  HETEROGENEITY	  IN	  MYELOMA	  IS	  PRESENT	  FROM	  THE	  EARLY	  
STAGES	  
Samples	   from	   4	  MGUS	   patients,	   26	  MM	   and	   2	   PCL	  were	   analysed	   by	  WES.	   From	   4	   of	   the	  MM	  
samples	  paired	   samples	  at	   the	   time	  of	   SMM	  were	  also	  available.	  All	   the	  SMM	  samples	  met	   the	  
criteria	   for	   high-­‐risk	   SMM	   according	   to	   the	   Spanish	   definition	   293.	   Median	   number	   of	   non-­‐
synonymous	   (NS)-­‐SNVs	   in	   the	  MGUS	  exomes	  was	  13	   (range	  8–18),	   in	  SMM	  28	   (range	  20–69),	   in	  
MM	  31	  (range	  15–46)	  and	  in	  the	  PCL	  samples	  59	  (50–68).	  The	  data	  show	  that	  the	  number	  of	  NS-­‐
SNVs	   increases	  with	  disease	  progression	  from	  MGUS	  to	  PCL.	  The	  kernel	  density	  plots	   in	  Figure	  4	  
show	  several	  distinct	  peaks	  indicating	  a	  similar	  level	  of	  heterogeneity	  exists	  at	  all	  stages	  of	  disease	  
from	  MGUS	  to	  PCL.	  	  
	  
	  
Figure	  4.	  Clonal	  heterogeneity	  is	  present	  in	  all	  disease	  states.	  Gaussian	  kernel	  density	  plots	  indicating	  the	  
frequency	  of	  cells	  carrying	  all	  acquired	  exonic	  mutations.	  Frequency	  is	  calculated	  by	  adjusting	  mutant	  allele	  burden	  by	  
copy	  number	  of	  the	  loci	  mutated.	  Top	  row,	  MGUS	  samples;	  Middle	  rows,	  matched	  SMM/MM	  samples;	  bottom	  row,	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PCL	  samples.	  
	  
This	   intra-­‐clonal	  heterogeneity	  at	  the	  MGUS	  stage	  is	  consistent	  with	  clonal	  diversity	  arising	  early	  
on	  in	  the	  process	  of	  myelomagenesis	  and	  with	  clonal	  competition	  being	  an	  essential	  requirement	  
from	  the	  earliest	  phases	  of	  disease.	  The	  rate	  of	  transformation	  from	  MGUS	  to	  MM	  is	  slow,	  which	  
is	   consistent	   with	   the	   requirement	   for	   the	   acquisition	   of	   multiple	   mutations	   that	   are	   able	   to	  
deregulate	   driver	   genes,	   but	   these	   constitute	   rare	   events.	   Having	   shown	   the	   presence	   of	   intra-­‐
clonal	   heterogeneity	   at	   each	   stage	   of	   the	   disease,	   we	   were	   keen	   to	   understand	   how	   the	  
relationship	  between	  sub-­‐clones	  changes	  with	  the	  development	  of	  clinical	  symptoms	  and	  whether	  
this	   relationship	   followed	   Darwinian	   principles.	   In	   order	   to	   accurately	   determine	   the	   changes	  
occurring	  in	  the	  transition	  from	  SMM	  to	  MM,	  we	  analysed	  three	  sets	  of	  patients	  with	  paired	  SMM	  
and	  MM	  samples	  taken	  at	  least	  21	  months	  apart.	  Of	  the	  total	  acquired	  SNVs,	  93%	  (range	  91–95%)	  
were	  detected	  in	  both	  the	  SMM	  and	  MM	  samples,	  with	  81%	  (range	  64–94%)	  of	  the	  variants	  being	  
present	  in	  less	  than	  half	  of	  the	  tumour	  cells	  at	  both	  stages.	  Only	  3.3%	  (range	  0.3–8.1%)	  of	  variants	  
were	  present	  in	  greater	  than	  90%	  of	  MM	  cells.	  This	  observation	  suggests	  that	  both	  SMM	  and	  MM	  
contain	   many	   sub-­‐clones	   at	   low	   frequencies,	   a	   feature	   that	   would	   be	   anticipated	   if	   disease	  
progression	   was	   the	   result	   of	   clonal	   competition.	   After	   calculating	   the	   proportion	   of	   cells	   that	  
contained	  each	  variant,	  by	  combining	  base	  calls	  and	  copy	  number	  data,	  it	  was	  possible	  to	  define	  
the	  sub-­‐clonal	  composition	  of	  each	  disease	  stage.	  Typically,	  around	  six	  clusters	  were	  identified	  per	  
sample	  pair,	  and	  although	  these	  variant	  clusters	  do	  not	  directly	  represent	  clones,	  they	  can	  be	  used	  
to	  demonstrate	  clonal	  evolution	  over	  time.	  	  
One	  paired	   set	   of	   samples	  was	   sourced	   from	  a	  patient	  who	  was	   treated	  with	   lenalidomide	   and	  
dexamethasone	   and	   clearly	   demonstrates	   that	   chemotherapy	   results	   in	   a	   reduction	   in	   clonal	  
complexity	  (Figures	  5d-­‐f).	  For	  example,	  cluster	  A	  was	  dominant	  at	  the	  SMM	  stage,	  with	  mutations	  
present	  in	  80–100%	  of	  cells,	  but	  after	  treatment	  it	  has	  decreased	  to	  0–20%	  of	  cells.	  Some	  clusters	  
were	  largely	  unaffected	  by	  the	  treatment	  (clusters	  B,	  E,	  F,	  H	  and	  I).	  Conversely,	  cluster	  D	  has	  gone	  
from	  0	  to	  20%	  of	  cells	  at	  SMM	  and	  risen	  to	  40–60%	  at	  progression	  to	  MM,	  perhaps	  due	  to	  therapy	  
resistance.	  	  
	  
	   75	  
	  
Figure	   5.	   Clonal	   evolution	   of	   paired	   HR-­‐SMM	   and	  MM	   samples	   from	   an	   untreated	   (a–c)	   and	   a	  
treated	  patient	   (d–f).	   (a,	   d)	  Kernel	  density	  plots	  of	   the	  proportion	  of	  cells	   containing	  each	  variant	   from	  whole-­‐
genome	  sequencing	   in	  HR-­‐SMM	  (blue)	   and	  MM	   (red);	   (b,	   e)	   Comparison	  of	   the	  proportion	  of	   cells	   containing	  each	  
variant	   in	  HR-­‐SMM	  and	  MM	  samples.	  Positive	  and	  negative	  vertical	  deviations	  from	  the	  main	  diagonal	  (marked	  at	  a	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dashed	  line)	   indicate	  an	  increase	  or	  decrease	  in	  the	  variant	  from	  the	  HR-­‐SMM	  to	  MM	  stage	  respectively.	  (c,	   f)	  After	  
estimating	  the	  noise	  using	  a	  nearest-­‐neighbour	  based	  classifier,	  an	  EM	  based	  clustering	  strategy	  was	  used	  to	  define	  
clusters	  of	  variants.	  Most	  of	  the	  variants	  in	  HR-­‐SMM	  occur	  at	  low	  frequency,	  but	  a	  distinct	  increase	  in	  frequency	  for	  a	  
large	  set	  of	  variants	  is	  seen	  in	  the	  MM	  sample.	  
	  
There	  were	  on	  average	  433	  additional	   novel	   and	  unique	  mutations	   (range	  341–517)	   gained	  per	  
sample	  during	  the	  transition	  from	  SMM	  to	  symptomatic	  MM,	  few	  (mean	  2.3)	  were	  present	  within	  
coding	  regions	  and	  only	  one	  was	  NS.	  Understanding	  the	  rate	  of	  mutation	  acquisition	  is	  important,	  
and	  as	  the	  time	  to	  progression	  for	  the	  studied	  patients	  was	  known	  the	  number	  of	  variants	  unique	  
to	  each	  SMM	  and	  MM	  sample	  was	  used	  to	  calculate	  the	  rate	  at	  which	  new	  mutations	  were	  gained	  
and	  existing	  mutations	  lost,	  or	  at	  least	  became	  undetectable	  at	  the	  level	  of	  sensitivity	  of	  the	  test	  
used.	  The	  mean	  across	  the	  three	  cases	  was	  19	  mutations	  gained	  and	  36	  mutations	  lost	  per	  month.	  
From	  a	  mechanistic	  perspective	  it	  seems	  that	  copy	  number	  change	  occurs	  relatively	  early	  in	  these	  
cases,	  as	  using	  fluorescence	  in	  situ	  hybridization,	  at	  a	  macroscopic	  level,	  significant	  copy	  number	  
change	   during	   the	   transition	   could	   not	   be	   seen,	   a	   feature	   that	   was	   recapitulated	   when	   the	  
sequencing	  data	  were	  used	  to	  generate	  copy	  number	  data	  across	  the	  genome.	  These	  data	  indicate	  
that	  in	  the	  three	  cases	  untreated	  paired	  cases,	  the	  acquisition	  of	  copy	  number	  abnormalities	  does	  
not	   facilitate	   the	   transformation	   between	   the	   two	   disease	   stages	   and	   was	   a	   feature	   of	   earlier	  
stages	  of	  the	  disease.	  
The	   limited	   number	   of	   novel	   NS-­‐SNVs,	   indels	   and	   translocations,	   which	   characterize	   the	  
transformed	  MM	   samples	   indicates	   that	   by	   the	   time	   a	   case	   has	   evolved	   to	   the	   SMM	   stage	   the	  
majority,	   if	  not	  all,	  of	   the	  exonic	  genetic	  diversity	  necessary	   to	  give	   rise	   to	  an	  aggressive	  clinical	  
state	   is	   already	   present.	  We	   show	   that	   1732	  mutations	   were	   acquired	   in	   the	  MM	   samples,	   of	  
which	  only	  one	  was	  NS.	  However,	  there	  is	  a	  substantial	  intronic	  diversity,	  the	  significance	  of	  which	  
has	  not	  previously	  been	  demonstrated.	  
1.3	  CLONAL	  EVOLUTION	  IN	  A	  XENOGRAFT	  MODEL	  
To	  evaluate	  clonal	  dynamics	  over	  time	  a	  xenograft	  model	  was	  also	  used.	  In	  parallel,	  1x106	  CD138+	  
cells	   derived	   from	   the	   diagnostic	   sample	   of	   one	   patient	   were	   injected	   into	   the	   tibia	   of	  
NOD/SCIDyc(null)	   mice	   286;	   presentation	   and	   relapse	   sample	   from	   the	   patient	   (who	   had	   been	  
treated	  with	  Bortezomib	  containing	  regimen)	  and	  two	  of	  the	  engrafted	  myelomas	  were	  analysed	  
by	  WES	  sequencing	  (Figure	  6a).	  The	  data	  demonstrated	  the	  existence	  of	  a	  complex	  phylogenetic	  
history	   with	   fluctuations	   in	   the	   sub-­‐clonal	   composition	   at	   relapse	   and	   in	   the	   two	   engrafted	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myelomas	  when	  compared	  with	  the	  presentation	  sample.	  To	  prevent	  any	  false-­‐positive	  results	  due	  
to	   mouse	   DNA	   contamination,	   only	   mutations	   present	   in	   the	   two	   patient	   samples	  
(presentation/relapse)	  were	  tested	  in	  the	  two	  engrafted	  samples,	  excluding	  mutations	  specific	  to	  
the	   engrafted	  myelomas.	  We	   identified	   152	   single	   nucleotide	   variants	   in	   all	   4	   samples.	   Briefly,	  
mutations	   in	   74	   genes,	   including	   ATM	   or	   TP53,	   were	   shared	   across	   all	   samples.	   Although	   26	  
mutations	  were	  characteristic	  of	  the	  presentation	  sample,	  42	  were	  specific	  to	  the	  relapse	  stage.	  It	  
is	  noteworthy	  that	  three	  mutations	  were	  shared	  between	  the	  xenograft	  samples	  and	  the	  relapse	  
sample.	  We	  postulate	  that	  these	  mutations	  were	  present	  at	  diagnosis,	  but	  at	  undetectable	  levels,	  
probably	   in	   negligible	   sub-­‐clones.	   We	   used	   a	   genetic	   algorithm	   to	   group	   mutations	   present	   in	  
these	  four	  samples	  into	  sub-­‐clonal	  populations,	  and	  distinguished	  seven	  clones	  (Figure	  6b).	  These	  
were	  related	  by	  a	  complex	  branching	  pattern	  and	  all	  had	  different	  number	  of	  mutations	   (Figure	  
6c).	   The	   earliest	   ancestral	   clone	   carried	   six	  mutations,	   two	  out	   of	  which	  were	   non-­‐synonymous	  
single	  nucleotide	  variants	  in	  DNAH14	  and	  FAM47C	  (clone	  1).	  These	  mutations	  were	  present	  in	  all	  
four	  samples	  at	  a	  100%	  frequency,	  supporting	  clone	  1	  as	  the	  phylogenetic	  root	  (Figures	  6b	  and	  c).	  
There	   was	   a	   remarkable	   fluctuation	   in	   the	   clonal	   proportion	   in	   each	   sample	   (Figure	   6d).	   Four	  
clones	  were	  detected	  at	  diagnosis	  with	  populations	  5	  and	  7	  being	  the	  predominant	  fractions	  (59%	  
and	   23%,	   respectively).	   Patient	   treatment	   caused	   a	   significant	   population	   bottleneck	   in	   which	  
clones	  2,	  4	  and	  7	  were	  extinguished	  and	  41	  new	  mutations	  were	  acquired.	  Consequently,	  clones	  3	  
and	  6	  emerged	  at	  relapse	  (17	  and	  33%,	  respectively;	  Figures	  6b–d).	  These	  clones	  originated	  from	  
the	   earliest	   ancestral	   clone	   1,	   which	  was	   undetected	   at	   diagnosis	   (Figures	   6b–d).	   These	   results	  
support	   the	   idea	  that	  earlier	  ancestral	  clones	  may	   lead	  to	  relapse.	  The	  analysis	  of	   the	  engrafted	  
myelomas	   showed	   the	   clonal	   extinction	  of	   clones	  2,	   4	   and	  7,	   and	   the	   re-­‐emergence	  of	   clone	  1,	  
which	   was	   present	   at	   undetectable	   levels	   at	   diagnosis.	   Both	   xenograft	   samples	   had	   similar	  
mutation	   frequencies,	   with	   slight	   variations	   between	   clones	   1	   and	   5	   (Figure	   6d).	   Although	   the	  
genetic	   architecture	   of	   these	   engrafted	   myelomas	   may	   be	   even	   more	   complex	   due	   to	   the	  
accumulation	   of	   additional	   mutations	   not	   tested	   in	   this	   analysis,	   the	   results	   demonstrate	   that	  
three	   clones	   were	   outcompeted	   by	   the	   remaining	   ones	   both	   during	   patient	   treatment	   and	  
xenotransplant	  transitions.	  In	  addition,	  we	  show	  that	  earlier	  clones	  lead	  to	  relapse	  or	  engraftment	  
(Figure	   6d).	   Altogether,	   these	   findings	   emphasize	   the	   different	   survival	   properties	   of	   myeloma	  
clones	   as	   a	   consequence	   of	   restrictive	   population	   bottlenecks	   such	   as	   patient	   treatment	   or	  
xenotransplantation.	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Figure	  6.	  Changes	  in	  clonal	  architecture	  following	  patient	  treatment	  and	  in	  vivo	  NOD/SCID	  IL2Rγnull	  
transplantation.	   (a)	  Patient	  history	  with	  xenograft	  experiments	  outlined.	  Isolated	  DNA	  from	  CD138+	  cells	  purified	  
from	  paired-­‐patient	  samples	  at	  presentation	  12	  and	  relapse	  are	  analysed	  using	  exome-­‐sequencing.	  DNA	  from	  CD138+	  
cells	   purified	   from	   two	   independent	   myeloma-­‐xenograft	   samples	   is	   also	   studied.	   DTPACE:	   dexamethasone,	  
thalidomide,	   cisplatin,	   adriamycin,	   cyclophosphamide	   and	   etoposide;	   ASCT:	   autologous	   stem	   cell	   transplantation;	  
CVD:	   cyclophosphamide,	   bortezomib	   and	   dexamethasone.	   (b)	   Cluster	   of	   cancer-­‐cell	   fractions	   for	   all	   124	   SNVs	  
identified	   in	   the	   four	   samples.	   Sub-­‐clones	   are	   defined	   on	   the	   left	   using	   genetic	   algorithms.	   A	   selection	   of	   genes	   is	  
shown	  with	  coloured	  lines	  indicating	  the	  sub-­‐clone	  in	  which	  such	  genes	  were	  firstly	  mutated	  (right).	  (c)	  Phylogenetic	  
natural	  history	  of	  this	  PCL	  patient.	  The	  seven	  sub-­‐clones	  detected	  by	  whole-­‐exome	  sequencing	  and	  genetic	  algorithms	  
are	  depicted	  with	  the	  same	  colours	  as	   in	   (b).	  The	  number	  of	  new	  mutations	  and	  non-­‐synonymous	  single	  nucleotide	  
variants	  (NS-­‐SNVs)	  together	  with	  a	  selection	  of	  key	  mutated	  genes	  are	  shown	  in	  the	  transition	  between	  clones.	  (d)	  The	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proportion	   of	   sub-­‐clonal	   populations,	   shown	   as	   percentages	   next	   to	   each	   clone,	   fluctuated	   in	   the	   four	   analysed	  
samples.	  There	  were	  clones	  described	  at	  presentation	  that	  were	  undetected	  and,	  therefore,	  potentially	  extinguished	  
at	  relapse	  or	  at	  the	  engrafted-­‐myelomas	  (clone	  4	  or	  5).	  Conversely,	  new	  clones	  (sub-­‐clones	  3	  and	  7)	  emerged	  at	  the	  
relapse	  stage	  as	  a	  result	  of	  a	  further	  accumulation	  of	  mutations	  in	  sub-­‐clones	  1	  and	  6,	  respectively.	  
2.	  SERUM	  FLC	  AS	  A	  MARKER	  OF	  IMPACT	  FROM	  INTRA-­‐CLONAL	  
HETEROGENEITY	  
To	  evaluate	  the	  impact	  of	  intra-­‐clonal	  heterogeneity	  from	  a	  clinical	  point	  of	  view,	  we	  analysed	  520	  
of	  647	  (80.5%)	  patients	  treated	  within	  the	  MM	  IX	  trial	  that	  had	  relapsed.	  A	  significant	  increase	  in	  
both	  paraprotein	  and	  FLC	   levels	   (PLC	   relapse)	  was	  observed	   in	  35.2%	   (183/520),	  whilst	  258/520	  
(49.6%)	   relapsed	  with	  a	   significant	   increase	  only	  of	   their	  paraprotein	   levels	   (PO	   relapse)	   and	  25	  
had	   relapse	   detected	   clinically.	   In	   54/520	   (10.4%)	   patients	   the	   relapse	  was	   characterized	   by	   an	  
increase	   in	   FLC	   without	   a	   correspondent	   increase	   in	   paraprotein	   level,	   a	   phenomenon	   termed	  
“serum	  free	  light	  chain	  escape”	  294;	  these	  patients	  represented	  6.5%	  (24/369)	  of	  IgG	  patients	  and	  
19.9%	   (30/151)	   of	   IgA	   patients,	   respectively.	   In	   46/54	   (85%)	   patients	   the	   increase	   in	   involved	  
serum	  FLC	  was	  >200mg/l,	  that	  is	  the	  level	  of	  increase	  recommended	  for	  defining	  relapse	  requiring	  
treatment	  in	  the	  absence	  of	  clinical	  symptoms	  290.	  In	  these	  54	  FLC	  escape	  patients	  only	  28	  (51.8%)	  
had	  a	  >200mg/l	  increase	  in	  urine	  FLC	  levels.	  	  
The	  paraprotein	   levels	  at	  presentation	  were	  significantly	   lower	   in	  both	  IgG	  and	  IgA	  patients	  who	  
relapsed	  with	  FLC	  escape	  (LCO)	  as	  compared	  to	  patients	  who	  relapsed	  with	  a	  PLC	  or	  PO	  (Fig	  7a).	  
The	  FLC	  levels	  at	  presentation	  and	  relapse	  were	  significantly	  higher	  in	  patients	  who	  relapsed	  with	  
FLC	  escape	  compared	  to	  those	  relapsing	  with	  PO	  relapse	  (Figure	  7b).	  Similarly	  at	  relapse	  FLC	  levels	  
were	  significantly	  higher	  for	  patients	  with	  IgG	  FLC	  escape	  relapse	  compared	  to	  patients	  with	  IgG	  
PLC	   relapse	  but	   there	  was	  no	   significant	   difference	  between	   these	   groups	   for	   patients	  with	   IgA	  
myeloma	  (Figure	  7b).	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a.	   	   	   	   	   	   	   	   b.	  
	  
Figure	  7.	  Whisker	  box	  plots	  showing	  the	  median,	  25th	  and	  75th	  centiles	  for	  (a)	  paraprotein	  and	  (b)	  
absolute	   levels	  of	   the	   involved	   light	   chain	  at	  presentation,	  maximum	  response	  and	   relapse.	   Tails	  
represent	  5th	  and	  95th	  centiles.	  IgG	  PO	  n=186,	  IgG	  PCL	  n=138,	  IgG	  LCO	  n=24,	  IgA	  PO	  n=72,	  IgA	  PCL	  n=45	  and	  IgA	  LCO	  
n=30.	  Mann-­‐Whitney	   U	   tests	   were	   performed	   to	   assess	   the	   statistical	   significance	   of	   the	   differences	   between	   the	  
groups.	  PO,	  paraprotein	  only;	  PLC,	  paraprotein	  and	  light	  chain;	  and	  LCO,	  free	  light	  chain	  escape.	  
*	  	  	  p<0.05	  when	  compared	  to	  PO	  at	  the	  same	  time	  point	  
**	  	  p<0.01	  when	  compared	  to	  PO	  at	  the	  same	  time	  point	  
X	  	  	  p<0.05	  LCO	  versus	  PLC	  at	  the	  same	  time	  point	  
XX	  p<0.01	  LCO	  versus	  PLC	  at	  the	  same	  time	  point	  	  
Shaded	  column	  represents	  normal	  range	  for	  sFLC.	  
	  
A	  difference	   in	  survival	  between	   IgG	  and	   IgA	  myeloma	  patients	  has	  been	  previously	  established,	  
and	   reflects	   the	   short	   duration	   of	   remission	   in	   IgA	   patients	   295.	   In	   this	   study	   PFS	   and	   OS	   from	  
relapse	  are	  24	  vs.	  20	  months	  (p=0.003)	  and	  33.6	  vs.	  28.6	  months	  (p=0.071)	  for	  IgG	  and	  IgA	  patients	  
respectively.	  
PFS	  was	  similar	  between	  all	  relapse	  groups	  (21.9	  vs.	  18.0	  vs.	  20	  months	  for	  FLC	  escape,	  PLC	  and	  PO	  
relapse	  respectively,	  p=0.766).	  Conversely,	  the	  median	  OS	  of	  patients	  relapsing	  with	  a	  light	  chain	  
involvement	   (either	   FLC	   escape	   or	   PLC)	   was	   approximately	   13	   months	   shorter	   compared	   to	  
patients	  relapsing	  with	  a	  whole	  paraprotein	  (PO)	  (Figure	  8a,	  p=0.015);	  this	  was	  mostly	  attributable	  
to	   a	   significantly	   shorter	   survival	   from	   relapse	   (27.7	   vs.	   23.5	   vs.	   37.4	  months,	  p=0.002,	   for	   FLC	  
escape,	  PLC	  and	  PO	  respectively,	  Figure	  8b).	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a.	   	   	   	   	   	   	   	   b.	  
	  
Figure	   8.	   (a)	  Kaplan-­‐Meier	  curves	  of	  overall	   survival	   from	  diagnosis	   for	  patients	   relapsing	  with	  whole	  paraprotein	  
secretion	   (PO),	  both	  paraprotein	  and	   light	   chains	   (PLC)	  or	  patients	  with	  FLC	  escape	  phenomenon;	   (b)	   Kaplan-­‐Meier	  
curves	  of	  survival	  from	  first	  relapse	  for	  patients	  relapsing	  with	  whole	  paraprotein	  secretion	  (PO),	  both	  paraprotein	  and	  
light	  chains	  (PLC)	  or	  patients	  with	  FLC	  escape	  phenomenon	  
	  
Examining	   the	  OS	   from	  diagnosis	   and	   first	   relapse	  by	   paraprotein	   isotype,	   IgG	  patients	  with	   PO	  
relapse	   had	   a	   significantly	   improved	  OS	   from	   diagnosis	   (64.5	   vs.	   43.4	   and	   47.3	  months	   for	   FLC	  
escape	  and	  PLC	  respectively,	  p=0.007).	  There	  was	  a	  trend	  towards	  increased	  OS	  from	  diagnosis	  for	  
IgA	  patients	  who	   relapsed	  with	  PO,	  although	   this	   failed	   to	   reach	   statistical	   significance	   (50.9	  vs.	  
50.7	  vs.	  40.2	  months	  for	  PO,	  FLC	  escape	  and	  PLC	  respectively,	  p=0.066).	  Survival	  from	  relapse	  was	  
increased	   for	  patients	   relapsing	  without	  FLC	   involvement	   in	  both	   isotype	  subgroups	   (median	  OS	  
from	   relapse	   40	   and	   33.2	  months	   for	   IgG	   and	   IgA	   respectively)	   compared	   to	   patients	   in	   which	  
relapse	  was	  characterised	  by	  an	   increase	   in	  the	   involved	  FLC	   level	   (median	  survival	   from	  relapse	  
23.1	  and	  22.2	  months	   for	   IgG	  FLC	  escape	  and	  PLC	  and	  29.9	  and	  23.8	  months	   for	   IgA	  FLC	  escape	  
and	  PLC	  respectively,	  Figure	  9a	  and	  9b).	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a.	   	   	   	   	   	   	   	   b.	  
	  
Figure	   9.	   (a)	   Kaplan-­‐Meier	   curves	  of	   survival	   from	   first	   relapse	   for	   IgG	  patients	   relapsing	  with	  whole	  paraprotein	  
secretion	   (PO),	  both	  paraprotein	  and	   light	   chains	   (PLC)	  or	  patients	  with	  FLC	  escape	  phenomenon;	   (b)	   Kaplan-­‐Meier	  
curves	  of	  survival	  from	  first	  relapse	  for	  IgA	  patients	  relapsing	  with	  whole	  paraprotein	  secretion	  (PO),	  both	  paraprotein	  
and	  light	  chains	  (PLC)	  or	  patients	  with	  FLC	  escape	  phenomenon	  
	  
A	   Cox	   regression	   analysis	   including	   maximum	   response,	   age,	   paraprotein	   isotype,	   treatment	  
pathway,	  thalidomide	  therapy	  and	  the	  type	  of	  relapse	  identified	  a	  maximum	  response	  ≥VGPR,	  an	  
IgG	  paraprotein,	  intensive	  treatment	  and	  the	  type	  of	  relapse	  as	  variables	  independently	  associated	  
with	  an	  extended	  OS;	  treatment	  pathway	  and	  the	  type	  of	  relapse	  were	  also	  found	  to	  be	  variables	  
associated	  with	  a	  longer	  survival	  from	  first	  relapse	  (Table	  2).	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Table	  2.	  Multivariate	  analysis	  of	  variables	  associated	  with	  an	  increased	  overall	  survival	  and	  survival	  
from	  relapse	  
OS	  
	   HR	   CI	   p	  
Max	  resp	  ≥VGPR	   1.353	   1.048-­‐1.746	   0.020	  
IgG	   1.353	   1.059-­‐1.726	   0.016	  
Intensive	  pathway	   1.677	   1.297-­‐2.167	   <0.000	  
Relapse	  type	   	   	   0.005	  
PO	  vs.	  PLC	   1.480	   1.169-­‐1.872	   0.001	  
PO	  vs.	  FLC	  escape	   1.130	   0.772-­‐1.655	   0.528	  
Survival	  from	  relapse	  
Intensive	  pathway	   1.375	   1.066-­‐1.775	   0.014	  
Relapse	  type	   	   	   0.001	  
PO	  vs.	  PLC	   1.560	   1.232-­‐1.975	   0.000	  
PO	  vs.	  FLC	  escape	   1.284	   0.873-­‐1.887	   0.204	  
Max	  resp:	  maximum	  response;	  VGPR:	  very	  good	  partial	  response;	  IgG:	  IgG	  isotype	  myeloma;	  Intensive	  pathway:	  treatment	  in	  the	  
intensive	  pathway	  of	  MRC	  Myeloma	   IX	   trial;	  PO:	  paraprotein	  only	   relapse;	  PLC:	  paraprotein	  and	   light	   chain	   relapse;	   FLC	  escape:	  
serum	  free	  light	  chain	  escape	  relapse	  
3.	  LONG	  TERM	  EFFECT	  OF	  LENALIDOMIDE	  EXPOSURE	  ON	  THE	  BONE	  
MARROW	  
We	  were	   than	   interested	   in	   finding	  out	  whether	  a	   long-­‐term	   treatment	  with	   IMiDs	  might	  affect	  
the	   composition	   of	   the	   bone	  marrow,	   thus	   partly	   explaining	   Lenalidomide	   side	   effects	   and	   the	  
potential	   increase	   in	  second	  primary	  malignancies	  development	  reported	   in	  some	  studies.	  Using	  
MPF	  we	  were	  able	   to	  observe	   that	   the	  percentage	  of	  B	   cells	  was	   lower	   in	   lenalidomide	   treated	  
patients	   compared	   with	   patients	   not	   on	   treatment	   (median	   1%	   and	   2%	   of	   total	   marrow	  
mononuclear	  cells	  for	  LTL	  and	  STL	  respectively	  versus	  5%	  for	  the	  control	  group).	  The	  decrease	  in	  B	  
cells	  was	  proportional	   to	   the	  time	  patients	  had	  been	  on	   lenalidomide	  treatment,	  and	   it	   reached	  
statistical	   significance	   when	   comparing	   LTL	   versus	   controls	   (Figure	   10a,	   p=0.04).	   To	   be	   able	   to	  
identify	  a	  possible	  higher	  incidence	  of	  immature	  lymphoid	  precursor	  forms	  in	  lenalidomide	  treated	  
patients	  we	  selected	  a	  panel	  of	  antibodies	  that	  would	  enable	  us	  to	  detect	  for	  precursors	  as	  well	  as	  
naïve	   B-­‐lymphocytes.	   We	   observed	   that	   the	   decrease	   of	   B-­‐lymphocytes	   in	   patients	   receiving	  
lenalidomide	  was	  due	  to	  a	  reduction	  of	  the	  more	  mature	  forms	  (naïve	  and	  mature	  B	  cells,	  Table	  3).	  
Higher	   levels	   of	   immature	   forms	   (haematogones	   and	   pre-­‐B	   cells)	   could	   not	   be	   demonstrated	  
	   84	  
(Table	  3),	   and	  no	  aberrant	  population	  or	  phenotype	   could	  be	   identified.	   The	   lowest	   values	  of	  B	  
cells	  were	  observed	  in	  LTL	  patients.	  A	  concomitant	  relative	  increase	  in	  non-­‐B	  lymphoid	  population	  
(Figure	  10b)	  was	  seen,	  explained	  by	  an	  increase	  in	  T	  cells	  (Table	  3	  and	  Figure	  10a).	  
When	   looking	   at	   the	   myeloid	   fraction,	   no	   significant	   difference	   could	   be	   seen	   between	  
lenalidomide	   treated	   and	   non-­‐treated	   patients,	   irrespectively	   of	   the	   time	   on	   treatment	   (Figure	  
10c).	   Looking	   in	   more	   details	   at	   the	   different	   subset	   of	   myeloid	   cells,	   similar	   proportions	   of	  
myelocytes,	   metamyelocytes,	   and	   neutrophils	   were	   observed,	   both	   in	   treated	   and	   untreated	  
patients.	  Time	  on	  treatment	  did	  not	  affect	   the	  myeloid	  population	   (Table	  3,	  Figure	  10c)	  with	  no	  
increase	  in	  immature	  forms	  nor	  the	  presence	  of	  aberrant	  phenotypes.	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Table	  3.	  Mean	  and	  median	  values	  of	  different	  bone	  marrow	  population	  as	  detected	  by	  MPF	  
	   	   Mean	  (±SD)	   Median	  (IQR)	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BM:	   bone	   marrow;	   SD:	   standard	   deviation;	   IQR:	   interquartile	   range;	   STL:	   short-­‐term	   lenalidomide;	   LTL:	   long-­‐term	  
lenalidomide;	  No	  Len:	  never	  treated	  with	  lenalidomide	  	  
For	  All	  BM	  populations	  and	  Myeloid	  population	  values	  are	  expressed	  as	  percentages	  of	  bone	  marrow	  mononuclear	  
cells;	   for	   Lymphoid	   population	   values	   of	   B	   cells	   and	   CD19-­‐	   cells	   are	   expressed	   as	   percentage	   of	   bone	   marrow	  
lymphocytes	  and	  values	  of	  B	  cells	  subpopulations	  are	  expressed	  as	  percentage	  of	  B	  cells	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Figure	   10.	   Lenalidomide	   impact	   on	   the	   different	   BM	   populations.	   The	   following	   bone	   marrow	  
populations	  were	   identified:	   i)	  myeloid	   cells	   CD45+/MPO+/CD79a-­‐/CD3-­‐/CD19-­‐;	   ii)	   B	   cells	   CD45+/CD19+/CD79a+/MPO-­‐
/CD3-­‐/CD7-­‐;	   iii)	   T-­‐cells	   CD45+/CD3+/CD7+/CD19-­‐/CD79a-­‐/MPO-­‐.	   Specific	   subpopulations	   of	   B	   and	   myeloid	   cells	   were	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identified	   as	   follows:	   a)	   haematogones:	   CD45+/CD10+/TdT+/CD19+/CD20-­‐;	   b)	   pre	   B	   lymphocytes	  
CD45dim/CD10+/CD19+/CD38+;	   c)	   naïve	   B	   lymphocytes	   CD45+/CD19+/CD10-­‐/TdT-­‐;	   d)	   mature	   B	   lymphocytes	  
CD45+/CD19+/CD20+/CD10-­‐;	   myeloid	   precursors	   CD45+/HLADR+/CD117+/CD34+/CD11b-­‐/CD16-­‐;	   e)	   myelocytes	  
CD45+/CD13dim/CD11b+/CD16-­‐;	   f)	   metamyelocytes	   CD45+/CD13+/CD11b+/CD16dim/+;	   g)	   neutrophils	  
CD45+/CD13++/CD11b++/CD16++.	  (A)	  Box	  plots	  showing	  median	  values	  of	  B	  cells	  (CD19+),	  T	  cells	  and	  myeloid	  cells	  for	  
patients	  treated	  with	  lenalidomide	  for	  less	  than	  12	  months	  (Len	  <	  12	  m),	  more	  than	  12	  months	  (Len	  >	  12	  m)	  or	  never	  
treated	  with	  lenalidomide	  (No	  Len).	  Patients	  receiving	  lenalidomide	  show	  lower	  values	  of	  B	  cells	  and	  a	  correspondent	  
increase	  on	  T	  cells.	  No	  difference	  in	  myeloid	  cells	  was	  observed.	  Values	  are	  expressed	  as	  percentages	  of	  bone	  marrow	  
mononuclear	  cells.	  (B)	  Box	  plots	  of	  lymphocytes	  showing	  a	  significant	  decrease	  of	  CD19+	  lymphocytes	  in	  lenalidomide	  
treated	  patients,	  proportional	  to	  the	  time	  on	  lenalidomide.	  A	  concomitant	  significant	  increase	  in	  CD19-­‐	  lymphocytes	  is	  
observed.	   Values	   are	   expressed	   as	   percentage	   of	   bone	  marrow	   lymphocytes	   (gated	   based	   on	   CD45+	   positivity	   and	  
SSC).	   (C)	   Box	  plot	  of	  myeloid	   cells	   showing	  no	  differences	   in	   the	  median	   values	  of	  myeloid	  precursors,	  myelocytes,	  
metamyelocytes	  and	  neutrophils	  in	  lenalidomide	  treated	  and	  naïve	  patients.	  Values	  are	  expressed	  as	  percentages	  of	  
bone	  marrow	  mononuclear	  cells.	  	  
Significance	  was	  assessed	  with	  the	  Mann-­‐Whitney	  U	  or	  the	  Kruskall-­‐Wallis	  test	  as	  appropriate.	  Only	  significant	  values	  
are	  reported	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DISCUSSION	  
The	  presence	  of	   intra-­‐clonal	  heterogeneity	  has	  been	  has	  been	  revealed	  in	  a	  number	  of	  solid	  and	  
haematological	   tumours,	   using	   different	   approaches	   6-­‐9,11,12,145,296,297.	   The	   aim	   of	   the	   present	  
research	  project	  was	   to	   identify	  and	  better	  characterise	   intra-­‐clonal	  heterogeneity	   in	  MM,	  using	  
both	  a	  biological	  and	  a	  clinical	  approach.	  In	  the	  first	  part	  of	  the	  project	  WES	  and	  single-­‐cell	  genetic	  
analysis	   were	   successfully	   combined	   to	   unravel	   the	   complex	   phylogeny	   of	   intra-­‐clonal	  
heterogeneity	   in	  MM.	   Nonetheless	   these	   results,	   though	   reporting	   the	   existence	   of	   genetically	  
variegated	  sub-­‐clones	  in	  MM,	  may	  have	  under-­‐estimated	  such	  clonal	  complexity.	  First,	  the	  single-­‐
cell	   analysis	  was	   focused	  on	   a	   small	   list	   of	  NS-­‐SNVs,	  which	  were	   selected	   for	  mutating	  putative	  
driver	   myeloma	   genes	   according	   to	   previous	   literature	   and/or	   their	   CCFs.	   For	   instance,	   the	  
putative	  ancestral	  clone	  1	  identified	  in	  one	  patient,	  carrying	  only	  the	  t(11;14),	  may	  likely	  harbour	  
additional	  mutations	   untested	   in	   this	   analysis.	   Second,	   clones	   present	   at	   very	   low	   levels	   (<1%)	  
cannot	  be	  detected	  due	  to	  the	   limited	  number	  of	  sorted	  cells.	  Despite	  these	  pitfalls	   the	  study	   is	  
still	  able	  to	  unravel	  the	  main	  clonal	  phylogenetic	  relationships.	  
In	   this	   serie	   of	   t(11;14)	   myelomas,	   even	   at	   first	   clinical	   presentation,	   at	   a	   time	   when	   clinical	  
symptoms	  are	  present	  and	  treatment	  is	  required,	  evidence	  for	  the	  persistence	  of	  the	  earliest	  MPC	  
clone	   was	   found.	   Two	   cases	   were	   characterized	   by	   the	   presence	   of	   a	   sub-­‐clone	   carrying	   the	  
t(11;14)	   as	   the	   sole	   clonal	   abnormality.	   This	   observation	   together	   with	   the	   detection	   of	   the	  
translocation	  in	  most	  of	  the	  interrogated	  cells	  supports	  the	  etiological	  significance	  of	  the	  t(11;14).	  
This	   is	   also	   in	   agreement	   with	   the	   translocation	   being	   present	   in	  MGUS,	   the	   earliest	   phase	   of	  
myeloma	   103	   associated	   with	   fewer	   mutations	   than	   myeloma	   136.	   Once	   the	   founding	   clone	   is	  
established,	  the	  acquisition	  of	  additional	  mutations	  inevitably	  leads	  to	  the	  genetic	  and	  phenotypic	  
variegation	  within	  the	  progeny	  of	  the	  MPC-­‐founder	  clone.	  These	  heterogeneous	  MPC-­‐descendants	  
are	  characterized	  by	   the	  ability	   to	   self-­‐renew	  and	  proliferate,	  and	  can	  be	  considered	  as	  units	  of	  
selection	  in	  terms	  of	  a	  Darwinian	  basis	  for	  tumour	  evolution	  298.	  Our	  results	  suggest	  that	  the	  clonal	  
remnants	  of	  the	  earliest	  stages	  of	  the	  disease	  may	  persist	  late	  in	  the	  myeloma	  natural	  history.	  
Clonal	   phylogenetic	   relationships	   have	   important	   implications	   for	   both	   chemotherapy	   and	  
targeted	   treatment	   strategies.	  Although	   in	  our	  analysis	  both	   the	  presence	  of	  a	   linear	  pattern	  of	  
myeloma	   progression	   and	   a	   branching	   pattern	  were	   described,	   a	   unifying	   interpretation	   of	   the	  
data	   supports	   a	   branching	   evolutionary	  pattern	   as	   being	   the	  more	  plausible	   route	   for	  myeloma	  
progression,	  where	  contemporaneous	  clones	  accumulate	  independent	  genetic	  hits,	  shaping	  their	  
variegated	  mutational	  and	  phenotypic	  profiles.	  Even	  in	  the	  samples	  that	  showed	  a	  linear	  evolution	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it	  is	  worth	  considering	  the	  potential	  existence	  of	  additional	  clonal	  branches,	  which	  we	  could	  simply	  
not	  describe.	  Moreover,	  as	  ancestor	  clones	  are	  still	  present	  in	  a	  tumour	  with	  a	  linear	  pattern,	  they	  
may	  eventually	  accumulate	  new	  mutations,	  hence	  sprouting	  extra	  phylogenetic	  branches.	  Lastly,	  
sampling	   bias	  may	   also	   confound	   a	   linear	  model,	  with	   different	   sub-­‐clonal	   branches	   potentially	  
present	  at	  other	  tumour	  sites	  6,145,297.	  
Under	   the	   same	   environment	   and	   similar	   selective	   pressures,	   independent	   but	   not	   far-­‐related	  
clones	   may	   acquire	   similar	   mutations	   conferring	   important	   growth	   or	   survival	   advantages,	   a	  
phenomenon	   known	   as	   parallel	   evolution.	   This	   work	   demonstrate,	   for	   the	   first	   time,	   clear	  
evidence	   of	   parallel	   evolution	   at	   the	   single-­‐cell	   level	   in	  myeloma,	   as	   the	   same	   genetic	   pathway	  
(RAS/MAPK)	   is	   altered	  more	   than	   once	  within	   the	   same	   tumour	   but	   in	   divergent	   clones,	  which	  
further	   evolve	   independently.	   This	   finding	   is	   similar	   to	   data	   reported	   in	   primary	   tumour	   and	  
metastatic	  renal	  cell	  carcinoma	  6.	  RAS	  mutations	  represent	  true	  driver	  mutations	  in	  myeloma,	  as	  
any	  sub-­‐clone	  with	  activating	  KRAS/NRAS	  mutations	  is	  able	  to	  clonally	  expand	  and	  compete	  under	  
the	   same	   selective	   pressure	  during	  myeloma	  progression.	   It	  may	   represent	   the	  Achilles’	   heel	   in	  
myeloma	  based	  on	  the	  use	  of	  targeted	  treatment,	  as	  recently	  seen	  for	  BRAF	  165.	  This	  opens	  a	  new	  
therapeutic	  window	  by	  which	  pruning	  aggressive	  myeloma-­‐clonal	  branches	  could	  positively	  select	  
the	  more	  indolent	  ancestor	  clones.	  
It	   has	   also	   been	   thought	   that	   the	   acquisition	   of	  mutations	   over	   time,	   either	   in	   a	   linear	   or	   in	   a	  
branching	   fashion,	   leads	   to	   the	   progression	   of	   cancer	   from	   an	   essentially	   benign	   to	   clinically	  
aggressive	   behavioural	   states.	   In	   this	   analysis	   the	   number	   of	   NS	   mutations	   defining	   cases	   of	  
symptomatic	  MM	   is	   roughly	   23,	   a	   number	   intermediate	  between	   simple	   cancers,	   such	   as	   acute	  
myeloid	   leukaemia	  140,	  and	  the	  more	  complex	  solid	  cancers	  141.	  These	  data	  confirm	  our	  previous	  
single-­‐cell	   analysis,	   showing	   that	   approximately	   six	   predominant	   clones	   can	  be	  detected	   in	  MM	  
samples,	  with	  much	  greater	  complexity	  existing	  below	  the	  sensitivity	  of	  the	  sequencing	  approach	  
used.	  MGUS	  has	   fewer	  NS	  mutations	   than	   the	   later	   stages	  of	   disease,	   including	   SMM,	  MM	  and	  
PCL.	  However,	  looking	  at	  the	  nature	  and	  sites	  of	  mutation	  present	  at	  each	  disease	  stage,	  they	  do	  
not	   differ,	   an	   observation	   that	   is	   consistent	  with	   the	   same	  molecular	  mechanisms	   being	   active	  
throughout	   the	  course	  of	   the	  disease.	  To	  date,	   the	  genomes	  of	   the	  premalignant	   stages	  of	  MM	  
have	  not	  been	  sequenced	  and	  compared	  with	  those	  of	  symptomatic	  MM	  or	  PCL,	  but	  the	  data	  here	  
reported	   demonstrate	   that	   there	   is	   an	   increase	   in	   the	   number	   of	   NS	  mutations	   as	   the	   disease	  
progresses	   from	  MGUS	  to	  SMM	  and	  MM.	  This	   is	   in	   line	  with	  previous	  copy	  number	  abnormality	  
data,	  which	  indicate	  that	  the	  genetic	  complexity	  of	  the	  disease	  increases	  toward	  MM	  299-­‐301.	  MGUS	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is	  known	  to	  take	  >25	  years	  to	  progress	  to	  symptomatic	  MM,	  whereas	  SMM	  with	  high-­‐risk	  features	  
takes	  <5	  years	  to	  progress.	  In	  this	  context,	  it	  is	  interesting	  to	  note	  that	  the	  MGUS	  samples	  are	  very	  
much	  less	  complex	  compared	  with	  symptomatic	  MM,	  having	  approximately	  half	  the	  number	  of	  NS	  
mutations,	   whereas	   the	   SMM	   samples	   have	   an	   equal	   number	   of	   mutations	   compared	   with	  
symptomatic	  MM.	  Clear	  evidence	  of	  sub-­‐clonal	  heterogeneity	  in	  all	  stages	  of	  disease	  from	  MGUS	  
to	   PCL	   was	   seen,	   which	   is	   an	   essential	   substrate	   for	   Darwinian	   type	   evolution,	   once	   more	  
reinforcing	  our	  hypothesis	  that	  MM	  progression	  is	  mediated	  via	  competition	  between	  sub-­‐clones	  
and	  outgrowth	  of	  the	  fittest.	  Importantly,	  it	  was	  seen	  that	  intra-­‐clonal	  heterogeneity	  is	  present	  in	  
MGUS,	   the	   earliest	   clinically	   recognizable	   stage	   of	  MM,	   and	   that	   it	   is	   also	   present	   in	   the	   later	  
stages	  of	  the	  disease,	  including	  SMM	  and	  PCL.	  These	  observations	  are	  consistent	  with	  intra-­‐clonal	  
heterogeneity	  being	  a	  critical	  and	  consistent	  feature	  of	  both	  the	  early	  and	  late	  stages	  of	  myeloma.	  
It	  is	  also	  consistent	  with	  clonal	  competition	  being	  active	  from	  the	  earliest	  phases	  of	  disease	  until	  
its	   highly	   aggressive	   late	   stages	   and	   provides	   direct	   evidence	   to	   support	   the	   hypothesis	   that	  
Darwinian	   evolution	   mediates	   progression	   through	   the	   multiple	   steps	   of	   the	   disease	   model	   of	  
MM.	   The	   development	   of	   PCL	   via	   this	   complex	   evolutionary	   process	   characterized	   by	   extreme	  
deregulation	   of	   the	   behaviour	   of	   the	   normal	   cellular	   counterpart	   is	   consistent	   with	   the	   poor	  
results	  of	  treatment	  associated	  with	  this	  stage	  of	  the	  disease.	  This	  situation	  can	  be	  contrasted	  with	  
the	  results	  of	  the	  treatment	  of	  de-­‐novo	  acute	  leukaemia	  which	  can	  be	  cured	  probably	  because	  of	  
the	  significantly	   less	  number	  of	  genetic	  hits	  required	  to	  deregulate	  a	  hematopoietic	  stem	  cell.	   In	  
order	  to	  directly	  demonstrate	  the	  sub-­‐clonal	  relationships	  underlying	  the	  transitions	  between	  the	  
disease	  phases	  of	  myeloma,	  particular	  attention	  was	  paid	  to	  the	  SMM/MM	  transition	  using	  serial	  
samples	  from	  the	  same	  individuals.	  This	  is	  a	  critical	  transition,	  where	  an	  essentially	  benign	  state,	  
that	   it	  not	  treated,	  undergoes	  a	  change	  that	  results	   in	  clinical	  symptoms	  consistent	  with	  clonally	  
destructive	  behaviour	   and	   the	  development	  of	   end-­‐organ	  damage.	  Using	   kernel	   plot	   analysis	   of	  
these	  paired	  samples,	  changes	  in	  clonal	  composition	  can	  be	  seen,	  mediated	  via	  the	  expansion	  of	  
specific	  sub-­‐clones,	  associated	  with	  the	  transition,	  an	  observation	  that	  is	  consistent	  with	  previous	  
observations	   concerning	   the	   clonal	   expansion	   of	   genetically	   abnormal	   cells	   299.	   Looking	   at	   the	  
clonal	  composition	  of	  the	  paired	  samples,	  we	  show	  that	  the	  transformation	  of	  SMM	  to	  MM	  is	  not	  
the	  result	  of	  the	  outgrowth	  of	  a	  single	  clone	  but	  results	  from	  the	  outgrowth	  of	  a	  number	  of	  sub-­‐
clones,	  already	  present	  in	  the	  SMM	  sample.	  It	  seems	  that,	  in	  MM,	  up	  to	  six	  clones	  change	  during	  
the	   SMM-­‐MM	   transition,	   which	   is	   more	   than	   that	   has	   been	   suggested	   previously	   in	   paediatric	  
acute	   lymphoblastic	   leukaemia	   8,	   reflecting	   the	   increased	   genetic	   and	   sub-­‐clonal	   heterogeneity	  
	   92	  
seen	   in	  MM	  compared	  with	   this	   rather	  simple	  cancer	  model.	  The	  question	   then	  arises	  as	   to	   the	  
nature	  of	  the	  molecular	  mechanisms	  driving	  the	  sub-­‐clonal	  changes.	  At	  the	  SMM	  time	  point,	  we	  
show	   that	   the	   majority	   of	   the	   NS	   exonic	   changes	   are	   already	   present	   and	   that	   only	   a	   few	  
additional	  changes	  are	  seen	  following	  transformation.	  Apart	  from	  inactivating	  mutations	  in	  RUNX2	  
and	   acquired	   translocations	   into	   BRCA2	   and	   UNC5D,	   we	   could	   not	   identify	   any	   truly	   acquired	  
genetic	  abnormalities	  between	  the	  paired	  samples	  despite	  thoroughly	  checking	  for	  coding	  SNVs,	  
indels	   and	   copy	   number	   abnormalities.	   Having	   exhaustively	   searched	   for	   acquired	   mutational	  
change	   to	   explain	   the	   transition	   and	   having	   found	   only	   limited	   numbers	   of	   potential	  molecular	  
drivers	   to	   explain	   the	   development	   of	   clinical	   symptoms	   and	  how	  disease	   progression	   could	   be	  
mediated,	  alternative	  explanations	  should	  be	  considered.	  There	  are	  a	  number	  of	  non-­‐mutational	  
changes	   that	   could	   mediate	   the	   transition	   including	   epigenetic	   changes,	   which	   have	   been	  
described	  previously	  3,302.	  Alternatively,	  on	  the	  basis	  of	  the	  changes	  in	  sub-­‐clonal	  composition,	  as	  a	  
consequence	  of	  an	  increase	  in	  tumour	  bulk	  there	  is	  a	  threshold	  effect	  above	  which	  the	  MM	  cells	  
modify	   the	  microenvironment,	   such	   that	   they	   favour	   increased	  proliferation	  and	  expansion	  of	   a	  
sub-­‐clone	  best	  suited	  to	  that	  environment,	  the	  net	  consequence	  of	  which	  is	  sub-­‐clonal	  expansion	  
and	  the	  development	  of	  end-­‐organ	  damage.	  When	  these	  observations	  based	  on	  the	  experimental	  
characterization	  of	  the	  multiple	  disease	  phases	  of	  myeloma	  and	  the	  transition	  of	  SMM	  to	  MM	  in	  
particular	  are	  considered,	   it	  seems	  likely	  that	  SMM	  is	  not	  a	  distinct	  disease	  entity	  but	  is	  rather	  a	  
transition	   state	  between	  MGUS	  and	  MM,	  where	   the	   sub-­‐clonal	   structure	   is	  evolving.	  MGUS	   is	  a	  
benign	   clinical	   state,	   which	   is	   stable	   with	   no	   clinical	   symptoms,	   that	   contrasts	   with	   presenting	  
myeloma	  when	  tumour	  bulk	  has	  reached	  a	  critical	  threshold	  and	  clinical	  damage	  has	  developed.	  
The	   in-­‐between	   state,	   SMM,	   seems	   to	   represent	   a	   phase	   characterized	  by	   ongoing	   competition	  
between	   sub-­‐clones	   with	   the	   rate	   of	   transformation	   depending	   upon	   the	   nature	   and	   rate	   of	  
mutations	  that	  drive	  the	  process.	  We	  present	  a	  coherent	  hypothesis	  based	  on	  the	  data	  we	  find	  in	  
myeloma	  tumour	  sequencing	  data.	  In	  this	  hypothesis,	  adaptation	  is	  driven	  by	  genetic	  variation	  in	  
the	  tumour	  cells.	  At	  presentation	  the	  only	  selective	  pressures	  are	  those	  that	  occur	  naturally	  and	  
would	   involve	  competition	   for	   the	  myeloma	  cell	  niche	   in	   the	  BM	  and	  the	  avoidance	  of	   selective	  
pressures	   exerted	   by	   the	   immune	   system.	   Once	   treatment	   has	   been	   initiated,	   the	   selective	  
pressures	   change	   and	   possibly	   the	   evolution	   of	   the	   tumour	   are	   enhanced	   by	   exposure	   to	  
treatment.	  
Remnant	   ancestor	   clones,	   although	   not	   necessarily	   the	   primordial	   founding	   clone,	   have	   been	  
shown	   to	   lead	   to	   relapse	   4,9,11,136,137.	   These	   clones	   are	   postulated	   to	   represent	   MPC	   units	   of	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selection,	  critical	  for	  progression	  through	  the	  clinical	  stages	  of	  myeloma,	  and	  for	  relapse.	  Using	  a	  
xenograft	   model	   we	   could	   see	   that	   early,	   and	   likely	   founding,	   MPC-­‐clones	   remain	   present	   at	  
diagnosis,	   and	   that	   different	   clones	   exhibit	   distinct	   survival	   and	   propagating	   abilities	   following	  
patient	   treatment	   and	   xeno-­‐transplantation.	   Early	   clones	   present	   at	   low,	   or	   even	   undetectable,	  
levels	   at	   diagnosis	   were	   able	   to	   survive	   treatment	   and	   lead	   patient	   relapse	   generating	   new	  
prevalent	  clones.	  This	   finding	  was	  partially	   reproduced	   in	  xenograft-­‐samples.	   It	   seems	  clear	   that	  
sub-­‐clonal	  populations	  are	  involved	  in	  selection	  and	  competition	  during	  myeloma	  progression	  and	  
that	  their	  fluctuation	   is	  conditioned	  under	  changes	   in	  their	  cell	  micro-­‐environments	  as	  produced	  
by	  patient	  treatment	  or	  xeno-­‐transplantation.	  	  
Since	   the	   finding	   that	   intra-­‐clonal	   heterogeneity	   is	   an	   important	   feature	   in	   MM,	   a	   number	   of	  
studies	   have	   biologically	   evaluated	   this	   issue	   using	   different	  molecular	   and	   genetic	   approaches	  
11,12,111,136,303,304.	  However	  the	  clinical	  impact	  that	  intra-­‐clonal	  heterogeneity	  may	  have	  on	  patients’	  
outcome	   is	   still	   not	   completely	  understood.	   Furthermore	   it	  would	  be	   important	   for	   clinicians	   to	  
have	  a	  quick	  and	  easy	  tool	  that	  allows	  them	  to	  assess	  the	  presence	  of	  intra-­‐clonal	  heterogeneity	  
from	  a	  clinical	  perspective.	  Monitoring	  for	  the	  type	  of	  immunoglobulin	  produced	  and	  secreted	  at	  
relapse	  (either	  a	  whole	   immunoglobulin	  or	   just	  a	   light	  chain)	  provides	  an	  excellent	  tool	   to	  study	  
the	  global	   impact	  of	   intra-­‐clonal	  heterogeneity.	   The	  basic	  premise	   in	   this	  model	   is	   that	  patients	  
harbour	  different	  clones	  with	  different	  secretory	  behaviour	  305	  i.e.	  one	  clone	  is	  able	  to	  produce	  a	  
complete	  antibody,	  while	  the	  other	  secretes	  only	  a	  FLC	  and	  this	  can	  be	  used	  as	  a	  marker	  for	  sub-­‐
clonal	   progression.	   There	   is	   great	   heterogeneity	   in	   the	   patterns	   of	  monoclonal	   immunoglobulin	  
types	   and	   levels	   secreted	   by	   the	   myeloma	   clones	   of	   different	   patients	   at	   presentation,	   before	  
therapy	   has	   been	   administered.	   This	  was	   clearly	   shown	  by	   the	   observation	   that	   patients	   in	   the	  
different	  groups,	  despite	  having	  similar	  proportions	  of	  kappa	  (61-­‐67%)	  and	  lambda	  subtypes,	  had	  
very	   different	   levels	   of	   FLCs	   and	   paraprotein	   since	   presentation.	   As	   expected,	   the	   groups	   with	  
higher	  FLC	  levels	  at	  presentation	  (FLC	  escape	  and	  PCL)	  had	  a	  higher	  proportion	  of	  patients	  in	  which	  
light	  chains	  were	  detectable	  in	  the	  urine	  at	  presentation.	  Within	  individual	  patients	  these	  patterns	  
and	  levels	  may	  change	  as	  the	  patient	  enters	  remission	  and	  relapse,	  reflecting	  changes	  in	  numbers	  
and	  proportions	  of	  sub-­‐clones.	  
We	  describe	  that	  patients	  relapsing	  with	  increasing	  levels	  of	  free	  light	  chain	  have	  a	  worse	  outcome	  
from	   this	   time	   point	   than	   patients	   who	   relapse	   with	   increasing	   levels	   of	   only	   the	   whole	  
paraprotein.	  Importantly	  we	  describe	  for	  patients	  relapsing	  after	  presentation	  with	  an	  IgG	  or	  IgA	  
paraprotein	  10.4%	  relapse	  with	  FLC	  escape,	  49.6%	  with	  an	  increase	  only	  in	  whole	  paraprotein	  and	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35.2%	  with	  an	  increase	  in	  both	  FLC	  and	  paraprotein	  levels.	  In	  order	  to	  explain	  these	  observations	  
we	  postulate	  that	  chemotherapy	  is	  differentially	  active	  against	  the	  clonal	  cells	  producing	  the	  intact	  
paraprotein	  or	  the	  FLC	  only	  secreting	  clone.	  In	  such	  a	  model	  the	  type	  of	  relapse	  is	  a	  marker	  of	  a	  
heterogeneous	  disease,	  in	  which	  different	  clones	  predominate	  at	  different	  time	  point	  (Figure	  11).	  
	  
	  
Figure	  11.	  Model	  of	  Darwinian	  evolution	  in	  MM	  assessed	  by	  the	  type	  of	  paraprotein	  secreted.	  One	  
clone	   is	   able	   to	   produce	   a	   complete	   antibody,	   while	   the	   other	   secretes	   only	   a	   FLC.	   Chemotherapy	   is	   differentially	  
active	   against	   the	   different	   clones,	   as	   different	   is	   the	   impact	   of	   other	   evolutionary	   bottlenecks	   such	   as	  
microenvironment	   or	   competition	   for	   the	   stem	   cell	   niche.	   The	   different	   selective	   pressures	   applied	  will	   determine	  
which	   of	   the	   clone(s)	   will	   survive	   and	   give	   rise	   to	   the	   relapse.	   The	   different	   clonal	   composition	   at	   relapse	   will	  
ultimately	  impact	  on	  the	  different	  sensitivities	  to	  subsequent	  treatments	  and	  therefore	  on	  survival.	  	  
P	   Intact	  immunoglobulin	  secreting	  plasma	  cell	  
L	   Light	  chain	  only	  secreting	  plasma	  cells	  
Relapse	  type	  1	   relapse	  characterised	  by	  both	  free	  light	  chains	  and	  intact	  immunoglobulin	  secreting	  plasma	  cells	  
Relapse	  type	  2	   relapse	  characterised	  only	  by	  free	  light	  chains	  secreting	  plasma	  cells	  
Relapse	  type	  3	   relapse	  characterised	  only	  by	  intact	  immunoglobulin	  secreting	  plasma	  cells	  
	  
The	   better	   outcome	   from	   relapse	   for	   patients	   relapsing	   without	   increasing	   levels	   of	   FLC	  might	  
reflect	   the	   presence	   of	   higher	   sensitivity	   to	   treatment	   in	   the	   clone	   characterised	   by	   whole	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paraprotein	   production	   only.	   This	   hypothesis	   is	   strengthened	   by	   the	   fact	   that	   having	   a	   relapse	  
characterised	   only	   by	   an	   increase	   in	   paraprotein	   levels	   (PO)	   retained	   its	   prognostic	   value	   in	   a	  
multivariate	   analysis	   that	   included	   treatment	   received	   at	   diagnosis	   (thalidomide	   vs.	   non	  
thalidomide	  based),	  treatment	  pathway	  and	  response	  achieved.	  	  
These	   results	   provide	   further	   evidence	   to	   support	   the	   idea	   that	   intra-­‐clonal	   heterogeneity	   and	  
clonal	   evolution	   are	   a	   general	   feature	   associated	   with	   disease	   progression	   and	   treatment	  
resistance	  in	  myeloma.	  	  
To	  evaluate	  the	  impact	  of	  a	  long-­‐term	  treatment	  on	  the	  BM	  of	  MM	  patients	  we	  performed	  a	  flow	  
cytometric	  analysis	  of	  patients	  treated	  with	  lenalidomide	  for	  different	  lengths	  of	  time.	  Our	  results	  
show	   that	   lenalidomide	  has	   a	  minimal	   impact	   on	  bone	  marrow	   cellular	   compartment,	   but	   does	  
have	   an	   impact	   on	   the	   B	   cells	   with	   a	   significant	   decrease	   in	   the	   number	   of	  mature	   B	   cells.	   An	  
increase	   in	  T	   cells	  was	   seen	  but	  no	  discernible	   impact	  on	   the	  myeloid	   compartment	  was	  noted.	  
None	  of	  these	  features	  seem	  to	  correlate	  with	  a	  mechanism	  that	  could	  explain	  an	  excess	  risk	  of	  
SPMs	  reported	  in	  some	  studies	  with	  the	  use	  of	  lenalidomide	  maintenance	  151,159,161.	  	  
We	  demonstrate	  a	  significant	  decrease	  in	  the	  percentage	  of	  B	  cells	  between	  lenalidomide	  treated	  
and	  lenalidomide	  untreated	  patients.	  These	  results	  confirm	  data	  previously	  reported	  306,	  however,	  
we	   were	   able	   to	   show,	   for	   the	   first	   time,	   that	   this	   decrease	   is	   proportional	   to	   the	   time	   on	  
lenalidomide	  treatment,	  and	  it	  is	  more	  pronounced	  in	  patients	  that	  have	  been	  on	  lenalidomide	  for	  
more	  than	  one	  year.	  Our	  data	  provide	  further	  evidence	  to	  support	  the	  immunomodulatory	  effect	  
of	  lenalidomide,	  which	  is	  proportional	  to	  the	  time	  on	  treatment.	  
Lenalidomide	   is	  known	  to	  potentiate	  the	   immune	  response	  via	  the	  stimulation	  of	  T	  and	  NK	  cells	  
153,307-­‐311,	  and	  indeed	  we	  found	  a	  higher	  number	  of	  T	  cells	  in	  lenalidomide	  treated	  patients.	  	  
In	  vitro	  studies	  have	  shown	  that	  lenalidomide	  does	  not	  affect	  the	  myeloid	  stem	  cell	  compartment,	  
but	   it	   may	   impair	   terminal	   maturation	   312.	   Our	   analysis	   showed	   that	   there	   was	   no	   long-­‐term	  
impact	   on	   neutrophil	  maturation	   in	   lenalidomide	   treated	   patients.	   The	   impact	   on	   the	   different	  
myeloid	  subpopulations	  was	  comparable	  between	  all	  the	  three	  groups	  analysed.	  These	  data	  are	  in	  
line	   with	   lenalidomide	   being	   non-­‐toxic	   for	   the	   bone	  marrow	  myeloid	   compartment.	   Consistent	  
with	  this	  and	  in	  contrast	  to	  previous	  reports	  312,	  we	  did	  not	  observe	  a	  decrease	  in	  the	  neutrophil	  
percentage	   in	   lenalidomide	   treated	   patients,	   which	   is	   likely	   explained	   by	   the	   fact	   that	   all	   the	  
patients	  had	  the	  bone	  marrow	  performed	  at	  the	  end	  of	  the	  resting	  week,	  before	  starting	  a	  new	  
treatment	   cycle,	   and	   therefore	   when	   neutrophils’	   count	   had	   recovered.	   In	   vitro	   studies	   have	  
already	   shown	   that	   IMiDs	   reversibly	  down-­‐regulates	  PU.1	   312,	   a	   transcription	   factor	   required	   for	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the	  terminal	  differentiation	  of	  myeloid	  precursors	  into	  competent	  neutrophils	  and	  PU.1	  deficient	  
hematopoietic	  progenitors	  have	  reduced	  neutrophils	  maturation	  313.	  	  
Importantly	  we	  did	  not	  identify	  any	  cellular	  indication	  that	  lenalidomide	  treated	  patients	  are	  more	  
likely	  to	  develop	  hematologic	  SPMs,	  such	  as	  a	  significantly	  higher	  percentage	  of	   immature	  forms	  
or	  the	  co-­‐expression	  of	  aberrant	  markers.	  These	  results	  were	  confirmed	  with	  morphological	  and	  
histological	   assessments,	   and	   are	   in	   line	   with	   data	   previously	   reported	   that	   did	   not	   find	   any	  
significant	  difference	  between	  the	  number	  of	  dysplastic	  alterations,	  before	  and	  after	  lenalidomide,	  
as	   assessed	   by	   morphology	   and	   by	   flow	   306.	   Although	   we	   only	   examined	   a	   small	   number	   of	  
patients,	  we	  did	  not	   find	  any	   indication	  that	   long-­‐term	  treatment	  with	   lenalidomide	  significantly	  
modifies	   the	   myeloid	   compartment	   and	   our	   observations	   confirm	   the	   reversible	   effect	   of	  
lenalidomide	  on	  the	  bone	  marrow	  of	  MM	  patients.	  
CONCLUSIONS	  
Based	   on	   our	   results,	   we	   conclude	   that	   MM	   is	   a	   heterogeneous	   disease	   characterised	   by	   the	  
accumulation	   of	   mutations	   and	   genomic	   aberrations	   at	   clonal	   and	   sub-­‐clonal	   levels	  
11,12,105,136,137,303.	  We	  successfully	  combine	  two	  state-­‐of-­‐the-­‐art	  techniques	  such	  as	  WES	  and	  single-­‐
cell	  genetic	  analyses	  to	  better	  define	  the	  phylogenetic	  relationships	  between	  clonal	  populations	  in	  
myeloma	  at	   clinical	  presentation	  and	   relapse.	  We	  conclude	   that	   the	  most	  plausible	   scenario	   for	  
myeloma	  development	  is	  through	  a	  branching	  evolutionary	  pattern,	  and	  we	  also	  describe	  parallel-­‐
branching	   evolution	   where	   two	   divergent	   clones	   independently	   acquired	   the	   same	   convergent	  
phenotype	   (RAS/MAPK	   pathway	   activation).	   We	   provide	   evidence	   of	   the	   utility	   of	   monitoring	  
clinically	  for	  the	  presence	  of	  intra-­‐clonal	  heterogeneity,	  and	  we	  suggest	  the	  free	  light	  chain	  assay	  
as	  a	  useful	  tool	  to	  follow	  this	  heterogeneity	  from	  a	  clinical	  point	  of	  view.	  We	  also	  show	  that	  long-­‐
term	  treatment	  with	  IMiDs,	  although	  having	  an	  effect	  on	  the	  bone	  marrow,	  does	  not	  significantly	  
modify	  the	  myeloid	  compartment	  and	  does	  not	  increase	  the	  percentage	  of	  immature	  cells	  or	  the	  
development	  of	  aberrant	  phenotypes.	  	  
Taken	   all	   together	   these	   findings	   support	   the	   idea	   that	   clonal	   diversity	   is	   the	   elementary	  
foundation	   for	   Darwinian	   selection	   and	   underlies	   disease	   progression	   of	   the	   disease	   and	   the	  
development	   of	   treatment	   resistance.	   These	   findings	   have	   substantial	   implications	   for	   biopsy-­‐
based	  prognosis	  and	  targeted-­‐therapy	  strategies.	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